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Introduction
Prostate cancer
The prostate is a part of the male reproductive system and consists of tubular-alveolar 
glands surrounded by stroma. In the glands citrate, polyamines and several enzymes are 
stored that are secreted during ejaculation. The surrounding stroma is built up from smooth 
muscle cells and dense connective tissue. The prostate consists of different anatomical 
zones: the peripheral zone, central zone and transition zone. In the transition zone often 
at older age the nonmalignant condition benign prostatic hyperplasia (BPH) occurs (1). 
This is a benign enlargement of the prostate and can result in increasing pressure on the 
urethra. Other common diseases of the prostate are prostatitis, which is an inflammation 
of the prostate, and prostate cancer, which is the most common noncutaneus cancer in 
men. The estimated number of new prostate cancer diagnoses in the Netherlands is 10.390 
(2). Recently, the disease has become the second leading cause of cancer-related death in 
men (3). Approximately 70% of the cancers arise in the peripheral zone, about 30% in the 
transition and central zone (4). Three generally recognized risk factors for prostate cancer 
are older age, ethnicity, and heredity; however, not all risk factors are known yet (5). 
Due to the rising age of the population and the increasing number of prostate-specific 
antigen (PSA) blood tests, the incidence of prostate cancer is increasing. PSA is a protease 
produced by epithelial cells of the prostate and normally secreted into the glands. It is 
suggested that the disruption in the architecture of the glands in prostate cancer causes 
leakage of PSA in the capillary bed (6,7). As a consequence, an increased level of PSA in 
the blood stream can be an indication of prostate cancer (7). However, also with BPH often 
an increase in PSA level is observed, which limits the specificity of the blood test (7). An 
elevated PSA level and/or suspicious finding of a digital rectal examination, are reason to 
take biopsies of the prostate to assess the presence of prostate cancer. These biopsies are 
often obtained under transrectal ultrasound (TRUS) guidance. By means of histopathologic 
examination of biopsy tissues, the presence of prostate cancer can be confirmed, and, if 
cancer is present, the Gleason score will be determined. The Gleason score is the pathologic 
measure of prostate cancer aggressiveness (8-10). 
In 1974, the pathologist Gleason and his colleagues published a grading system for prostate 
cancer based on the over-all pattern of growth (10). They graded the tumors from a scale 1 
to 5 with increasing aggressiveness, corresponding to increased de-differentiation of tumor 
cells. During the 2005 International Society of Urological Pathology (ISUP) Consensus 
Conference, the ISUP modified Gleason grading system was initiated (Figure 1.1) (9). 
Because about half of the tumors consist of more than one grade, the Gleason score of a 
tumor consists of the primary and secondary Gleason grade (8,10). There is a difference in 
determining the Gleason score from a biopsy sample and radical prostatectomy specimen. 
The pathologist bases the primary and secondary Gleason grades in a prostatectomy 
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sample on their prevalence. As biopsy tissue represents only a small part of the tumor, the 
primary and the highest grade determine the Gleason score. When a third grade occupies 
more than 5% of the tumor tissue in a prostatectomy sample, a tertiary grade can be included 
in the Gleason score (9). Tumors with a tertiary Gleason score of 5 have a higher risk of 
extraprostatic extension and PSA recurrence than tumors with the same score but without 
a tertiary pattern (11-13).
Figure 1.1.  Schematic diagram of the ISUP modified Gleason grading system (9). While Gleason grade 1 
 and 2 consist of closely packed, but separate small glands that are in a circumscribed 
 nodule, Gleason grade 3 can infiltrate between noncancerous glandular tissue and consists of 
 smaller glands. Pattern 4 includes ill-defined and cribriform glands. Pattern 5 on the other 
 hand has lost all glandular structure and sporadically necrosis can be seen. 
Prostate cancers are often nonaggressive, which is illustrated by the much-heard 
expression that more men die with prostate cancer than from prostate cancer. A database 
study demonstrated that only a quarter of the diagnosed prostate cancers were of high 
aggressiveness (PSA > 20 ng/ml, Gleason score ≥ 8 and/or T2c-3a) in the 2004-2006 period 
(14). Furthermore, in autopsies, studying men who died of other causes than prostate 
cancer, often prostate cancer was found (15). The percentage of men having latent prostate 
cancer at autopsy increased with increasing age of the investigated men (15). It has been 
proposed to screen for prostate cancer by means of PSA testing. However, the high number 
of indolent prostate cancers raises the question whether this screening should be realized. 
A large European study showed that over an 11 year period in 37 men prostate cancer would 
need to be detected by PSA screening of 1055 men to prevent one death from prostate 
cancer (16). It is estimated that half of these diagnosed men would not have presented 
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Outline of the thesis
 
An important aspect in prostate cancer management is the assessment of its aggressiveness. 
As TRUS guided biopsies often miss the tumor or underestimate its Gleason score, other 
approaches are highly desired. One interesting approach is the use of magnetic resonance 
(MR) techniques. The technique is noninvasive and with MR imaging excellent soft 
tissue contrast can be obtained. Besides the use of MR to obtain anatomical images, MR 
offers also possibilities to obtain more functional information that could be related with 
cancer aggressiveness. In this thesis the performance of two MR techniques is studied 
for noninvasive assessment of aggressiveness. These techniques are: MR spectroscopic 
imaging (MRSI) and diffusion-weighted imaging (DWI). 
Chapter 2 starts with the basic principles of MR, MR imaging (MRI) and MRSI. Then more 
detail about the role of MR(S)I for prostate cancer management is provided. Usually a multi-
parametric approach is used for a prostate MR exam, which means that anatomical imaging 
any clinical symptoms during the rest of their lives without the screening (17). They will 
probably experience more inconvenience from the treatment and its side effects than from 
the indolent tumor. In order to prevent overdiagnosis and overtreatment, there is a need for 
good methods to determine cancer aggressiveness.
There are several models (e.g. D’Amico classification and Partin tables (18,19)) based on 
clinical parameters that are used to classify prostate cancer and assist in the treatment 
planning. These models are based on the PSA level, biopsy Gleason score and the clinical 
stage determined by a digital rectal exam. However, prostate cancer is often multifocal and 
heterogeneous, which might lead to sampling errors with TRUS guided biopsy (Figure 1.2). 
Several studies have demonstrated discrepancies between the Gleason score of the biopsy 
tissue and the subsequent radical prostatectomy specimen (20,21). Better guidance of the 
biopsy needle to the most aggressive part of the tumor or alternative methods to assess 
tumor aggressiveness are therefore required. 
Figure 1.2. TRUS-guided biopsy has limitations, as the tumor can be missed (A), a clinically insignificant 
 tumor can be found (B) or the biopsy underestimates the  aggressiveness of the tumor (C). 
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is combined with one or more functional imaging methods such as DWI and MRSI. The focus 
will be on the hardware, acquisition methods, information content and applications of MRSI 
and DWI for prostate MR. 
MRSI is a technique that enables spatial mapping of metabolites in a tissue that are present 
in high concentration. Using 1H MRSI, the metabolites choline, polyamines, creatine and 
citrate can be studied. During MRSI acquisition, spectra are acquired from which the relative 
amounts of the metabolites can be derived and expressed in a metabolite ratio. The most 
used metabolite ratio for prostate cancer management is the choline plus creatine to citrate 
ratio since in prostate cancer an increase in choline and decrease in citrate is observed. 
In chapter 3 the use of the metabolite ratio for prostate MRSI is discussed. All aspects 
that affect the metabolite ratio are described, from acquisition to post-processing, and 
recommendations for standardization of this ratio are provided. 
Next, in chapter 4, this metabolite ratio is used to assess the aggressiveness of the tumor. 
The ratio is related to the Gleason score of the tumor to study whether a correlation exists. 
It is investigated how well indolent tumors can be separated from more aggressive tumors. 
While MRSI is used to study metabolites, DWI provides information about the restriction of 
water motion in tissue. This restriction is expressed as the apparent diffusion coefficient 
(ADC). As the diffusion of water-molecules is different between healthy tissue and cancer 
tissue, different ADC values are obtained. In the study described in chapter 5, the ADC 
values are correlated with the Gleason score, as are the metabolite ratios. Furthermore, the 
metabolite ratios and ADC value are combined to study their complementary value to assess 
the aggressiveness. Distinction is made between the origin of the tumors, peripheral zone or 
transition zone, to study the zonal performance of the two techniques. 
Important aspects that should be considered are the underlying mechanisms that cause 
the changes in metabolite concentrations or ADC value. A change in ADC value represents a 
change in compartmentalization, which is probably caused by a decrease in luminal space 
and increase in cell density. As citrate, the most important factor in the metabolite ratio, is 
stored in the luminal space, a decrease in citrate could also reflect the changed structure in 
cancer. However, another theory is that citrate decreases because cancer cells oxidize it. In 
chapter 6 the structural changes in prostate cancer are studied in detail and correlated with 
the metabolite ratio and the ADC value. In this way, more insight is gained in the possible 
underlying mechanisms and potential complementary value of the two techniques. 
While with 1H MRSI of the prostate mainly choline, creatine and citrate are studied, the 
technique offers possibilities to study more metabolites. One of the metabolites that can be 
of importance for aggressiveness assessment and treatment selection is lactate. Lactate is 
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an indicator for hypoxia and the Warburg effect. In chapter 7 a sequence was developed for 
lactate detection in the prostate. With this sequence, MRSI was performed in 17 patients with 
highly aggressive tumors. In these patients the minimal detectable lactate concentration 
was calculated to obtain an impression about the lactate levels in prostate cancer.
Besides a decrease in citrate also an increase in choline is observed in prostate cancer. 
The choline signal represents the resonances from free choline, glycerophosphocholine and 
phosphocholine. These last two metabolites contain a phosphorus-atom, and can therefore 
be studied in more detail with 31P MRSI. To study these and other phosphorus metabolites, 
the increased signal-to-noise ratio and spectral resolution of a high field strength are very 
beneficial. Therefore, dedicated coils were developed that enabled the implementation of 31P 
MRSI for in vivo prostate measurements on a 7T system. In chapter 8 an extensive safety 
validation is presented of this coil setup. The safety validation consists of simulations, 
phantom measurements and an in vivo temperature examination. In this chapter the first in 
vivo 31P spectra of the human prostate at 7 T are presented, demonstrating the feasibility of 
our setup. This study paves the way for more clinical studies to investigate the use of 31P 
MRSI for prostate cancer management in general, and more specific for assessing prostate 
cancer aggressiveness. 
Finally chapter 9 summarizes all chapters. The results of the different studies are discussed 
and put in perspective. An outlook to future directions is given. 
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Introduction
In the diagnostics of patients with clinical signs suspicious for prostate cancer transrectal 
ultrasound (TRUS) guided biopsy specimens, analyzed by histopathology, are the standard 
to confirm the presence of cancer and describe its further characterization. Magnetic 
resonance (MR) is a versatile modality with potential to aid the diagnostic workup of patients 
with prostate cancer, but currently its role is still limited (1). In oncology MR is commonly 
used to outline anatomical features, but also offers many possibilities to acquire more 
functional information, in particular of physiologic and metabolic nature, which may help 
to increase diagnostic specificity and sensitivity.  For instance, dynamic contrast enhanced 
MR imaging (DCE-MRI) may be used to assess vascular functionality, diffusion-weighted 
imaging (DWI) to assess tissue characteristics associated with restrictions in water motion 
and MR spectroscopy (MRS) to assess tissue metabolism and physiology. 
Magnetic resonance
MR makes use of the property that the magnetic moment of certain nuclei aligns with a 
magnetic field. In this external magnetic field the nuclei acquire magnetic energy. Nuclei with 
an odd mass number (spin-½-nuclei) have two energy levels and the energy difference (ΔE) 
between these states is given by: 
    (2.1)
in which γ is the gyromagnetic ratio, h is Planck’s constant and B0 the external magnetic field 
(Figure 2.1A). 
	  
0hBE γ=Δ
Figure 2.1. A) The dependence of the magnetic energy of a spin-½-nucleus on the strength of the external 
 magnetic field. B) The spin energy of nuclei aligns parallel (spin state α) or anti-parallel (spin 
 state β) with the external magnetic field. Source: (2). 
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When an oscillating electromagnetic wave is applied perpendicular to the main magnetic 
field, resonance will occur if the energy of the oscillating field equals the magnetic energy. 
The energy of the electromagnetic wave is given by:  
    (2.2)
in which ν0 is the frequency of the electromagnetic wave. Combining equation 2.1 and 2.2 
leads to: 
     (2.3)
This equation is the Larmor equation and v0 is better known as Larmor frequency. 
The two energy levels of the spin-½-nuclei depend on the orientation of the spin energies: 
either parallel (low energy state) or anti-parallel (high energy state) to the main magnetic 
field (Figure 2.1B). The spins precess in the magnetic field at the Larmor frequency under an 
angle of 55.7˚ and have a magnetic moment of μz in the longitudinal direction (Figure 2.2A). 
In a sample, many spins are present and in thermal equilibrium slightly more spins align in 
the direction of the magnetic field. Using the Boltzmann equation, the population difference 
can be calculated: 
    (2.4)
In this formula is na the number of spins in the low energy state, nb the number of spins in
the  high energy state, k is the Boltzmann constant and T is the absolute temperature.
	  
0hvE =Δ
	  
00 Bv γ=
Figure 2.2. A) In the external magnetic field, the nuclear spin precesses with an angle θ and amplitude 
 μz in the longitudinal direction. B) The spins  arrange in the two orientations (α and β) and 
 distribute randomly over the cones, so there is no transverse magnetization. Adapted from 
 (2).
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h
e
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The longitudinal magnetization is the sum of μz of all spins in the sample. The spins do 
not have the same phase and their transversal vector components are randomly distributed 
(Figure 2.2B). Therefore, there is no transverse magnetization in thermal equilibrium and 
only the longitudinal magnetization vector remains. At thermal equilibrium, the longitudinal 
magnetization equals:  
    (2.5)
which follows from an expansion and truncation of a Taylor series of equation 2.4, assuming 
that hn is much smaller than kT. In this equation is n the sum of na and nb. For MR purposes, 
the most used nucleus with spin ½ is the proton (1H), because it has a high natural abundance 
and high gyromagnetic ratio, which means it has a high sensitivity as can be derived from 
equation 2.5.
When a radiofrequency (RF) pulse is applied to the spins at the Larmor frequency, the spins 
will start to arrange more equally over the two energy states and will gain phase coherence. 
When the pulse is applied long enough, M0 can be excited completely in the transverse plane 
(90˚ degree excitation). The magnetization can even be inverted to the –z-axis (inversion).
 
After the pulse, the spins will return to thermal equilibrium and lose phase coherence. This 
process is called relaxation and this process is measured during an MR experiment. The 
return of the longitudinal magnetization is called T1 relaxation. The loss of phase coherence 
in the transverse plane is called T2 relaxation. The T1 and T2 relaxation times are tissue 
dependent. 
MR imaging
MRI makes use of the differences in T1 and T2 relaxation times between various tissues. An 
MRI sequence can be made sensitive to T1 or T2 relaxation to visualize these differences. 
There are many methods available to make MR images. It is beyond the scope of this thesis 
to discuss all methods; only the spin echo sequence will be discussed. This sequence starts 
with a 90˚ excitation pulse (along the –x axis) to transfer the magnetization to the transverse 
plane (Figure 2.3B). As the magnetic field has small inhomogeneities, not all spins will have 
the same Larmor frequency and this will result in dephasing of the spins (Figure 2.3C). After 
a certain time, defined as half the echo time (TE), a 180˚ inversion pulse is given along the 
y axis that will mirror the magnetization vectors with respect to this axis (Figure 2.3D). 
As the spins will experience the same field inhomogeneities, they will rephase. Complete 
rephasing will occur after the second delay of half TE and an echo will be formed (Figure 
2.3E). There will be some decrease of signal intensity in the transverse plane due to T2 
relaxation (microscopic dephasing).   
	  
( ) ⎟
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⎜
⎝
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=
kT
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A signal can be recorded during the echo, because the transverse magnetization induces a 
current in the receive coil. This received signal is transformed into an image. To obtain an 
image the spin echo sequence described above needs to be expanded with magnetic field 
gradients. When a magnetic field gradient is turned on, a spatial variation in the magnetic 
field strength is added to the main magnetic field. As a result, there is a spatial variation 
Figure 2.3. A) The spin echo-experiment, in which a 90˚ excitation and 180˚ inversion pulse are followed 
 by an echo. (B-E) show the orientation of the spins in the transvers plane during the 
 experiment. B) Immediately after the 90˚ pulse there is full coherence of the spins in the 
 transverse plane. C) The spins will lose their coherence dueto inhomogeneities in the magnetic 
 field. D) The 180˚ inversion pulse mirrors all magnetization vectors and due to the same 
 inhomogeneities the spins will rephase. E) At TE complete rephasing has occurred leading to 
 an echo. Source: (2).
Figure 2.4.  In the presence of a gradient, only the spins with a Larmor frequency within the bandwidth 
 (Δf) of the RF pulse will be excited. The thickness of the slice (Δz) depends on the gradient 
 strength. 
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in the Larmor frequency of the spins. When an RF pulse is played out in the presence of a 
gradient, only the spins with a Larmor frequency within the bandwidth of the pulse will be 
excited. This way, a slice can be excited of which the thickness can be varied by the strength 
of the gradient (Figure 2.4).
By applying a slice selection gradient during the excitation and refocusing pulse, the coil will 
only receive signal from this one slice during the echo. To obtain spatial information within 
the slice, frequency and phase encoding gradients can be used (Figure 2.5). The frequency 
encoding gradient is turned on during the acquisition of the echo. As a result, the spins will 
have a frequency that is dependent on their position along the direction of the gradient. The 
signal consists thus of a range of frequencies that are proportional to the gradient strength 
and this can be related to their position. 
Figure 2.5.  A spin echo sequence consists of a 90˚ and 180˚ pulse during which a slice selection gradient 
 is applied. During acquisition of the echo, a frequency encoding gradient is used and after 
 each acquisition the phase encoding gradients are altered. This way, spatial information is 
 obtained that is used to make an image.
In the last direction phase encoding is used. To this end, a short gradient is applied before 
acquisition and during this gradient the frequency of the spins is altered. After the gradient, 
the spins return to their original frequency, but have gained a spatially determined phase shift. 
One acquisition with a phase shift contains not enough information to obtain all necessary 
spatial information in this direction. To this end, the gradient strength (and thus the phase 
shift) is slightly altered in each following acquisition. The number of phase encoding steps 
26
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necessary depends on the desired resolution. The complete spin echo sequence with 
gradients in shown in Figure 2.5. 
 
The coil receives signals during the echo and these are stored in a matrix called k-space. The 
MR image is obtained after Fourier transformation of k-space. 
MR Spectroscopy 
While MR imaging essentially uses the signal of only water and lipids, a broader range 
of molecules can be viewed by MRS, as it exploits the specific resonance frequencies 
(chemical shifts) that MR sensitive nuclei in different chemical groups possess, and which 
are sensitive to their chemical and physiological environment. 
 
Electronic shielding causes the chemical shift. In a magnetic field, electrons surrounding a 
nucleus will rotate in such a way that they induce a small magnetic moment in the opposite 
direction of the spin’s precession (Figure 2.6A). This small magnetic moment will reduce the 
effective magnetic field of the nucleus and in this way, its Larmor frequency. 
The resonance frequency of the nucleus (ν) is defined as: 
     (2.6)
where σ is the shielding constant. The amount of electronic shielding depends on the atoms 
close to the proton. Nearby electro-negative atoms will decrease the electronic shielding of 
the proton and in this way, increase the Larmor frequency (Figure 2.6B). Protons at different 
positions in a molecule and protons from different molecules will have specific resonance 
frequencies (Figure 2.6C). 
This chemical shift (δ) is expressed in parts per million (ppm):  
     (2.7)
and νref is the resonance frequency of a reference compound. 
An MR spectrum obtained from a location in the body contains signals of which the patterns 
and intensity reflect the identity, physiological state and amount of the compounds present 
at that location. In clinical applications of MRS the proton plays a dominant role, because 
it is present in most body compounds, and has a relatively high sensitivity. Since clinical 
MR machines are dedicated to detect protons in water and fat, the hardware is readily 
available, which simplifies implementation of 1H MRS. However, as the tissue concentration 
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δ
27
2
M
RI and M
RSI of the prostate
Figure 2.6.  A) Electronic shielding: a nucleus is surrounded by electrons that induce a small magnetic 
 moment μe. μe has the opposite direction as the nuclear spin and this lowers the effective 
 magnetic field of the nucleus and thus its Larmor frequency. B) The lactate molecule 
 possesses an electro-negative oxygen atom that shifts electrons from the protons away 
 from the nucleus and reduces its electronic shielding,which results in an increase in the 
 Larmor frequency. The protons in the methylgroup experience a different electronic shielding 
 than the other non-exchangeable proton and have thus a different Larmor frequency 
 (chemical shift). C) Their differences in chemical shift (expressed in parts per million (ppm)) 
 are visible in the spectrum. Source: (2). 
of biochemicals is much lower than that of water, their detection at sufficient signal-to-noise 
(SNR) is only possible at a relatively low spatial resolution and for metabolite levels above 
~ 0.5 mM. This implies that MRS is not suited for detailed anatomical imaging, but rather for 
a coarse spatial mapping of metabolism and physiology.   
Besides differences in chemical shift, there is another feature that can be used to distinguish 
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between different biochemicals, that is, the splitting of resonances due to scalar coupling. 
This coupling comes from the electrons in the chemical bonds between two nuclei. In an 
isolated atom, the electron spin and nuclear spin prefer an anti-parallel arrangement. When 
there are two uncoupled protons with a different chemical shift, there are four different 
energy states possible, these are shown in Figure 2.7A. There are four permitted transitions 
and the energy differences for the two transitions of proton 1 are both equal (= hνH1) and 
both transitions of proton 2 are hνH2. Therefore, the corresponding spectrum will show two 
spectral lines (singlets) positioned at the chemical shifts of proton 1 and 2 (Figure 2.7C). 
When the atoms are coupled, slight changes in the energy levels occur due to the Pauli 
exclusion principle. This principle demands that the electron spins in a bond are in anti-
parallel orientation. This leads to less favorable energy states for the α-α and β-β spin states, 
where the nuclear spins cannot be both anti-parallel to the electron spins. As a consequence, 
the energy increases with an amount of J/4, where J is the scalar coupling constant, also 
known as J-coupling constant. 
Figure 2.7. The effect of J-coupling on the spectra. A and B show the energy levels for two spins with 
 different chemical shifts and the possible transitions. There are four energy levels for these 
 two spins; both spin state α (lowest energy state), one spin α and one spin β, and both spin 
 β (highest energy state). A) For uncoupled spins are the energy differences for both 
 transitions of proton 1 equal (=hνH1), as are the energy differences for proton 2 (=hνH2). As 
 a result, there are two spectral lines in the corresponding spectrum in C. B) For coupled spins, 
 the bonding electrons cannot be anti-parallel to the nuclear spins for the α-α and β-β spin 
 states, leading to energetically less favorable states. This leads to slight changes in the 
 energy differences. The energy differences for the two transitions of proton 1 are no longer 
 equal: h(νH1+J/2) ≠ h(νH1-J/2). As a consequence, small changes in the frequencies occur and 
 this results in a splitting of the resonances in the spectrum in D. 
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In the α-β and β-α spins states, the nuclear spin and electron spins can be in anti-parallel 
directions, which leads to an energetically more favorable state and an energy decrease of 
J/4 (Figure 2.7B). The energy differences for the two transitions of proton 1 are no longer 
equal: h(νH1+J/2) ≠ h(νH1-J/2). This leads to small changes in the Larmor frequencies and 
results in a splitting of the resonances in the spectrum (Figure 2.7D). In principle scalar 
coupling constants are considered for one chemical bond; however, 1H-1H interactions 
stretch over three bonds.  
MR Diffusion-weighted Imaging
Water molecules are in constant Brownian motion. When this random motion of the water 
molecules is unrestricted, the molecules can diffuse freely. The Einstein relation describes 
how the mean square displacement (<Δr2>) of a particle over a certain time (Δt) depends on 
the diffusion coefficient (D): 
     (2.8)
The diffusion coefficient depends on the mass of the molecules, the temperature and 
viscosity of the medium (3). Assuming a D in biological tissue of 1·10-9 m2/s (4) and a Δt of 
50ms, an average displacement of water molecules of approximately 17 μm can be derived 
(equation 2.8). As a typical cell has a diameter of about 10 μm, this means that the water 
molecules will encounter cell membranes during the diffusion time. This will restrict the 
motion of the water molecules. As a result, in a diffusion-weighted MR experiment, not purely 
the true diffusion coefficient is measured. We speak therefore of the apparent diffusion 
coefficient (ADC).
The degree of movement can be visualized with MR by extending the spin echo sequence 
with diffusion-sensitizing gradients as described by Stejskal and Tanner (5). They placed 
two strong gradients around the 180˚ pulse. During the first diffusion gradient, all spins will 
gain a phase shift due to the imposed gradient. The 180˚ pulse mirrors the magnetization 
vectors. During the second gradient, the static spins will rephase and no signal loss due to 
the gradients has occurred. However, the water molecules that have moved between the two 
gradients will not completely be rephased and a signal loss will occur (Figure 2.8). 
 
The signal attenuation is expressed as: 
     (2.9)
in which S0 is the signal intensity without diffusion weighting, S is the signal intensity 
with diffusion weighting and b is the diffusion-sensitizing factor (also known as b-value). 
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The b-value can be calculated in the following way: 
     (2.10)
in which G is the strength of the gradient, δ is the duration of the gradient and Δ is the time 
between the gradients. 
The chosen b-value determines what kind of diffusion is visible in the diffusion image. In 
a low b-value (50-100 s/mm2) image, large diffusion distances are needed to evoke signal 
attenuation. This is mostly intravascular diffusion and these images show tissue perfusion. 
Higher b-values are used to study water molecules that move slower or are more restricted 
by the tissue. A limitation of b-value images is that T2 relaxation effects are also present in 
the image. To overcome this problem, ADC maps were introduced that are calculated using 
multiple b-value images. The ADC value is a quantitative measure that is obtained by plotting 
an exponential function through the plot of the signal intensity against the b-value (Figure 
2.9). The higher the ADC value, the more freely the water molecules can move.  
 
Figure 2.8. Spin echo sequence expanded with diffusion-sensitizing gradients around the 180˚ pulse. 
 During the first gradient, all molecules will gain a phase shift. This phase shift is rephased by 
 the second gradient for static molecules and no signal loss due to the gradients will occur. 
 The phase shift of moving water molecules will not be re-phased completely during the 
 second gradient, leading to a signal loss. Source: (6).
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Hardware for MR of the prostate
MR images and spectra of the prostate are commonly obtained with a body coil for excitation 
and a external phased array coils around the pelvic area for data acquisition. It is fortuitous, 
for MR purposes, that the prostate can also be approached with a local loop via the rectum. 
The addition of an endorectal coil for MR signal reception gives a substantial gain in local 
SNR, which can be exploited in MRS and DWI to obtain a better resolution with improved 
clinical performance. Disadvantages of the use of an endorectal coil are patient discomfort, 
additional costs and the need for proper placement of the coil, which requires some skill 
and is time-consuming. There are inflatable and rigid endorectal coils in use. Inflatable 
endorectal probes are commonly used with a coil placed within a double balloon of which, 
after insertion in the rectum, the inner one is filled to press the coil close to the prostate 
(Figure 2.10). 
Inflatable coils can cause more compression of the prostate in the anterior/posterior 
direction than rigid coils (8). However, inflatable coils have a larger field of view and perhaps 
show less motion artifacts than rigid probes (9). Another advantage of inflatable coils is that 
the balloon can be filled with a tissue susceptibility matching fluid (e.g. perfluorcarbons) to 
avoid susceptibility problems due to air-tissue borders. This leads to better shim results than 
air-filled or rigid coils (9). The reception profile of the endorectal surface coil shows a spatial 
variation, which may be compensated for (10).
 
At 1.5 T the use of an endorectal coil for prostate MRSI is recommended if spatial resolutions 
Figure 2.9.  Calculation of the ADC value. A) The signal intensity depends on the used b-value and type 
 of tissue studied. B) To calculate the ADC value, the logarithm of the signal intensity is 
 plotted against the b-value. The ADC value corresponds to the slope of the plotted line. 
 Adaptedfrom: (7). 
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MR spectroscopic imaging of the prostate
About 20 years ago it was demonstrated that 1H MR spectra of extracts of prostate tissue 
showed a number of metabolite signals, including proton signals from citrate (Cit) and 
choline (Cho) compounds and that those of Cit were decreased and those of Cho compounds 
were increased in prostate cancer (22,23). After the introduction of endorectal coils it also 
became possible to obtain in vivo 1H MR spectra of small volumes (down to approximately 
0.3 cm3) of the prostate with sufficient SNR (24-26). The dominant peaks observed in these 
spectra included those from protons in Cit (at 2.6 ppm) and Cho compounds (total cholines 
at about 3.2 ppm). Compared to healthy peripheral zone or BPH tissue the signals of Cit 
Figure 2.10.  Endorectal coil for prostate MR imaging and spectroscopy. 
below about 1 cm3 are desired (11), as the SNR at such resolution will be relatively low with 
only external phased-array coils (12), which may result in poor quality data (13). Compared 
to 1.5 T, MRS at 3 T can have a better SNR and chemical shift dispersion. This better SNR 
may be used for MRSI without an endorectal coil depending on factors such as desired 
voxel size (11,14,15). A doubling in SNR was reported when moving from 1.5 T to 3 T for 
prostate MRS (16). A relative increase in SNR may also be caused by reduced intra-voxel 
dephasing if a higher spatial resolution is selected (16). At 3 T, a small but significant 
increase in the performance of MR spectroscopy for cancer localization was observed when 
an endorectal coil was compared to solely external phased-array coils (17). Thus the choice 
to perform MRSI at 3 T with or without endorectal coil mainly depends on the preference for 
best practicality or optimal spatial resolution. Also DWI can benefit from the gain in SNR. In 
several studies the endorectal coil is used for DWI of the prostate (e.g. (18-21)). The increase 
in SNR can be used for increased image quality of increased spatial resolution. 
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were reduced and those of Cho often increased in cancer tissue. Other prominent signals 
in prostate spectra are the methyl protons of creatine (at about 3 ppm) and usually also a 
set of signals for coupled polyamine protons in the same spectral region. Figure 2.11 shows 
a typical spectrum of healthy peripheral zone tissue obtained at 3 T with a point resolved 
spectroscopy (PRESS) sequence and TE of 145 ms. 
Figure 2.11.  Typical prostate spectrum of normal peripheral zone obtained with a PRESS sequence and a 
 TE of 145 ms. The spectrum contains the metabolites Cho, spermine (Spm), creatine (Cr) and 
 Cit. 
Because prostate cancer is often multifocal and tumor tissue can occur anywhere in 
the prostate it became clear that multi-voxel acquisition is preferable in clinical studies. 
As the prostate is relatively small and surrounded by adipose tissue, this required the 
implementation of advanced RF pulses and sequences to suppress interfering strong lipid 
signals. In this way 2 and 3-dimensional MR spectroscopic imaging sequences were realized 
(14,24,27,28) of which 3 dimensional (3D) variants are most favored as these can cover the 
whole prostate. 
An important step in the 1H MRSI acquisition protocol is the optimization (shimming) of the 
B0 field homogeneity. Bad homogeneity spoils spectral quality as it broadens the spectral 
lines, due to a faster decay of the apparent transverse magnetization. This will complicate 
good separation of metabolite signals, especially in the Cho, polyamine and creatine region, 
and hampers a reliable recognition and quantification of the metabolites. Good homogeneity 
is also essential for effective water and lipid signal suppression, as broadened or shifted 
signals may escape the frequency selective pulses needed for this suppression.  
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Localization protocols
In 1990, the first publication on in vivo 1H MR spectroscopy of the human prostate appeared 
(29). MR spectra were acquired with a spin echo sequence and the field of view of the rigid 
endorectal coil determined the localization (29). Later, localized single voxel spectra were 
obtained by point resolved spectroscopy (PRESS) (30) or stimulated echo acquisition mode 
(STEAM) (25). In the same period MRSI of the prostate was introduced (24,26,27). MRSI with 
PRESS localization is now the most common method in the clinic to acquire prostate MR 
spectra. Currently, 3D acquisitions at 1.5 – 3 T with sufficient SNR can be typically performed 
in 8 – 15 minutes at spatial resolutions down to ~ 0.3 cm3, depending whether an endorectal 
coil is used or not. A certain spatial resolution is important as tumor foci of < 0.5 cm3 are 
assumed to be clinically insignificant (31).  
For localization, spectral-spatial selective pulses can be used that prevent excitation 
of peri-prostatic lipids and water (16,32-34), but not all vendors have implemented these 
pulses. A common alternative is to use dual frequency pulses, added to a PRESS sequence 
for selective lipid and water suppression (double band-selective inversion with gradient 
dephasing (BASING) (34,35) or Mescher-Garwood (MEGA) (36)). Dual frequency pulses, 
surrounded by crusher gradients, selectively invert and dephase the lipid and water 
signals. Furthermore, outer volume saturation (OVS) slabs are placed around the prostate 
to decrease lipid signals. In these slabs, all signals are spatially excited and crushed by 
a series of dephasing gradients. OVS pulses have been optimized to further improve lipid 
suppression (37). Placement of these slabs is a subjective and time-consuming process, and 
only a limited number of slabs can be placed (Figure 2.12). Therefore, automated placement 
of these saturations slabs around the prostate has been developed (38,39), in which the 
number of OVS slabs can be increased through temporal ordering of the saturation slabs and 
flip angle modifications (39). While these methods still segment prostate volumes manually, 
MR vendors are working on complete automation of this segmentation, volume of interest 
(VOI) and field of view (FOV) selection, matrix size determination and OVS placement. This 
automation is an important step to encourage routine clinical use. 
In classical MRSI the limited number of steps in k-space acquisition causes signal 
contamination between neighboring voxels due to the side-lobes of the spatial response 
function (SRF). This contamination may be substantial if peri-prostatic areas with high 
lipids are included in the VOI. Optimization of the SRF helps to minimize contamination of 
these peri-prostatic lipid signals. One can smooth the SRF by applying an apodization filter 
in k-space, at the cost of some sensitivity loss and reduced spatial localization due to an 
increased voxel size (40). A Hanning window is a good compromise between sensitivity loss 
and improved SRF (40,41). As the whole k-space is sampled equally, this is a time inefficient 
approach. When k-space is sampled with a scheme similar to a Hanning function, the 
sensitivity can be preserved while improving the SRF (14,41). 
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Another approach to prevent lipid contamination is the use of very accurate localization 
techniques, such as selective adiabatic refocusing (LASER). When combined with positioning 
of the VOI completely within the prostate, LASER or semi-LASER volume selection is precise 
enough not to excite or refocus peri-prostatic lipids (42,43). However, as 70% of the prostate 
tumors occur in the peripheral zone, the usability of this approach is limited. A more practical 
approach would be the use of parallel transmit systems that enables the use of spatially 
customized RF pulses to excite only the prostate, although the demanded accuracy could 
be a challenge. These techniques were developed for higher field systems (44,45), but will 
probably find their way to the clinic, as 3T-systems nowadays can be equipped with multi-
channel transmit arrays. 
Prostate MR spectroscopy is prone to movement artifacts, due to the location of the prostate 
near the bowels and the relatively long acquisition times. To limit bowel movement, patients 
often receive an injection with anti-peristaltic drugs (e.g. glucagon or butylscopolamine 
bromide (Buscupan)). The use of a navigator has been proposed to reduce motion artifacts 
(46). The examination time can be reduced by weighted k-space sampling as described 
above. Implementation of spiral readout gradients could be used for acceleration as well 
Figure 2.12.  T2-weigthed image of the prostate of a 54-year-old man with biopsy-proven prostate cancer. 
 The white box indicates the volume of interest and outer volume saturation slabs for lipid 
 suppression surround the prostate. 
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as for correction of motion-induced phase variations, as each spiral starts in the center of 
k-space (47). Methods proposed to further decrease the acquisition time of prostate MRSI 
are e.g. flyback echo-planar encoding (48) and compressed sensing (49); however, these 
approaches come at an SNR cost, and will only be of use in a non-SNR-limited regime. 
Origin of the signals in prostate MR spectra
In particular for Cit it is of interest to consider its origin. It is well known that the normal 
human prostate accumulates Cit at high levels, in particular in the peripheral zone (50,51), 
mainly because in epithelial cells the oxidation of Cit is inhibited by the interaction of zinc 
ions with the mitochondrial enzyme m-aconitase (52). Although this results in an increased 
Cit level in epithelial cells (e.g. estimated between 1 and 2 mM in epithelial cells of the rat 
ventral prostate (50)), the majority of Cit is excreted into the luminal space. Cit levels in 
prostatic fluid between about 50 – 150 mM have been reported (50,52,53). As the volume 
percentage of the luminal space in the normal peripheral zone is approximately 30% (54) 
this means that in a spectroscopic voxel the average Cit level in the peripheral zone should 
be between about 15 and 50 mM. This is confirmed by absolute Cit levels estimated from 
MRS measurement which revealed mean peripheral zone levels of about 40 mM (55,56); a 
similar concentration for glandular tissue was calculated from high-resolution magic-angle 
spectroscopy (HRMAS) spectra (57). Interestingly in glandular BPH tissue Cit levels are 
increased (52,55,56). This may differentiate it from stromal BPH, which has a lower Cit level 
(57).
Polyamines, of which 50% - 95% is spermine (58,59), are secreted by specialized ductal 
cells in the prostate (60). In accordance with accumulation in the luminal space a linear 
relationship is observed between the content of polyamines and Cit (57,61,62). It has been 
suggested that such a relationship exists because of the association between spermine 
and Cit, which have opposite polarity (61). The tissue concentration of polyamines in the 
normal prostate has been reported to be about 12 mM (53). HRMAS studies have estimated 
their tissue content between 3 – 20 mmol/kg, with a low content for stromal tissue and high 
content for glandular tissue (57). 
Prostatic fluid contains relatively little Cho and creatine (61,63), thus the signals from 
these compounds come essentially from within prostate cells, which could be epithelial or 
stromal cells (mostly smooth muscle cells and fibroblasts). E.g. it may be expected that 
the coinciding signals of creatine and phosphocreatine at about 3.0 ppm largely arise from 
smooth muscles, which are the dominating component in the stromal fraction (64). From 
in vivo MRS measurements it was estimated that in normal prostate the average total Cho 
levels were 3.1 mM and total creatine 4.4 mM (24). HRMAS studies estimated total Cho to 
be about 7 mmol/kg and total creatine about 8 mmol/kg (57).   
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Cancer MR spectroscopy biomarkers
Already in 1964 it was reported that Cit levels are decreased in prostate cancer (65).  Later 
this was attributed to a decreased zinc build up in the process towards malignancy with 
consequent Cit oxidation in the Krebs cycle, leading to less Cit in malignant epithelial cells 
(52). Indeed, a relationship between the expression of the enzymes m-aconitase and acetyl 
citrate lyase and prostate Cit levels has been observed (66). However, it is also known that 
cancer growth decreases the luminal space and this inevitably causes lower tissue levels 
of Cit, even if Cit production would not diminish. For instance, it has been reported that 
in Gleason 6 and 7 cancers the luminal space fraction in the peripheral zone decreases 
from 30% to about 13% (54). Thus it is most likely that the decrease in Cit signal seen in 
voxels with prostate cancer is largely due to a decrease of luminal space; and thus reports 
a morphological change (Figure 2.13). As alterations in Cit metabolism have been proposed 
to occur in a premalignant stage before major histopathological changes are apparent (51), 
it would be of interest if lower Cit levels could be identified in this stage by in vivo MRS. 
Indeed, in premalignant lesions (high-grade prostatic intraepithelial neoplasia) a metabolic 
profile between normal peripheral zone and cancer tissue was seen, but it was unclear if this 
involved a lower Cit amount as only relative metabolite levels were assessed (67). It was 
concluded that this would not confuse cancer detection by MRSI as these nodules occur 
infrequently and generally are small compared to the MRSI voxel size. In this respect 1H 
HRMAS of representative biopsy tissue may be more informative (66,68,69). 
It is well established that polyamine signals decline in prostate cancer tissue (57,59,62,68,70). 
This goes together with the decline in Cit signals, which is in line with a reduction of the 
ductal space due to cancer growth. Despite the difficult quantification of the polyamine 
signals it is increasingly more used as an additional biomarker to assess the presence of 
prostate cancer in vivo (71).   
A metabolic hallmark of malignant transformation is a change in Cho metabolism (72), 
which commonly results in an increase in the methyl proton signal of Cho compounds at 3.2 
ppm in MR spectra. For the prostate this makes the ratio of the signals of Cho compounds 
over Cit signals an attractive index for the presence of prostate malignancy. From in vitro 
nuclear magnetic resonance studies of biopsy extracts the peak of “choline compounds” 
at 3.2 ppm turned out to be mainly composed of the resonances originating from protons 
in methyl groups of choline, phosphocholine and glycerophophocholine. The 1H chemical 
shift dispersion of the methyl protons is too small to be resolved in the in vivo spectrum 
and therefore the composite peak at about 3.2 ppm is commonly referred to as the total 
Cho peak, although it may also contain (smaller) contributions from other compounds (e.g. 
taurine, ethanolamine and myo-inositol (73)). 
The Cho compounds are involved in the biosynthesis and degradation of phospholipids 
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such as phosphatidylcholine, which is required for the build-up and maintenance of cell 
membranes. More specifically the signals of phosphocholine and glycerophosphocholine 
increase in tumors (72,73). The exact reason behind this increase is still a matter of research, 
but may be caused by increased Cho transport into tumor cells, increased choline kinase 
Figure 2.14.  A) Spectrum of tumor tissue showing high Cho and low creatine (Cr) and Cit resonances. 
 B) T2-weighted image of a 71-year-old patient with a Gleason 9 tumor in the peripheral zone. 
 The white circle indicates the location and true voxel size (after filtering and zero-filling) of the 
 spectrum in A.
Figure 2.13.  A) T2-weigthed image of the prostate of a 53-year-old man with biopsy-proven prostate 
 cancer in the left transition zone. B) Spectrum of normal peripheral zone tissue (left sphere in 
 A) containing Cho, creatine (Cr), spermine (Spm) and Cit resonances.C) Spectrum of tumor 
 tissue (right sphere in A) showing increased Cho and decreased Cit levels compared to B. 
 D) Corresponding slice of the excised prostate indicating the tumor. E) Hematoxylin and 
 eosin stained tissue of normal tissue and tumor tissue (F) of this patient. 
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activity and increased phospholipase expression and activity in tumors. Increases in the 
total Cho peak have also been associated with increased cell density and tumor hypoxia 
(74). For high grades of prostate cancer sometimes a very high Cho to creatine ratio can 
be observed (Figure 2.14), which also may reflect replacement of smooth muscle tissue by 
tumor cells. 
Potentially confounding spectral features in prostate cancer identification
Obviously, the dominant luminal origin of Cit and polyamine signals in vivo implies that any 
prostate condition, which substantially reduces the luminal space, may also lower these 
signals. For instance this could happen with inflammation of the prostate, but in a 2D MRSI 
study of patients clinically diagnosed to suffer from chronic prostatitis, we did not see a 
change in relative Cit levels (75). However, in other studies some, but not all, prostatitis 
lesions occurring in prostates next to cancer tissue did mimic the in vivo MRS profile of 
prostate cancer tissue (76,77). The differentiation of prostatitis from prostate cancer is also 
difficult for other MR approaches (78). 
Figure 2.15.  A) Spectrum of the seminal vesicles showing a high total Cho content. B) T2-weighted image 
 of a 63-year-old patient with small cancer lesions in the peripheral zone. The white circle 
 indicated the location and true voxel size (after filtering and zero-filling) of the spectrum in A. 
In the analysis of patient data it should also be taken into account that different regions of 
the healthy prostate such as peripheral zone, transition zone, and areas close to the urethra, 
the seminal vesicles and anterior fibromuscular stroma may have a different metabolite 
composition. For instance, seminal fluid contains relative high levels of cholines (79), which 
may affect spectra of voxels close to or overlapping the seminal vesicles (Figure 2.15). Cit 
levels are highest in the normal peripheral zone and lower in areas close to the urethra.  If 
BPH is mainly of stromal origin this can result in relative low Cit levels (57). 
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In addition, post-biopsy changes may affect spectral appearances. MRS has to be performed 
sufficiently delayed with respect to the time of biopsy to avoid a possible deleterious effect 
of a hemorrhage on spectral quality, due to magnetic field or morphological distortions (80). 
The presence of hemorrhages is best detected on T1-weighted MRI (81).   
Diffusion-weighted imaging of the prostate
The use of DWI for prostate MR examinations was introduced almost a decade later than 
MR spectroscopic imaging (82). Nevertheless, at this moment, DWI is more routinely used 
in clinical MR exams of the prostate. The technique is simple, fast and, in contrast to MRSI, 
readily available on clinical MR systems. 
Acquisition protocols
DWI of the prostate is often based on a spin echo sequence with diffusion gradients and an 
echo planar imaging read-out. As DWI is very sensitive to motion artifacts, fast acquisition is 
required. This was enabled by the introduction of echo planar imaging read-out and the use 
of parallel imaging. The administration of anti-peristaltic drugs is also advisable for prostate 
DWI to minimize motion artifacts. Usually, diffusion weighting gradients in three orthogonal 
directions are used. The European Society of Urogenital Radiology (ESUR) recommends the 
use of at least 3 b-values: 0, 100 and 800–1000 s/mm2. They recommend to make an ADC 
map by excluding the b-0 image and not to use b-values higher than 1000 s/mm2 for the ADC 
Figure 2.16.  A) T2 weighted image of the prostate of a 68 year-old patient with proven prostate cancer. 
 A tumor with Gleason score 3+4 is present in the right peripheral zone. B) Corresponding 
 apparent diffusion coefficient map showing a hypointense region at the tumor location, indic- 
 ative for reduced diffusion. For this map b-values of 50 and 800 s/mm2 were used. 
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calculation (11). In literature many different settings are used for DWI of the prostate and 
determination of the ADC map e.g. (20,83-85). The ADC maps can be generated automatically 
by the MR system. An example of an ADC map of the prostate is shown in Figure 2.16. 
To obtain a certain b-value, either the gradient strength, time between the gradients or duration 
of the gradient can be adapted (equation 2.10). As there is a limit to the gradient strength 
that can be used, long diffusion times are required to get high b-values. A diffusion interval 
between 40 to 80 ms is often used on clinical systems (86). The diffusion measurement is 
thus limited by SNR and T2 relaxation time. Therefore, it is recommended to use a TE as 
short as achievable (typically <90 ms) (11). 
As the SNR has to be high enough for DWI, the technique can benefit from the use of an 
endorectal coil and a higher field strength. This allows for higher image quality and increased 
spatial resolution. However, at higher field strength also larger susceptibility artifacts have 
to be overcome. When an endorectal coil is used for signal reception, more signal will come 
from the prostate area close to the endorectal coil. Since this coil profile is present in all 
b-value images, this effect is eliminated in the ADC map. At 1.5 T, axial slices of 5 mm thick 
and an in-plane resolution of 1.5×1.5 mm to 2.0×2.0 mm are used, while at 3 T, we can go to 
4 mm thick slices with a resolution of 1.0×1.0 mm to 1.5×1.5 mm (11). 
Features and information content of DWI of the prostate
The information that is obtained in a DWI experiment depends on the chosen settings. When 
a short diffusion time is chosen (and the gradient strength is increased to obtain a certain 
b-value), the average displacement of water molecules is smaller than the cell dimensions. 
This measured ADC value will be more a reflection of the true diffusion coefficient of the 
tissue (87). However, at longer diffusion times the water molecules will encounter barriers 
like cell membranes. Cell membranes are not impermeable for water molecules, but passing 
the cell membrane takes time. This hinders the water molecules and the ADC value reflects 
therefore more the compartmentalization of the tissue. In the prostate, there is a lot of 
glandular tissue. The size of the acini is much larger than cells, 0.3-0.5 mm on average in 
healthy tissue (88). The healthy peripheral zone contains approximately 30% of luminal 
space (54), in which the water molecules feel less restriction. As a consequence, healthy 
peripheral zone has a low signal intensity on high b-value images (figure 2.17) and a high 
signal intensity on the ADC map (18,82,89). 
In the transition zone often BPH occurs. BPH can have different appearances: it can be 
more glandular, more stromal, but often it is a mix between these glandular and stromal. The 
different compositions of the transition zone give rise to contrast differences in T2 weighted 
images (90) and ADC maps (83). The ADC value in glandular hyperplasia is higher than in 
stromal hyperplasia (83), which can be explained by the larger degree of freedom of the 
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water molecules to diffuse in the glandular tissue. 
In tumor tissue, there is a loss of glandular structure and an increased cellularity. This leads to 
lower ADC values than for the healthy peripheral zone (54,82,89). A correlation was reported 
between the ADC value and the histological grades of prostate cancer (well, moderately or 
poorly differentiated cells) (91). Furthermore, significant correlations between the ADC value 
and the cellularity and the area of luminal space are reported (54). 
Figure 2.17.  The logarithm of the signal intensity on normal appearing central gland and peripheral zone 
 tissue for several b-values (82). 
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Introduction
Prostate cancer is the most prevalent non-cutaneous cancer in men and the second leading 
cause of cancer related death in western countries (1). The use of MR in prostate cancer 
management is emerging, and the demand from patients and clinicians is increasing as 
a result of the growing number of men suspected of having prostate cancer due to the 
uptake of blood tests for prostate specific antigen. In clinical practice MR is used for its 
anatomical details in the detection, localization and characterization of the disease, but the 
technique also offers possibilities to obtain more functional information, for example by 
diffusion weighted imaging (DWI), dynamic contrast enhanced imaging (DCE-MRI) and MR 
spectroscopic imaging (MRSI) (2). 
Proton MR spectroscopy (1H MRS) enables one to study a range of (bio-)molecules, by 
making use of the signals of 1H nuclei in these molecules. In vivo, the detection of molecules 
is limited to those present at tissue levels of more than 0.5-1 mM. The first metabolite studied 
with in vivo 1H MRS of the prostate was citrate and a decrease in its resonances’ amplitude 
was observed in prostate cancer patients compared to healthy controls (3). Next, the choline 
methyl resonance gained attention as an increase in this signal in prostate cancer was 
observed (4,5). Due to frequency-selective water and lipid suppression, only signals of major 
metabolites between approximately 2.2 and 3.8 ppm remain in prostate spectra, which 
also includes those of creatine and polyamines. Because the choline and creatine methyl 
signals are only separated by a relatively small chemical shift difference, a non-optimal B0 
homogeneity, causing line broadening, will lead to signal overlap. The presence of polyamine 
signals between these two metabolite signals further complicates their separation. This 
potential overlap led to the introduction of the signal ratio of choline plus creatine divided 
by citrate [(Cho+Cr)/Cit] (4,6) and its inverted counterpart (citrate over choline plus creatine 
ratio (5)) as a marker for prostate cancer. 
In this paper the major variables that can influence the (Cho+Cr)/Cit ratio are discussed. 
An overview of the main metabolites detectable in the commonly obtained MR spectra of 
the prostate, their function and the acquisition parameters that influence their appearance 
in the spectrum will be provided. These metabolites form the basis for the (Cho+Cr)/Cit 
ratio, of which the intensity not only depends on the underlying physiology, metabolism and 
anatomy, but also on the acquisition parameters. This latter aspect is particularly relevant 
for the citrate and polyamine signals. 
Although 1H MRSI has great potential in prostate cancer management, its use in routine 
clinical practice is limited. A major hurdle towards clinical use is that several acquisition 
and processing steps still rely on manual procedures, in particular post-processing of the 
data, including quality control, and displaying easily visualized and interpretable results 
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(7). As is the case for DWI and DCE-MRI of the prostate, a more widespread consensus in 
the acquisition and fitting of data would also promote clinical translation. A generalized 
classification scheme for prostate MR spectroscopy to assist in prostate cancer management 
is not available. The second part of this article discusses the use of a protocol dependent 
classification scheme that could increase the clinical usability of the metabolite ratio for 
prostate cancer management. 
Prostate metabolites
The main metabolite signals in commonly obtained 1H MRSI spectra of the prostate are 
choline, creatine, polyamines and citrate (Figure 3.1). 
Choline
Different compounds containing a choline moiety can contribute to the main peak at 
about 3.2 ppm in in vivo 1H MR spectra. These are free choline, glycerophosphocholine and 
phosphocholine, but also contributions from protons in taurine, ethanolamines and myo-
inositol may be present at this spectral position (8). As a convenient shorthand we refer 
to this composite resonance as the “choline” signal. Choline-containing metabolites are 
precursors and breakdown products of the phospholipid phosphatidylcholine, a major cell 
membrane compound (9). In prostate cancer cell lines an increase in choline is observed, due 
to an altered phospholipid metabolism (10). This alteration is probably due to an increased 
expression and activity of choline-kinase, a higher rate of choline transport and an increased 
phospholipase activity (9,10).  
The choline moiety has nine chemically equivalent protons of three methyl groups resonating 
as a singlet around 3.19 ppm and two methylene groups, resulting in two multiplets at 4.05 
Figure 3.1.  1H MR spectrum of the peripheral zone of the prostate of a healthy male containing signals 
 of choline (Cho), spermine (Spm), creatine (Cr) and citrate (Cit). The spectrum is acquired at 
 3 T using a PRESS sequence with a TE of 145 ms and MEGA pulses for water and lipid 
 suppression.
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and 3.50 ppm (11). As the intensity of these multiplets is very low in in vivo MR spectra of 
the prostate it is common to only evaluate the nine-proton singlet at 3.19 ppm. Estimates 
of the T1 and T2 relaxation times of the choline methyl protons (Table 3.1) are valuable to 
determine the effect of the chosen TE and TR on the choline signal intensity. 
T1 T2
1.5 T 3 T 1.5 T 3 T
Heerschap et al. 
1997 (6)
Choline 0.84±0.09 s 0.23 ±0.06 s
Creatine 0.86 ±0.1 s 0.21±0.1 s
Citrate 0.34 ± 0.04 s
Heerschap et al. (62) Citrate 0.18± 0.1 s
Lowry et al. (45) Citrate 0.84 ± 0.08 s 0.14 ± 0.02 s (PZ)
0.12 ± 0.03 s (TZ)
Scheenen et al. (22) Choline 1.1 ± 0.4 s 0.22±0.09 s
Citrate 0.47 ± 0.14 s 0.17 ± 0.05 s
Chen et al. (63) Choline 0.96±0.25 s
Citrate 0.54±0.14 s
Creatine
Both creatine and phosphocreatine contribute to the methyl resonance observed at about 
3.0 ppm in 1H MRS of the prostate (referred to, in combination, as the creatine signal in 
this paper). Creatine plays a crucial role in the energy metabolism of tissues (12), as 
phosphocreatine acts as a spatial and temporal buffer to maintain constant adenosine 
triphosphate (ATP) levels in tissue through the creatine-kinase reaction. The stromal cells 
consist predominantly of smooth muscle cells (13), which are expected to contribute most 
to the creatine and phosphocreatine signals. 
Creatine has five non-exchanging protons: a methyl group resonating at 3.03 ppm and the 
methylene group at 3.93 ppm. The protons in each group are chemically equivalent and 
uncoupled, resulting in two singlets with a ratio of 3:2. The relaxation times of the methyl 
protons of creatine are given in Table 3.1. The concentration of creatine was estimated with 
in vivo MRS at 4.4 ±0.8 mM (6) and with ex vivo high-resolution magic angle spinning (HR-
MAS) spectroscopy as being between 7.6 ± 2.7 and 9.7 ± 4.4 mmol/kg for normal and cancer 
tissue (no significant differences) (14).
Table 3.1.  T1 and T2 relaxation times of the prostate metabolites choline, creatine and citrate. Unless 
 indicated, no distinction was made between the peripheral zone (PZ) and transition zone 
 (TZ).
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Citrate
The production and storage of citrate is one of the main functions of the prostate. Citrate is 
an intermediate in the tricarboxylic acid cycle (TCA cycle). In most organs citrate is quickly 
oxidized in the TCA cycle and is therefore only present in low concentrations. In contrast, 
prostate epithelial cells actively produce citrate and store it in the luminal space, where it 
is one of the main components of the prostatic fluid (15). Prostate tissue has high levels of 
zinc, which inhibits mitochondrial (m-)aconitase activity. This leads to the buildup of a high 
concentration of citrate (16). In prostate cancer a decrease in zinc levels is observed which 
leads to activation of m-aconitase and the consequential oxidation of citrate (16). At the 
same time, the morphology of the prostate gland changes, leading to a loss of luminal space, 
which might also cause a decrease in the observed (or total) citrate levels. 
Citrate contains two methylene groups that are magnetically equivalent (Figure 3.2A). The 
four protons of these groups form a strongly coupled AB spin system. The difference in 
chemical shifts (Δ), the midpoint of the chemical shifts (δ), and the scalar coupling (J) of this 
spin system depend on pH (17,18) and cation concentration (18) and are approximately 0.15 
ppm, 2.61 ppm, and 16.3Hz, respectively (Figure 3.2B). Because citrate is a strongly coupled 
spin system, its shape depends on inter-pulse timing, pulse shape, TE, and field strength (17-
23). In Table 3.1, the relaxation times for citrate at 1.5 and 3 T are given. The determination 
of the T2 relaxation time of citrate is less straightforward than for singlets. By increasing 
the TE in such an experiment, there is not just attenuation of the signal intensity due to T2 
relaxation, but also shape and intensity variation due to J-modulation. 
Figure 3.2.  A) Schematic chemical structure of citrate. B) The simulated spectral shape of citrate at 600 
 MHz. Indicated are the scalar coupling constant (J), the chemical shift difference (Δ) and the 
 midpoint of the chemical shifts of the second and third peak (δ). 
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In the first in vivo prostate 1H MRS studies at 1.5T, stimulated echo acquisition mode (STEAM) 
and point resolved spectroscopy (PRESS) techniques were used for volume localization 
(4,24). One advantage of the STEAM for these data is its ability to use a very short TE (at 
the expense of the general loss of half of the signal in a stimulated echo). In this way, the 
strongly coupled protons of citrate will have limited phase evolution, which will result in an 
almost completely in-phase citrate signal. Integration of the area of the citrate peak(s) will 
then result in maximal signal intensity. For the PRESS sequence generally longer TEs are 
used for prostate MRS and dispersive parts can be present in the spectrum that affect the 
peak area by cancellation with absorptive parts in simple integration. Several studies have 
been performed to determine the PRESS pulse timing with maximum absorptive signal at 
the central lines of the citrate signal. Van der Graaf et al. used a delay of 7.5 ms between 
excitation and the first refocusing pulse, and varied the TE. Their optimal TE was 130 ms at 
1.5 T (25). One sequence optimization procedure at 3 T led to an optimal TE of 75 ms (negative 
absorptive shape) and 145 ms (positive absorptive shape) with a delay of 25 ms between 
excitation and refocusing (22). However, other researchers found an optimal TE of 85 ms (26) 
and there are more possibilities that result in a favorable citrate signal (19). It is therefore 
not surprising that prostate MRSI acquisition software packages of three MR vendors at 3 T 
are equipped with quite different TEs, varying from 85 to 145 ms (27). The differences in the 
spectral shape of citrate in different pulse sequences will lead to variations in the integral 
of citrate signal at a constant citrate concentration. The influence of inter-pulse timing is 
also evident from matrix density simulations (19,22) illustrated in Figure 3.3, which shows 
simulated and in vivo spectra of one patient, using a PRESS sequence at 3 T with a TE of 145 
ms and a semi-LASER sequence (Localization by Adiabatic Selective Refocusing) at nearly 
the same TE of 144 ms (28). In the semi-LASER sequence the excitation pulse is followed by 
four adiabatic refocusing pulses. 
The optimal TR for citrate detection can be quite short, because of its relatively short T1 
(Table 3.1). It was calculated that the use of a TR of 750 ms, instead of 1500 ms, would 
lead to an increase in SNR per unit time of 17% for citrate and a decrease of 6% for choline 
for 3T data (22). When a weighted averaged acquisition scheme is used for MRSI, the use 
of a short TR allows for more averages in the centre of k-space in the same amount of 
measurement time. In this way, the acquisition of the phase encoding steps in k-space can 
be done following the shape of a Hanning filter. Apodization in k-spacewith a Hanning filter 
produces a point spread function with widened full-width-at-half-maximum, but strongly 
decreased signal contamination form more spatially distant signals (22). The effective voxel 
size increases, but extra-prostatic lipid signal contamination is strongly decreased.
In the physiological range of pH (6.8-7.4), variations in Δ of 3.2 Hz and variations in δ of 
0.025 ppm were observed using a 400MHz magnet (17). The changes in J are minimal in 
this pH range (17,18), but the concentrations of zinc, calcium and magnesium also influence 
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Figure 3.3.  A) The simulated spectral shape of citrate (Cit) using the PRESS sequence with an optimized 
 pulse timing (90˚ – 25ms – 180˚ – 72.5 ms – 180˚ - 47.5 ms – echo) at a TE of 145ms at 3T 
 (22). B) The simulated Cit shape using an optimized semi-LASER sequence at a TE of 144ms 
 (90˚ - 11 ms - 180˚ - 21 ms - 180˚ -  29 ms - 180˚ - 51 ms - 180˚ - 32 ms - echo) (28). C) T2 
 weighted image of the prostate of a 71 year old man with biopsy proven prostate cancer 
 (Gleason score 9). D) In vivo spectrum of the PRESS (TR=750 ms) of normal tissue and (E) 
 spectrum of corresponding region with the semi-LASER sequence (TR= 2070 ms). The region 
 is indicated in C with a blue circle. F) In vivo spectrum of tumor tissue (red circle in C) with 
 the PRESS. G, H and I) The corresponding fits of LCModel using the simulated citrate shape 
 of A and B show minimal residuals (J, K and L). Each spectrum is scaled to maximum 
 intensity. 
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the value of this coupling (18) which may have significant effects on the in vivo resonances. 
Figure 3.4 shows that small changes in Δ and J can have substantial influences on the 
spectral shape of citrate. Although in vitro a relation was found between the spectral shape 
of citrate and the ion concentration or pH, variations in the spectral citrate shape in vivo are 
difficult to relate to ion concentrations or pH, as these are hard to measure. For a good fitting, 
it is necessary to use a model signal that is based on J, δ, and Δ values that closely resemble 
those present in vivo. At our institution we use J=-16.2, δ=2.625, Δ=0.154 as this led to the 
smallest residuals for the citrate resonance using LCModel fitting (unpublished data). Using 
these parameters, the in vivo citrate shape closely resembles the simulated spectrum (see 
Figure 3.3). This was the case for both the PRESS spectrum and that obtained with the 
semi-LASER sequence, indicating that these values are a good approximation of the in vivo 
coupling parameters.
The side lobes of the citrate resonance extend to the 3 ppm region and contain a mixture of 
absorption and dispersion shapes at a TE of 145 ms at 3 T (22), which can result in a negative 
effect on the total intensity in this region. When a model signal is used for the fitting, this 
Figure 3.4.  Simulations with NMRSIM (part of Topspin, Bruker BioSpin Corporation, Billerica, MA) show 
 the influence of small differences in the scalar coupling and chemical shifts on the citrate 
 shape at a field strength of 3T with an optimized pulse sequence (TE 145 ms) (22). Line 
 broadening of 1 Hz (black spectra) and 4 Hz (red spectra) were used. Δ was 2.6105 ppm for 
 all spectra. For A-D, Δ was kept constant at 0.151 and the scalar coupling was varied 
 between 15.3Hz and 16.8Hz. For E-H, J was kept constant at 16.3 Hz and Δ was varied 
 between 0.141ppm and 0.156ppm. The amplitudes of all spectra are scaled to a reference 
 signal.  
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effect can be taken into account; however, when simple peak integration is used, one cannot 
fully compensate for this effect. Negative components of the citrate signal will be excluded 
from citrate quantification and one might need to revert to severe baseline corrections to 
prevent an influence on other metabolite signals.
The RF pulses that are used to suppress the large lipid and water signals may adversely 
affect the citrate signals. Often dual frequency-selective pulses are used to suppress 
both these signals simultaneously, mainly by MEGA (Mescher-Garwood (29)) or double 
BASING (Band Selective Inversion with Gradient Dephasing (30,31)) pulses. These pulses 
selectively invert the lipid and water resonances and are surrounded by crusher gradients. 
Their bandwidth and position in the frequency domain should be sufficient to invert all lipid 
signals, but distant enough from the chemical shift of citrate. When the bandwidth of the 
lipid inversion pulse is too broad, this will cause a decreased signal intensity of citrate (see 
Figure 3.5). As a consequence, healthy spectra may get a ‘cancerous’ profile. Therefore, a 
Figure 3.5.  A-C) In vivo prostate spectra of a healthy volunteer at 3T using PRESS with MEGA pulses for 
 water and lipid suppression. The spectra are from the same location, but the width of the 
 frequency selective inversion bands was 1.40 ppm in A, 1.45 ppm in B and 1.55 ppm in C, 
 leading to a decrease in the citrate (Cit) intensity, while the intensities of choline (Cho), 
 spermine (Spm) and creatine (Cr) remain unchanged. As a consequence the choline plus 
 spermine plus creatine to citrate [(Cho+Spm+Cr)/Cit] ratio increases influencing the 
 classification of the spectrum. D-F) shows the same effect in a phantom containing Cit, Cho, 
 Spm and Cr using MEGA pulses with a width of the inversion bands of 1.35 ppm in D, 1.45 ppm 
 in E and 1.55 ppm in F. G) the shape of the MEGA pulse in the frequency domain. Note: these 
 (Cho+Spm+Cr)/Cit ratios are determined with LCModel. In line with previously published 
 metabolite ratios, the citrate intensity in LCModel was scaled to the number of protons in 
 citrate, rather than to the magnitude integral at this TE, which is smaller due to cancellation 
 of signal intensity by the strongly coupled pattern.
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good adjustment of the dual frequency pulses is essential for obtaining consistent results. 
Spectrally selective refocusing pulses may be used instead of signal suppression pulses, 
that prevent refocusing of lipids by simultaneous volume and frequency selection (32,33). 
Care should be taken that these pulses fully excite or refocus the citrate spins and leave the 
lipid signals untouched. 
For proper selective suppression or spectral excitation, the homogeneity of the B0 field 
is critical. Poor homogeneity will not only negatively affect spectral quality as it causes 
broadening of the spectral lines; it will also decrease the effectiveness of frequency selective 
pulses. Broadened or shifted fat and water signals can suffer from diminished suppression 
and components of these signals may overlap with the resonances of interest. In addition, in 
the case of shifted or broadened spectral lines of citrate, the metabolite can be influenced by 
the frequency selective pulses for lipid and water suppression leading to decreased citrate 
intensities, comparable to the effect shown in Figure 3.5. 
The dependence of the citrate signals on inter-pulse timing can also be exploited for spectral 
editing. By varying this timing (at a constant TE) in such a way that citrate is inverted in 
one measurement and in phase in the next measurement, uncoupled resonances can be 
removed from the spectrum by subtraction (34,35). In this way, rapid citrate imaging without 
lipid suppression is possible. 
 
Polyamines / Spermine
The tissue concentration of polyamines in the prostate is relatively high. As spermine is 
the dominant polyamine in the prostate, we will focus on this compound. Polyamines are 
stored, like citrate, in the luminal space and a very strong correlation between the citrate and 
spermine concentration is reported for prostatic fluid specimens (36). A hypothesis for the 
strong correlation (r=0.94) is the formation of complexes between citrate and spermine since 
citrate is negatively charged, while spermine is positively charged. In this way ionic neutrality 
can be achieved (36). Polyamines play a role in prostatic growth and differentiation (37). A 
decrease in spermine has been suggested as a marker for prostatic malignancy (37,38). In 
prostate cancer a decrease in spermine or polyamine levels is observed compared to benign 
tissue using MR spectroscopy (38) and high resolution magic angle spinning experiments 
(14). The incorporation of polyamine levels measured with MR spectroscopy to improve 
detection of prostate cancer has been proposed and yielded an increased sensitivity at the 
same specificity (39). 
Spermine is a coupled spin system and contains, besides its amine groups, ten methylene 
groups. These methylene protons consist of symmetrical pairs giving a total of four protons 
that resonate approximately at 1.81 ppm with further groups of four at 2.11 ppm,  3.13 
ppm, 3.12 ppm and 3.18 ppm (40). These chemical shifts are pH dependent (41) and these 
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quoted chemical shifts were measured at pH 7 (40). At a higher pH the amine groups are 
more protonated and therefore the chemical shifts are more downfield (41). Protons near 
a nitrogen atom show the largest pH-dependence. Spermine proton chemical shifts are 
also sensitive to temperature differences. We did temperature measurements at 500 MHz 
with a spermine compound dissolved in water. These measurements showed that protons 
near a nitrogen atom had the highest temperature dependence (unpublished data). For that 
reason, when one wants to perform a phantom measurement to determine the shape of 
spermine (with a certain sequence), the phantom should be measured at body temperature 
and have a pH in the physiological range. Local chemical shift correction to improve the 
separation between choline and spermine is hindered by the dependence of the chemical 
shift of spermine on the environment. Also, usually no water reference measurement is done 
that could be used for this purpose. The metabolites in the prostate spectrum are unsuitable 
for this purpose, as the chemical shift of citrate is environment-dependent and choline is not 
always well separable from spermine. 
As with citrate, TE and inter-pulse timing influence the spectral shape of spermine and 
leading to dispersive components in the resonances. If dispersive parts are present in the 
3.1-ppm region, this can negatively affect the apparent intensity of choline and/or creatine 
resonances. Furthermore, BASING and MEGA pulses that are used for simultaneous 
water and lipid suppression, invert the 2.1- and 1.8-ppm resonances of spermine (42). 
Without these pulses and crushers, the 2.1- and 1.8-ppm resonances could be helpful for 
decomposition of spermine from the 3.1-ppm region. Figure 3.6 shows the influence of the 
MEGA pulses on the spectral shape of spermine. As expected, the resonances at 1.8 and 
2.1 ppm are (almost) completely crushed by the combination of MEGA pulses and crushing 
gradients. The resonances at 1.8 and 2.1 ppm are scalar coupled to the resonances in the 
Figure 3.6. The spectral shape of spermine measured in a phantom at 3T using PRESS with a TE of 145 
 ms (90˚ – 25ms – 180˚ – 72.5 ms – 180˚ - 45.5 ms – echo). The phantom contained 18 mM 
 spermine, 9 mM ZnCl, 15 mM MgCl2, 18 mM CaCl2, and 60 mM of KCl (41,71). The pH was 
 adjusted to 6.8 and the temperature was 310 K. A) The spermine spectral shape without the 
 use of MEGA pulses. B) The spermine spectral shape when two MEGA pulses for combined 
 water and lipid suppression are used surrounding the second refocusing pulse and in C) the 
 spectral shape when two MEGA pulses are used surrounding the first refocusing pulse. 
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3.1 ppm region; therefore, the selective refocusing of these upfield groups refocuses also 
the J-evolution of the downfield protons. This is evident from the difference in spectral 
shape and intensity of spermine in Figure 3.6B and 3.6C, where a different timing for the 
MEGA pulses is used. These measured spermine shapes can be used as prior knowledge 
for spectral fitting of the metabolites (42). Figure 3.7 demonstrates how the spermine shape 
can affect the choline and creatine region, showing two spectra from the same location in 
one volunteer that are measured with a different MEGA pulse timing, resulting in different 
(Cho+(Spm+)Cr)/Cit ratios. 
T1 and T2 values of spermine reported in the literature are obtained in vitro and the T2 values 
were rather short and dependent on the presence of ions and proteins (41). No in vivo data of 
relaxation times of spermine spins is available yet. 
Figure 3.7. A) Spectra of a healthy volunteer of the same voxel in two measurements, containing 
 resonances of choline (Cho), spermine (Spm), creatine (Cr) and citrate (Cit). The difference 
 between the measurements is the timing of the MEGA pulses. In the black spectrum, 
 the MEGA pulses surround the second refocusing pulse (as in Fig. 3.5B) and in the red 
 spectrum the MEGA pulses surround the first refocusing pulse (as in Fig. 3.5C). Two different 
 LCModel basis sets were used for the fitting (to take the differences in spermine shapes into 
 account) and the (Cho+Spm+Cr)/Cit amplitude ratios were: 0.35 (black and fit displayed in 
 B) and 0.46 (red and fit displayed in C). This demonstrates the influence of spectral spermine 
 shape on the (Cho+Spm+Cr)/Cit ratio. 
Evaluation of the metabolite ratio
Prostate 1H MRSI spectra can be evaluated qualitatively or (semi-)quantitatively. Qualitative 
guidelines are based on visual inspection of the height of choline compared to the citrate 
height (43,44). When using this qualitative approach of comparing peak heights in a 
prospective multi-centre setting, no additional value for 1H MRSI was found compared to the 
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use of MRI alone for the localization of prostate cancer in the peripheral zone (45). In this 
study, data homogeneity across different centers was not validated with e.g. mean values of 
non-cancer tissue across centers. This, together with the lack of a clear definition of tumor 
focus size that needed to be localized, could explain the disappointing results. 
A more quantitative aproach is determination of metabolite concentrations in prostate 
spectra with the help of a reference compound. If the tissue water concentration is known 
in the volume of interest and the individual metabolites are fitted reliably, water can be 
used as an internal reference to obtain absolute prostate metabolite concentrations (e.g. 
(6,46)). This requires additional time for a water reference measurement, which is often not 
available. More practical, and sufficient for diagnostic purposes, is the use of the (Cho+Cr)/
Cit ratio for classification. The usability of this ratio for prostate cancer localization was 
demonstrated in a prospective multi-centre study, where an area under the receiver operating 
characteristic curve of 0.88 was obtained for discriminating normal peripheral zone tissue 
from cancer (47). Classification thresholds for the (Cho+Cr)/Cit ratio are needed to apply MR 
spectroscopy for prostate disease in clinical routine.
Establishing the ratio of choline (plus spermine) plus 
creatine over citrate ratio
The simplest method of calculating the (Cho+Cr)/Cit ratio is to use integration techniques 
and calculate a ratio based on these values (integral values). This has been used by many 
researchers to calculate the ratio (Table 3.2). But as discussed above, strong coupling 
effects and a long echo time can produce a spectral shape of citrate that has an integral 
close to zero and small differences in citrate intensity will induce very variable ratios. One 
way to circumvent this problem is by fitting the metabolites to a model signal. Model signals 
can be measured with phantom solutions (e.g.(42)). Alternatively, they can be simulated, 
when the chemical shifts and J-coupling constants are known for the metabolites of interest 
(e.g.(42,48)). There are several software packages available that can be used to make model 
signals, e.g. NMRSIM (part of Topspin, Bruker BioSpin Corporation, Billerica, MA), GAMMA 
(49) and its successor VeSPA (http://scion.duhs.duke.edu/vespa/). The model signals can 
be used to obtain fits of the metabolites in the time (50,51) or frequency domain (52). The 
output is typically a relative metabolite concentration value incorporating the amount of 
protons of the metabolite. These relative concentrations depend on the goodness of the fit 
and correlation between fits; for overlapping metabolites overestimation of one metabolite 
at the cost of underestimation of another, will result in a ratio that is unrepresentative for the 
tissue if the metabolites have a different amount of protons. So if the metabolites are fitted 
individually with such a quantification algorithm, the concentrations must be reconverted to 
their relative spectral amplitude prior to summation and division in the ratio. This procedure 
removes individual information gained from each metabolite but improves the reliability of 
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the ratio. For spectral patterns dominated by absorption components, this amplitude ratio 
will give comparable results as the integral ratio. But in contrast to the integral ratio, the 
amplitude ratio is less sensitive to the dispersive parts of citrate. The amplitude ratio gave 
good results for discrimination between different prostate tissues in a 3T study, where the 
spectral citrate shape had non-negligible dispersive parts (47). 
The fit of the individual metabolites has been used to derive the choline over citrate plus 
spermine ratio [Cho/(Cit+Spm)], a ratio that takes the counteracting effects of the increase in 
choline and decrease in citrate and spermine in prostate cancer into account (42). However, 
due to the inherent uncertainty in individual metabolite quantification (53), we recommend 
to use a (Cho+Cr)/Cit ratio rather than a simpler choline/citrate (or Cho/(Cit+Spm)) ratio. In 
most studies, spermine is not fitted individually (e.g.(45,53-56)), and spermine resonances 
are included in the creatine and choline fits (39). The ratio should therefore be seen as the 
choline plus spermine plus creatine over citrate ratio. 
Classification thresholds for choline (plus spermine) plus 
creatine over citrate ratio
In the previous sections, the acquisition parameters that influence the prostate metabolite 
signals, and thus consequently the (Cho+(Spm+)Cr)/Cit ratio, were discussed. In principle it 
is possible to correct for T1, T2 relaxation and J-modulations, and obtain a ‘normalized’ ratio 
that is acquisition independent. However, this requires knowledge of their precise values, 
which are not available (current reports show quite some variation in T1, T2), and these 
values may also vary for different tissue morphology (e.g. cancer, benign disease and normal 
prostate). Moreover, fitting of the individual metabolite signals is also necessary, which can 
be challenging because of overlap between choline, creatine and spermine signals. For that 
reason, we cannot work with a ‘normalized’ ratio and the (Cho+Cr)/Cit ratio thus has to be 
established per institution or per protocol. 
The mean (Cho+Cr)/Cit plus two or three times the standard deviation of normal tissue 
was used as a cut off value to classify voxels as ‘cancerous’ (5,57-59). The use of a 5 point 
classification scale based on the mean and standard deviation of the (Cho+Cr)/Cit ratio of 
normal prostate tissue has been proposed (44). Because the (Cho+Cr)/Cit ratio is higher 
for normal transition zone tissue than for peripheral zone tissue, the cut off values vary for 
the two tissues. Table 3.2 and 3.3 provide an overview of reported mean (Cho+Cr)/Cit ratios 
for normal peripheral zone tissue at 1.5 and 3 T. For 1.5 T, the used TEs in these studies are 
quite similar (120 – 130 ms) and often the same platform and post processing methods are 
used, but still there is quite some variation in the reported (Cho+Cr)/Cit ratios. At 3 T, there 
are considerable differences between prostate spectroscopy packages of the vendors, with 
TEs varying from 85 to 145 ms and TRs from 750 to 1300 ms (27). At 7 T, optimal acquisition 
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Average (Cho+Cr)/Cit 
ratio ± stand. dev. Vendor Post processing method TE/TR (ms)
Weis et al. 2011 (72) 0.40 ± 0.09 (PZ)*
0.53 ± 0.12 (TZ)* 
Philips LCModel fitting 140 / 1500
Scheenen et al 2007 (54) 0.22 ± 0.12 (PZ)
0.34 ± 0.14 (TZ) 
Siemens Model spectra time domain 
using PRISMA
145 / 750
Selnaes et al 2012 (48) 0.38 (0.35-0.42)** (PZ) Siemens Model spectra time domain 
using PRISMA
145 / 750
Average (Cho+Cr)/Cit 
ratio ± stand. dev. Vendor Post processing method TE/TR (ms)
Kurhanewicz et al. 1996 
(5)
0.54 ± 0.11 (PZ)
0.83 ± 0.34 (TZ)
GE Integration of designated 
frequency ranges
130 / 1000
Males et al. 2000 (30) 0.22 ± 0.13 (PZ)*
0.31 ± 0.17 (PZ)
GE Integration of designated 
frequency ranges
130 / 1000
Mueller Lisse et al. 2001 
(64)
0.24 ± 0.13 (PZ) GE Integration of designated 
frequency ranges
130 / 1000
Shukla-Dave et al. 2007 
(39)
0.59 ± 0.03 (PZ) GE Integration of designated 
frequency ranges
130/1000
Mazaheri et al. 2008 (65) 0.73 ± 0.18 (PZ) GE Integration of designated 
frequency ranges
130/1000
García-Martín et al. 2011 
(42)
0.24 ± 0.06 (PZ) GE LCModel fitting (50) 130/1000
Weis et al. 2009 (66) 0.50 ± 0.16 Philips AMARES fitting in the MRUI 
software package (48)
130/1200
Kaji et al. 2002 (67) 0.58 ± 0.38 (PZ)
0.72 ± 0.51 (TZ)
Siemens Integrals of Lorentzian 
lineshapes using Luise (67)
135/1500
Dorsten et al. (68) 0.38 ± 0.15 (PZ)
0.43 ± 0.16 (TZ)
Siemens AMARES fitting in the MRUI 
software package (48)
120/1200
Scheenen et al. 2011 (51) 0.28 (0.21–0.37) (PZ)**
0.36 (0.28–0.44) (TZ)
Siemens Model spectra time domain 
using PRISMA
120 / 650
Table 3.2.  Average (Cho+Cr)/Cit ratios for benign tissue (either in the peripheral zone (PZ), transition 
 zone (TZ) or combined) at 1.5 T from different studies using different post processing meth- 
 ods.
 * Two techniques for water suppression were used. No statistical difference in the (Cho+Cr)/ 
 Cit ratio was found. 
 ** No average and standard deviation were provided, but the median and 25th and 75th 
 percentile. 
Table 3.3.  Average (Cho+Cr)/Cit ratios for peripheral zone (PZ) and transition zone (TZ) tissue at 3 T 
 from three studies using different post processing methods
 * Measured in males older than 51 years of age
 ** In brackets the confidence interval is given. 
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protocols still need to be established (60). The studies reporting (Cho+Cr)/Cit values for 
3T-spectra are still limited (Table 3.3), but it can be expected that the metabolite ratios for 
normal tissue at 3 T will be more variable among studies and quite different (Cho+Cr)/Cit 
values would be obtained for the same patient measured on systems of different vendors. 
The dependency on acquisition and post-processing protocols asks for assessment of the 
mean and standard deviation of normal tissue per institution or per used protocol. 
The derived classification thresholds are not necessarily institution-dependent. If the 
same acquisition protocol and post-processing method are used at different institutions, 
the (Cho+(Spm+)Cr)/Cit ratio can be compared between these institutions. Previously, no 
significant differences in the (Cho+Cr)/Cit amplitude ratio were found of any of the benign 
prostate tissues between patients among different institutions (47). Furthermore, the 
amplitude ratio gave good reproducibility in repeated measurements of the same subjects 
(61). 
Standardized threshold approach
A more advanced classification strategy is the use of the standardized threshold approach, 
which was introduced by Jung et al (62) to give more weight to the increase in choline and 
decrease in polyamines observed in prostate cancer. The standardized threshold approach 
was developed for use in the peripheral zone (62), but later expanded for the transition zone 
(63). In this approach, an initial score (from 1 to 5) is given to each spectrum (Table 3.4 and 
3.5) based on the mean (Cho+Cr)/Cit ratio of normal tissue and its standard deviation. . The 
initial score is adapted for certain choline over creatine (Cho/Cr) values. The fit for the Cho/
Cr ratio is simplified in cancer tissue, due to the decrease of polyamine resonances, and 
might therefore be more reliable in tumor voxels than in normal voxels. For voxels with an 
initial score of 2 or 3, the initial score is increased to 4 if the Cho/Cr ratio is larger than or 
equal to 2. An initial score of 4 or 5 is decreased to 3 or 4, respectively, if the Cho/Cr ratio is 
smaller than 2 (Table 3.4 and 3.5). With this reproducible approach (61), good accuracy (72-
87 %) for the differentiation of benign and malignant voxels was obtained in the peripheral 
zone (62) and transition zone (63). The cut off value for the Cho/Cr ratio was optimized 
to develop the standardized threshold approach as an aggressiveness assessment (55). 
Using this assessment it was found that only 10% of the highly aggressive tumors would be 
misclassified as less aggressive (55). The cut off values provided in Table 3.4 and 3.5 can 
only be used for spectra acquired with the same sequence, at the same field strength and 
similar post-processing (Note: no fitting of separate polyamines). If one wants to use the 
standardized threshold approach with other settings, one should first establish the correct 
cut off values. 
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Table 3.5.  Example of cut off values of the standardized threshold approach used at 3 T (55). The Cho+Cr/Cit 
 cut off values are based on the mean and standard deviation of normal tissue values 
 published in (54).  
Five-point standardized scoring system 
Score and Score definition Peripheral Zone 
(Cho+Cr)/Cit ratio
Central Gland (Cho+Cr)/
Cit ratio
Cho/Cr ratio adjustment
1: Definitely benign tissue ≤0.34 ≤0.48 - If Cho/Cr ratio ≥2, 
then: adjust  3 and 2 
into 4. 
- If Cho/Cr ratio < 2, 
then: adjust 5 into 4 and 
4 into 3.
2: Probably benign tissue 0.34<CC/C≤0.46 0.48<CC/C≤0.62
3: Possibly malignant tissue 0.46<CC/C≤0.58 0.62<CC/C≤0.76
4: Probably malignant tissue 0.58<CC/C≤0.70 0.76<CC/C≤0.90
5: Definitely malignant tissue >0.70 >0.90
CC/C = choline plus creatine to citrate
Concluding remarks
We have discussed different aspects of the acquisition and post-processing that influence 
the (Cho+Cr)/Cit ratio. In principle this ratio could be vendor-independent with similar 
acquisition protocols and post processing, which would be convenient for the common use 
of classification thresholds of the ratio for disease features. Although this may be the case 
for 1.5 T to some extent, it is not for 3T systems. Thus in all clinical applications, institution 
or protocol dependent thresholds have to be established. To promote clinical usability of 
prostate MR spectroscopic imaging it would be desirable if consensus could be reached on 
field strength dependent common acquisition and postprocessing protocols. 
Five-point standardized scoring system 
Score and Score definition Peripheral Zone 
(Cho+Cr)/Cit ratio
Central Gland 
(Cho+Cr)/Cit ratio
Cho/Cr ratio adjustment
1: Definitely benign tissue ≤0.44 ≤0.52 - If Cho/Cr ratio ≥2, 
then: adjust 3 and 2 
into 4. 
- If Cho/Cr ratio < 2, 
then: adjust 5 into 4 and 
4 into 3.
2: Probably benign tissue 0.44<CC/C≤0.58 0.52<CC/C≤0.66
3: Possibly malignant tissue 0.58<CC/C≤0.72 0.66<CC/C≤0.80
4: Probably malignant tissue 0.72<CC/C≤0.86 0.80<CC/C≤0.94
5: Definitely malignant tissue >0.86 >0.94
CC/C = choline plus creatine to citrate
Table 3.4.  Example of cut off values of the standardized threshold approach used at 1.5 T (73) (TE/TR 
 120/650 ms). The ratio is obtained from integrals of Gaussian lineshapes. 
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This chapter is based on the publication:
In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic 
imaging at 3T with an endorectal coil
T. Kobus, T. Hambrock, C.A. Hulsbergen-van de Kaa, A.J. Wright, J.O. Barentsz, A. Heerschap 
and T.W.J. Scheenen
European Urology, 2011 Nov;60(5):1074-80.
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Introduction
Prostate cancer is the most frequently diagnosed non-cutaneous cancer in European men 
and accounted for 9.3% of cancer-related deaths in men in 2008 (1). A large European 
study (2) showed that screening for prostate cancer by means of prostate-specific antigen 
(PSA) levels will result in a mortality reduction of 20% at the cost of overdiagnosis of many 
indolent cancers. If unnecessary side-effects due to overtreatment of indolent tumors are 
to be prevented, while at the same time all aggressive tumors are to be treated, accurate 
discrimination between indolent and life-threatening cancers is essential. 
Generally, transrectal ultrasound (TRUS)-guided biopsies are performed to confirm the 
presence of prostate cancer and to determine the Gleason score of the tumor. However, 
the multifocal nature and heterogeneity of these tumors cause sampling errors and may 
lead to underestimation of their aggressiveness. Several studies demonstrate discrepancies 
between the Gleason score identified in biopsies and the subsequent radical prostatectomy 
specimens (3,4). For optimal diagnosis the most aggressive tumor focus should be identified.
Proton magnetic resonance (MR) spectroscopic imaging (1H MRSI) provides spatial mapping 
of the tissue levels of the metabolites citrate (Cit), choline (Cho) and creatine (Cr) in the 
whole prostate gland (5,6). Prostate cancer tissue is characterized by lower Cit levels and/or 
higher Cho levels compared to normal tissue (7), resulting in the ratio of choline plus creatine 
to citrate [(Cho+Cr)/Cit] as a marker for prostate cancer (7,8). MR imaging (MRI) and 1H MRSI 
have detected high grade tumors in patients with elevated PSA with high sensitivity (9). 
Other studies found a correlation (10) and a trend (11) between the Gleason score and the 
(Cho+Cr)/Cit ratio at 1.5 T with the use of an endorectal coil. No relation with aggressiveness 
was found at 1.5 T without the use of an endorectal coil (12). At 3 T, no relation was  found 
using just body-array coils (6). The use of an endorectal coil increases the signal-to-noise 
ratio and might provide enough sensitivity at 3 T to classify tumor aggressiveness. 
Incorporation of the ratio of choline to creatine (Cho/Cr) is interesting since Cho supposedly 
increases in malignant tissue due to altered phospholipid metabolism (13) and increased 
Cho/Cr ratios have been used in standardized scoring systems for 1H MRSI of the prostate 
(14,15). High-resolution ex vivo magic angle spinning nuclear MR of prostate biopsies 
showed a significant correlation of the Gleason score to the Cho/Cr ratio, among other ratios 
(16). These studies suggest that the Cho/Cr ratio has additional potential to classify tumor 
aggressiveness in vivo. 
The purpose of this study was to validate the performance of 1H MRSI of the prostate at 3 
T with an endorectal coil in assessing tumor aggressiveness based on the (Cho+Cr)/Cit and 
Cho/Cr ratios, using the Gleason score from histopathology of the radical prostatectomy 
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specimen as the gold standard. 
Materials and methods
Subjects
This study was approved by the institutional ethics review board, and the need for informed 
consent was waived for the retrospective study. One hundred eight consecutive patients 
with biopsy-proven prostate cancer had a 3-T MR exam between October 2006 and 
February 2009 as well as a radical prostatectomy between October 2006 and April 2009. 
Of these patients, 72 had a 1H MRSI exam and were retrospectively selected for this study. 
Patients were excluded if they were not examined with an endorectal coil (n=4), had prior 
neoadjuvant therapy (n=9), had no tumor foci with a volume of at least 0.5 cm3 according to 
the histopathologic analysis (n=14), or had no reliable histopathology (n=2). 
Magnetic resonance data acquisition
All MR exams were performed on a 3T MR system (Magnetom Trio, Siemens, Erlangen, 
Germany). An endorectal surface coil (Medrad, Pittsburgh, PA, USA) was combined with body 
array coils for signal reception. In all patients, an intramuscular injection of 1 mg glucagon 
(GlucaGen, Novo Nordisk, Gentofte, Denmark) and an injection of 20 mg butylscopolamine 
bromide (Buscopan, Boehringer Ingelheim, Ingelheim, Germany) were used to suppress 
peristalsis. 
Fast-gradient echo sequences were used to check the position of the coils. High-spatial 
resolution T2-weighted images were made in three directions. A prostate specific MRSI 
sequence was used (17), including suppression of water and fat signals and an adapted 
sampling scheme (5,18). The actual volume of the spherical voxels was 0.37 or 0.64 cm3 (5).
Histopathologic analysis
All radical prostatectomy  specimens were uniformly processed and completely embedded 
according to a clinical protocol (19). After formalin fixation and inking of the surface, the 
prostate specimen was serially sectioned at 4 mm intervals, perpendicular to the dorsal-
rectal surface, and all slices were macroscopically photographed. One urological pathologist 
(C.A.H.K.) evaluated all radical prostatectomy  specimens and outlined for each slice the 
location of the tumor(s) on the photographs. Each tumor focus was graded according to the 
2005 International Society of Urological Pathology Modified Gleason Grading System (20), 
and each patient was staged following the 2002 TNM classification (21). 
The primary, secondary and tertiary Gleason grades were used for a qualitative grading of 
the tumor aggressiveness. Tumors were classified as low grade if they consisted only of 
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Figure 4.1. MRI and MRSI of a 65-year-old patient with prostate cancer (PSA level 5.3 ng/ml, Gleason 
 Score 4+5) A) T2-weighted MR image of the prostate with a tumor in the left peripheral zone. 
 For tumor localization the histopathology (B) is used as the gold standard. The spectroscopy 
 grid is displayed on top of the T2-weighted image in C. In the right and left peripheral zone 
 a non-cancer voxel and cancer voxel, respectively, are indicated, obtained with a echo time of 
 145ms and a repetition time of 750ms. D shows a spectrum of non cancer tissue, while in F 
 the spectrum of a cancer voxel is shown with deviating signal intensities for the different 
 metabolites. The calculated (Cho+Cr)/Cit ratio and the Cho/Cr ratio are indicated in the 
 spectra of both tissues. The metabolite map in E shows the (Cho+Cr)/Cit distribution over the 
 prostate. 
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No of patients 43
PSA level, mean, ng/ml (range) 8.33 (2.08 - 40.96)
Age, mean, yr (range) 61 (42-70)
Clinical stage 
   T2 19
   T3 23
   T4 1
Gleason score - Peripheral zone: No of tumors:
   3+2 low 2
   3+3 low 10
   3+3+4 intermediate 1
   3+4 intermediate 10
   3+4+5 high 3
   4+3 high 9
   4+3+5 high 2
   4+4 high 1
   4+5 high 2
Gleason Score - Central gland:
   2+3 low 2
   3+2 low 3
   3+2+4 intermediate 1
   2+4+5 high 1
   4+3 high 1
   4+3+5 high 3
Gleason score - Both zones:
   4+3 high 1
   4+4 high 1
Table 4.1:  Patient and tumor characteristics. 
 *The tumors are classified according to their aggressiveness 
 There were 17 low grade, 12 intermediate grade and 24 high grade tumors. 
Voxel selection and statistical analysis
One radiologist (T.H.), blinded to the spectra, used the results of the histopathologic analysis 
to assign all spectroscopic voxels containing tumor tissue on high-resolution T2-weighted 
images with the voxel matrix of the spectroscopic exam projected over these images 
grades 2 and/or 3; as intermediate grade, with a secondary or tertiary grade of 4 but no 5 
component; or as high grade with 4 as primary and/or 5 as a primary/secondary or tertiary 
grade (Table 4.1). 
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(Figure 4.1C). Only clinically significant tumors with a minimal size of 0.5 cm3 (22,23) on 
the histopathologic analysis were included. Figure 4.1 shows an example of a T2-weighted 
image and corresponding histopathology. 
The signals of interest were fitted with a prototype software package (metabolite report, 
Siemens), and the (Cho+Cr)/Cit and Cho/Cr ratios were calculated automatically. Two 
spectroscopists independently (T.K. and T.W.J.S.) inspected the quality of the automated fit 
for sufficient signal-to-noise ratio, the absence of lipid signals, and the absence of baseline 
distortions. Only voxels that were approved by both spectroscopists were included in the 
remainder of the study. 
For every tumor, the voxel with the highest (Cho+Cr)/Cit ratio and the voxel with the highest 
Cho/Cr ratio were determined. The highest (Cho+Cr)/Cit and Cho/Cr values of all data from 
each aggressiveness class were checked for normality and compared with each other 
using a Kruskal-Wallis test. The Pearson correlation coefficient was used to determine 
the correlation between the two ratios. To test the correlation between the ratios and the 
different aggressiveness classes the Kendall τ rank correlation coefficient was determined. 
To enable incorporation of both metabolite ratios in discrimination of aggressiveness classes, 
the standardized threshold approach (14,15) was used. The conventional standardized 
threshold approach uses an initial malignancy rating (ranging from 1 [definitely benign] to 5 
[definitely malignant]) based upon the mean and standard deviation (SD) of the (Cho+Cr)/Cit 
ratio of noncancereous tissue (distinction is made between peripheral zone (PZ) and central 
gland (CG)) with an adjustment to the initial rating based upon the Cho/Cr ratio (Table 4.2) 
(15). 
This malignancy rating was determined for all accepted voxels in each tumor using the mean 
(Cho+Cr)/Cit ratios and SDs of noncancereous tissue described earlier (6). To optimize the 
Table 4.2.  Conventional standardized threshold approach definitions
Five-point standardized scoring system 
Score and Score definition Peripheral Zone 
(Cho+Cr)/Cit ratio
Central Gland (Cho+Cr)/
Cit ratio
Cho/Cr ratio adjustment
1: Definitely benign tissue ≤0.34 ≤0.48 - If Cho/Cr ratio ≥2.3, 
then: adjust  3 and 2 
into 4. 
- If Cho/Cr ratio < 2.3, 
then: adjust 5 into 4 and 
4 into 3.
2: Probably benign tissue 0.34<CC/C≤0.46 0.48<CC/C≤0.62
3: Possibly malignant tissue 0.46<CC/C≤0.58 0.62<CC/C≤0.76
4: Probably malignant tissue 0.58<CC/C≤0.70 0.76<CC/C≤0.90
5: Definitely malignant tissue >0.70 >0.90
CC/C = choline plus creatine to citrate
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standardized scoring system for aggressiveness assessment with 3T data, the Cho/Cr cut 
off level, which adjusts the initial malignancy rating, was varied between 1 and 4 with 0.1 
intervals. For all 31 of these Cho/Cr “adaptation levels” the highest malignancy rating per 
tumor was calculated and used to obtain receiver operating characteristic (ROC) curves to 
determine the accuracy. 
The area under the curve (AUC) of the ROC curves were determined to study the performance 
of discrimination of low-grade from higher-grade tumors and high-grade from lower-grade 
tumors using the maximum (Cho+Cr)/Cit, maximum Cho/Cr and the five-point scale of the 
standardized threshold approach. All AUCs were compared for statistical differences (24).
Statistical analyses were performed with GraphPad Prism software (GraphPad Software Inc, 
La Jolla, CA, USA) and MATLAB (Mathworks, Natick, MA, USA). For all statistical tests a p 
value of 0.05 was used to show significance. 
Results 
Of the 108 patients, 43 passed the inclusion criteria. A summary of patient and tumor 
characteristics is provided in Table 4.1. The mean time between the MR exam and radical 
prostatectomy was 6 weeks (range: 0-21). The MR exam (example in Figure 4.1) was 
performed on average 46 days after TRUS-guided biopsy (range: 19-107). The total number 
of clinically significant tumors was 53 in 43 patients. Forty tumors were located in the PZ, 11 
in the CG and 2 tumors covered both zones (assigned as PZ tumor for analysis). The average 
tumor size on histopathology was 6.3 cm3 (range: 0.52-33.5). The patient Gleason scores of 
the tumors that were excluded because the volume was smaller than 0.5 cm3 were 2+3 (n=2), 
3+3 (n=9), 3+4 (n=2) and no malignancy detected (n=1).
In total, the radiologist selected 1892 tumor voxels. Of these voxels, 77% (1463 of 1892) 
passed the quality inspection of both spectroscopists. Three patients - and therefore 5 
tumors - had to be excluded from the analysis, because none of the spectra of the selected 
voxels were usable. 
A small, but significant correlation was found between the maximum (Cho+Cr)/Cit ratio and 
the aggressiveness classes (p=0.02, r=0.27; Figure 4.2A). The comparison of the medians 
of the three aggressiveness classes revealed a significant difference between the low 
and high grade tumors. The maximum Cho/Cr ratio also correlated significantly with the 
aggressiveness classes (p<0.01, r=0.31; Figure 4.2B). The median Cho/Cr of the low grade 
tumors was significantly different from the high grade tumors. Table 4.3 shows the AUCs 
representing the performance of the aggressiveness assessments.  
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Figure 4.3.  The maximum (Cho+Cr)/Cit ratio for each tumor focus plotted against the maximum Cho/Cr 
 ratio of that focus. The tumors are divided by aggressiveness class. The (Cho+Cr)/Cit ratio of 
 one high grade tumor was cut off at 3 for displaying purposes
The correlation between the maximum (Cho+Cr)/Cit ratio and the maximum Cho/Cr ratio 
was 0.51 (p<0.001).  For each tumor, the maximum (Cho+Cr)/Cit was plotted against the 
maximum Cho/Cr value (Figure 4.3). 
Figure 4.2. A) The distribution of the maximum (Cho+Cr)/Cit ratio per tumor aggressiveness class. The 
 horizontal bars indicate the median. One high grade tumor had a maximum (Cho+Cr)/Cit 
 ratio of 58 which has been plotted at a (Cho+Cr)/Cit ratio of 3 for displaying purposes. B) 
 Distribution of the maximum Cho/Cr ratio per aggressiveness class. The horizontal bars 
 indicate the median. 
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Figure 4.4.  The highest malignancy ratings according to the standardized threshold approach for each 
 tumor in the aggressiveness classes. A Cho/Cr adaptation level of 2.3 was used. 
A Cho/Cr adaptation level of 2.3 for the standardized threshold approach gave the highest 
AUCs when discriminating high-grade from low- and intermediate-grade tumors (AUC=0.73) 
and low- from the combined high- and intermediate-grade tumors (AUC=0.78). The malignancy 
ratings, using an adaptation level of 2.3, are shown in Figure 4.4, and the median malignancy 
rating of the high (median=5) and low (median=3) grade tumors was significantly different. 
In all discriminations between aggressiveness classes (Table 4.3), the AUCs of the 
standardized threshold method with an adaptation level of 2.3 were higher than the AUCs for 
the maximum (Cho+Cr)/Cit or Cho/Cr ratio alone, but these differences were not significant.
Discussion
With an increasing number of reports on overdiagnosis (2,25), an individualized prostate 
cancer aggressiveness assessment is essential. Currently the pretreatment aggressiveness 
is determined with biopsies, but often the Gleason score is underestimated (3,4). MRI/MRSI 
Low-grade vs high- & intermediate-
grade tumors
High-grade vs low- & intermediate-
grade tumors
Maximum (Cho+Cr)/Cit 0.70 0.69
Maximum Cho/Cr 0.74 0.71
Standardized threshold approach 0.78 0.73
Table 4.3.  The areas under the ROC curves for the discrimination among different aggressiveness 
 classes using the maximum (Cho+Cr)/Cit ratio Cho/Cr and the standardized threshold 
 approach. For the standardized threshold approach an optimized Cho/Cr rating adaptation 
 level of 2.3 was used.
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could be a prognostic noninvasive approach to differentiate among patients as suitable 
candidates for active surveillance and patients that need immediate treatment. Moreover, 
it would enable targeted therapy, such as intensity-modulated radiotherapy or high-intensity 
focused ultrasound, to be applied to the most aggressive part of the tumor. In a detection 
setting, MRI/MRSI could guide a biopsy so that it could be taken from the most aggressive 
part of a tumor. Validation is the first step in the development of such a prognostic MRSI 
approach. We assessed the tumor aggressiveness differentiation by the AUC of the ROC 
curves and this method produced similar results when using either the (Cho+Cr)/Cit ratio 
(0.70) or the Cho/Cr raio (0.74). The performance of combining both ratios was better 
(0.78), although this difference was not statistically significant, because of a relative small 
sample size. The AUCs reflect considerable overlap between the ratios in the different 
aggressiveness classes, similar to what has been reported in other studies concerning the 
relationship between the (Cho+Cr)/Cit ratio and Gleason score (10,11).
We investigated whether a combination of both ratios would increase the performance 
of separating low-grade from higher-grade tumors. The original standardized threshold 
approach was developed to improve tumor localization at 1.5 T with a Cho/Cr level of 2 to 
adjust the initial  malignancy rating (14,15). As the timing of the MRSI pulse sequence at 3 
T is different (17) from the timing at 1.5T, we optimized the Cho/Cr adaptation level of the 
standardized threshold approach for tumor aggressiveness classification at 3 T, retaining the 
original concept of defining the thresholds based on the mean and SDs of noncancereous 
PZ and CG tissues. When all tumors with a malignancy rating of 4 or 5 would be classified 
as high grade, only 10% of the high-grade tumors would be misclassified as a lower grade. 
Fifty-two percent of the intermediate- and low-grade tumors would be misclassified as high 
grade, which is better than previous results (68%) using MRI and 1H MRSI in patients with an 
elevated PSA level (9). 
As in current clinical practice, MR examinations of the prostate are often multiparametric; 
the standardized threshold approach could be extended to include more predictive variables 
for the assessment of aggressiveness. Features such as the apparent diffusion coefficient 
or pharmacokinetic parameters of dynamic contrast-enhanced MRI could be included to 
improve the performance (26). 
 
The tumors of the patients in this study were divided into three clinically useful classes of 
aggressiveness: low, intermediate and high. The nature of the Gleason score does not lend 
itself to a linear relationship with an aggressiveness marker. Using three aggressiveness 
classes, the tertiary Gleason scores could be taken into account and Gleason 7 tumors could 
be divided into primary grade 3 and primary grade 4 tumors. The primary grade 4 tumors are 
more aggressive and have an increased risk for progression (27,28). Tumors with a tertiary 
Gleason score of 5 have a higher risk of extraprostatic extension (29) and PSA recurrence 
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(28,30) than tumors with the same score without a tertiary pattern. For these reasons, three 
classes of aggressiveness were used, which still enabled us to answer clinically relevant 
questions on aggressiveness. 
Our study had several limitations. First, it was a retrospective single-institution study with a 
limited number of patients; therefore, our results may not be extrapolated to the general patient 
population. The data can be considered as promising but preliminary, and our conclusions 
need confirmation by a prospective, multicentre trial, which is currently underway. We did 
not correct for possible correlation between multiple tumors in a single patient (6 cases of 
two clinically significant tumors within one prostate). Although we distinguished between 
tumors in the PZ and those in the CG, we did not do a separate aggressiveness analysis 
for the two regions because of the limited number of CG tumors(n=11). We excluded 14 
patients from our initial patient cohort because of tumor size on histopathology of less than 
0.5 cm3. Next to the fact that these small tumors are clinically insignificant (no high grade 
cancer present), the actual volume of the voxels of our MRSI examinations was too large to 
represent tumor foci of these sizes without too much surrounding noncancereous tissue 
within the voxel of interest. Metabolite ratios of these voxels would represent a mixture 
between cancer and noncancereous tissue. 
Conclusion
This study showed that proton MR spectroscopic imaging offers potential for in vivo 
noninvasive assessment of prostate cancer aggressiveness, which has  important 
implications. We have modified the existing standardized threshold approach to assess 
tumor aggressiveness at 3 T. The initial results of combining the (Cho+Cr)/Cit and Cho/Cr 
ratio were promising for the discrimination among different aggressiveness classes.
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Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-
weighted imaging at 3 T
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Introduction
Prostate cancer is the most common cancer in American men, with approximately 217 
730 new cases reported in 2010 (1). In 30%–50% of the men in whom prostate cancer is 
diagnosed, the disease is indolent and not life threatening (2). However, in some patients, 
the tumor is aggressive and will lead to death if it is not treated. Screening for prostate 
cancer by measuring prostate-specific antigen (PSA) levels will lead to a 20% reduction in 
the number of deaths from prostate cancer after 9 years (3). Estimates show that 50% of 
the men in whom prostate cancer is diagnosed on the basis of screening findings would not 
have had any clinical symptoms for the rest of their lives (4). Autopsy studies showed that 
high-grade prostatic intraepithelial neoplasia, a precursor of prostate cancer, is present in up 
to 86% of the men aged 80 years or older (5). To prevent overtreatment in patients with an 
indolent tumor, one must account for life expectancy and clinical features, such as clinical 
stage, PSA level, and biopsy Gleason score (2). Currently, the Gleason score is determined 
by histopathologic analysis of transrectal ultrasound (TRUS)-guided biopsies; this leads to 
underestimation of the Gleason score in 26%–41% of biopsy specimens when compared 
with prostatectomy specimens (6-9). Thus, a reliable and preferably noninvasive measure of 
prostate cancer aggressiveness is needed. 
For several years, a number of groups have investigated whether magnetic resonance (MR) 
techniques can yield information about tumor aggressiveness. One of these techniques 
is diffusion-weighted imaging (DWI), which measures the mobility of water molecules due 
to Brownian motion. The apparent diffusion coefficient (ADC) is a quantitative measure 
that reflects the compartmentalization of water in tissues. In malignant prostate tissue, 
the cellular density is increased, resulting in increased restriction of free water diffusion 
represented by a decreased ADC value (10,11). Several studies have been performed to 
investigate the correlation between the Gleason score and the ADC value of the tumor, with 
conflicting results. Contrary to earlier findings lacking a significant correlation (12-14), more 
recent articles have reported on the existence of a correlation between the ADC value and 
the Gleason score (15-19) or the level of differentiation of the tumor (20). Three-dimensional 
(3D) proton MR spectroscopic imaging (1H MRSI) enables detection of the metabolites 
choline (Cho), polyamines (mainly spermine), creatine (Cr), and citrate (Cit). The (Cho+Cr)/
Cit ratio has been suggested as a marker for prostate cancer, since a decrease in the Cit 
level and an increase in the Cho level is observed in malignant prostate tissue (21,22). When 
the (Cho+Cr)/Cit ratio was related to the Gleason score, a significant correlation (23,24), a 
trend (25), or no correlation (26) were reported. Although these results are promising, both 
modalities show substantial overlap between the different Gleason scores and the metabolic 
ratio or ADC values. 
The ADC value was combined with the Cho/Cit ratio (27,28) or the Cho plus polyamines 
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plus Cr to Cit ratio (29) to improve the localization of prostate cancer. The combination was 
significantly better than use of either the metabolic ratio (27,29) or the ADC value (27,28) 
alone. However, to our knowledge, no study has been performed in which the researchers 
attempted to combine both modalities to assess prostate cancer aggressiveness. 
The improved tumor localization with both modalities and the correlation between the 
Gleason score and the ADC value and that between the Gleason score and the metabolic 
ratio are an indication that the combination of DWI and 1H MRSI might enable noninvasive 
assessment of prostate cancer aggressiveness. The aim of this study was to determine 
the individual and combined performance of MRSI and DWI at 3 T in the in vivo assessment 
of prostate cancer aggressiveness by using histopathologically defined regions of interest 
(ROIs) on radical prostatectomy specimens to define the prostate cancer regions to be 
investigated.
Materials and methods
Subjects
The institutional ethics review board of the Radboud University Nijmegen Medical Centre 
approved this retrospective study and waived the requirement for informed consent. A 
total of 122 consecutive patients with biopsy-proven prostate cancer underwent a clinical 
MR examination performed with a 3T system and radical prostatectomy between October 
2006 and December 2009. The following inclusion criteria were used: (a) 1H MRSI and DWI 
performed during the same examination, (b) use of an endorectal coil for signal reception, 
(c) performance of detailed histopathology where at least one tumor focus with a volume 
of 0.5 cm3 or more was detected, and (d) no neoadjuvant therapy. A total of 54 patients met 
all inclusion criteria and were retrospectively included in this study. The other patients were 
excluded because MRSI was not performed (n = 41), an endorectal coil was not used (n = 4), 
the tumor was too small (n = 14), or neoadjuvant therapy was administered (n = 9).
MR Examination
A whole-body 3T system (Magnetom Trio; Siemens Healthcare, Erlangen, Germany) was 
used for the MR examinations. For signal reception, an endorectal coil (Medrad, Pittsburgh, 
PA, USA) and an eight-element phased-array coil (Siemens Healthcare) were used. The 
balloon of the endorectal coil was filled with inert perfluoropolyether liquid (Fomblin; Solvay 
Solexis, Bollate, Italy) to minimize susceptibility differences between the endorectal coil and 
the tissue. To suppress peristalsis, the patients received intramuscular injections of 1 mg 
glucagon (GlucaGen; Novo Nordisk, Gentofte, Denmark) and 20 mg of butylscopolamine 
bromide (Buscopan; Boehringer Ingelheim, Ingelheim, Germany).
First, the relative positions of the patient and endorectal coil were checked with fast gradient-
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echo images. Next, high-spatial-resolution T2-weighted images (Table 5.1) were obtained. 
DWI was performed with a singleshot echo-planar imaging sequence with diffusion-
encoding gradients in three directions (Table 5.1). The section thickness was 3 mm, and an 
in-plane resolution of 1.5 x 1.5 mm was used. The imager software automatically calculated 
the ADC maps from the images with b values of 0, 50, 500, and 800 sec/mm2 by fitting signal 
attenuation as a function of the b value to mono-exponential decay.
For 3D 1H MRSI, a point-resolved spectroscopic sequence was used with outer volume 
suppression and Mescher-Garwood dual-frequency water and lipid suppression (30) (Table 
5.1). Weighted elliptical sampling of the k-space, zero filling, and Hanning filters were used 
to shorten acquisition time and minimize signal contamination from adjacent voxels. The 
nominal voxel size before apodization with the Hanning function was either 5 x 5 x 5 mm or 
6 x 6 x 6 mm; after apodization, voxel size was best approximated by a sphere with a volume 
of 0.37 or 0.64 cm3, respectively (3
Echo time 
(ms)
Repetition 
time (ms)
Matrix size Field of View 
(mm)
Slice thick-
ness (mm)
T2-weighted transversal image 84-116 3030-5460 222 x 448 89 x 180 3
T2-weighted sagittal image 98-125 3360-5710 268 x 384 134 x 192 3
T2-weighted coronal image 98-127 2400-4290 192 x 384 96 x 192 3
Diffusion weighted imaging 81-96 2300-4100 136 x 136 204 x 204 3
Spectroscopic imaging 145 750 Resolution: 5 x 5 x 5 or 6 x 6 x 6 mm
Histopathologic Evaluation
Immediately after surgery, the prostatectomy specimens were injected with formalin and 
fixed overnight in 10% neutral buffered formaldehyde. After ink was applied to the surface, 
the prostate was cut into 4-mm-thick transverse slices perpendicular to the dorsal rectal 
surface, and each slice was photographed. After routine hematoxylineosin staining, a 
urologic pathologist (C.A.H.) with 20 years of experience evaluated all prostatic specimens 
and outlined the location of the tumor or tumors on the photographs for each slice (32). 
Each tumor was graded according to the 2005 International Society of Urological Pathology 
Modified Gleason Grading System (33), and lesions in each patient were staged by following 
the 2002 TNM classification (34). 
Tumors were classified into aggressiveness classes on the basis of the primary, secondary, 
and tertiary  Gleason grade, provided at least 5% of a third pattern was present. The 
subdivision was as follows: low-grade tumors were those that consisted of only Gleason 
grade 2 and/or 3 components. Intermediate-grade tumors were those that had a secondary 
Table 5.1.  Parameters of the MR exam
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or tertiary Gleason grade 4 component but no grade 5 component. High-grade tumors were 
those with a primary grade 4 component and/or a grade 5 component present (primary, 
secondary, or tertiary grade).
ROI Selection
3D 1H MRSI resulted in voxels with the lowest spatial resolution of the two functional imaging 
modalities; therefore, we based the choice of ROIs on the size and location of spectroscopic 
imaging voxels. The voxel matrix of the spectroscopic examination, which did not contain the 
spectra, was placed over the T2-weighted images. A radiologist (T.H.) used the photographs 
of the specimen  sections with the tumors outlined to assign all MRSI voxels representing 
tumor tissue. To obtain unbiased measures, the radiologist was blinded to the spectra and 
ADC maps. Only clinically important tumors with a volume of at least 0.5 cm3 were included 
(35,36). Voxels that had more than 50% of their volume outside the prostate were not 
included. Metabolite Report (Siemens Healthcare) was used for automated fitting of the 
spectra of the selected tumor voxels and calculation of the (Cho+Cr)/Cit and Cho/Cr ratios 
(Figure 5.1C,E). The software plots the original signal, the fit, and the residuals; these were 
inspected by two spectroscopists (T.K., T.W.J.S; 3 and 10 years of experience, respectively) 
working independently. The spectroscopists were asked to accept only spectra with correct 
positions of the resonances, sufficient signal-to-noise ratio, adequate phasing, absence of 
baseline distortions, and absence of lipid signals. Only voxels that passed the inspection of 
both spectroscopists were included in the MRSI analysis. The percentage of voxels that was 
accepted was determined.
To combine the ADC values with the spectroscopy voxels, home-built software (37) was 
used to plot a semitransparent ADC map over the T2-weighted images. If the patient had 
moved between the two recordings, a manual rigid translation of the ADC maps compared 
with the T2-weighted image was performed by a spectroscopist (T.K., 3 years experience) 
in consensus with a radiologist (T.H., 6 years experience) to overlay the prostate on both 
images. The outline of the prostate, bladder, seminal vesicles, and endorectal coil was used 
as a reference. The radiologist checked the ADC map for good quality. The MRSI matrix was 
then placed over the ADC map. Around each selected MRSI voxel (also around the voxels 
rejected by the spectroscopists), a spherical ROI of the true size of that voxel was drawn 
(Figure 5.1F), and the 25th percentile ADC value of all ADC pixels in that ROI was determined. 
The 25th percentile was chosen to take into account tumor heterogeneity and to capture 
focal regions of higher cellularity. This is in accordance with several other studies involving 
dynamic contrast-enhanced imaging that used a percentile of pharmacokinetic values 
to obtain information about the so-called hot spots, which are regions with the greatest 
microvessel density (37-39). The most aberrant part (ie, the highest grade or cellularity) of 
the tumor on the ADC map (ADC hot spot) could be smaller than the spectroscopic imaging 
voxels. For this reason, the 25th percentile, a measure for the lowest ADC values in a ROI, 
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was chosen. If the ROI was partly outside the prostate, the ADC values of this region were not 
representative of the tumor. Thus, the ROI was readjusted so it contained only intraprostatic 
tissue.
Data Analysis
The data were analyzed by one spectroscopist (T.K., 3 years experience). The analysis was 
performed at the tumor level, and multiple tumors in one patient were treated as independent 
tumors. The volume of each tumor was calculated based on dimensions reported by the 
pathologist, and the average tumor volume of all tumors was determined. In all patients, the 
average time between the MR examination and biopsy and between the MR examination and 
prostatectomy were calculated. 
For each tumor, the following three variables were computed to perform the analysis: 
(a) the maximum (Cho+Cr)/Cit ratio of all approved spectroscopy voxels; 
(b) the maximum Cho/Cr ratio of all approved spectroscopy voxels; 
(c) the minimum of all 25th percentile ADC values of the ROIs. 
The maximum metabolic ratios were used (24), as it was expected that the highest ratios 
represented the most aberrant part of the tumor. For the ADC values, the opposite relationship 
was expected; therefore, the minimum 25th percentile ADC value was chosen. Analysis of 
tumors originating in the peripheral zone (PZ) and those originating in the transition zone 
(TZ) was performed separately. Tumors that covered both zones were considered TZ tumors 
when the tumor covered at least 70% of the TZ (40); otherwise, they were considered PZ 
tumors. The three variables were related to the aggressiveness classes. The correlation 
between the aggressiveness classes and the (Cho+Cr)/Cit ratio, Cho/Cr ratio, and ADC 
variables was determined with the Spearman rank correlation coefficient. All aggressiveness 
classes were tested for normality with a Kolmogorov-Smirnov test, which was performed 
for all three variables. The medians of the non-normally distributed aggressiveness classes 
were determined and compared with a Kruskal-Wallis test with a Dunn post hoc test to 
account for multiple comparisons.
The performance of all individual measures in the discrimination of low-grade tumors from 
the combined intermediate- and high-grade tumors was evaluated with receiver operating 
characteristic (ROC) curves. The area under the ROC curve (AUC) was calculated as a 
measure of performance. All confidence intervals of the AUC were calculated as described 
by Hanley and McNeil (41). 
The standardized-threshold approach (STA) was presented previously to combine the 
(Cho+Cr)/Cit ratio and the Cho/Cr ratio into one measure for malignancy probability and 
aggressiveness assessment (24,42,43). In the STA, the (Cho+Cr)/Cit ratio is used to obtain 
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Figure 5.1.  Transverse T2-weighted image (A) and ADC map (D) of the prostate with a tumor (Gleason 
 score, 3+4) in the peripheral zone, as shown at histopathologic examination (B). 
 E) Spectroscopy matrix with plots of the spectra of the voxels that are completely in the 
 tumor and one spectrum in more detail (C). F) ADC image shows corresponding local regions 
 of interest (red spheres). Spheres represent the true size of a spectroscopy voxel.
an initial rating of the malignancy, which is adapted for deviating Cho/Cr ratios. The initial 
rating (range, 1–5) is based on the mean and standard deviation of the (Cho+Cr)/Cit ratio of 
noncancerous tissue (26), and distinction is made between PZ and TZ (40) (Table 5.2). The 
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Five-point standardized scoring system 
Score and Score definition Peripheral Zone 
(Cho+Cr)/Cit ratio
Central Gland (Cho+Cr)/
Cit ratio
Cho/Cr ratio adjustment
1: Definitely benign tissue ≤0.34 ≤0.48 - If Cho/Cr ratio ≥2.3, 
then: adjust  3 and 2 
into 4. 
- If Cho/Cr ratio < 2.3, 
then: adjust 5 into 4 and 
4 into 3.
2: Probably benign tissue 0.34<CC/C≤0.46 0.48<CC/C≤0.62
3: Possibly malignant tissue 0.46<CC/C≤0.58 0.62<CC/C≤0.76
4: Probably malignant tissue 0.58<CC/C≤0.70 0.76<CC/C≤0.90
5: Definitely malignant tissue >0.70 >0.90
CC/C = choline plus creatine to citrate
Table 5.2.  Standardized threshold approach definitions
optimal Cho/Cr adaptation level of 2.3 for aggressiveness assessment (24) is used in this 
study to adapt the initial rating. When Cho/Cr ratio is at least 2.3, an initial score of 3 or 2 is 
increased to 4. When Cho/Cr ratio is less than 2.3, an initial score of 5 is adapted to 4, and a 
score of 4 is adapted to 3 (Table 5.2). For all MRSI voxels, the malignancy rating of the STA 
was determined, and the maximum malignancy rating of all voxels within one tumor was 
used to differentiate tumor aggressiveness classes.
To combine all three variables, a logistic regression model (LRM) was used to classify the PZ 
and TZ tumors into either low- or higher-grade tumors. The higher-grade category comprised 
intermediate- and high-grade tumors. The output of the LRM is an aggressiveness likelihood, 
with a score of 0–1 representing the probability that a tumor belonged to the higher-grade 
class. ROC curves were used to determine the accuracy of the aggressiveness likelihoods. 
To compensate for testing these models with the same data used to build the model, a 
bias-corrected AUC was determined. To this end, 1000 random bootstrap samples with 
replacement were drawn from the original data. Each bootstrap sample was used to train 
an LRM without variable selection, the original data set was tested with this model, and an 
ROC curve was constructed. Next, the average difference of the bootstrapped AUCs and 
the initial AUC, which was obtained earlier by training and testing with the original data, 
was determined. By subtracting the average difference from the initial AUC, a bias-corrected 
measure was obtained (25,44). The bias-corrected AUC and standard error were calculated 
and compared with the AUC of the individual ADC value, (Cho+Cr)/Cit ratio, Cho/Cr ratio, and 
STA (45). Since data were obtained in the same patients, the correlation between the AUCs 
had to be taken into account (45). To be able to do this for the LRM, the aggressiveness 
likelihoods of the original data set were used to determine the correlation. Bonferroni 
correction was used to compensate for the multiple comparisons. 
Finally, the correlation between the variables was investigated. By determining the 
correlation between the values of the different variables derived from the same location, 
an impression of their complementary value was obtained. To this end, the spectroscopy 
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voxel with the highest (Cho+Cr)/Cit ratio was selected, and the Cho/Cr ratio of this voxel and 
the 25th percentile ADC value of the corresponding ROI were determined. The Spearman 
correlation coefficient between the (Cho+Cr)/Cit ratio and each of the two corresponding 
variables was determined. The same procedure was followed to determine the correlation 
between the voxel with the highest Cho/Cr ratio and the two other variables that belong to 
that voxel. Finally, this was performed for the ROI with the lowest 25th  percentile ADC value 
and the two corresponding ratios. In 14 tumors, the quality of the corresponding spectrum 
was not accepted, and the values of these tumors could not be included in the correlation 
analysis. The Spearman correlation coefficients were also determined for all voxels that 
were accepted based on the quality of the spectra. Matlab (version 7.7.0.471; Mathworks, 
Natick, MA, USA) was used for statistical analysis. For all statistical tests, a P value of .05 or 
less indicated a significant difference.
Results
On the basis of the selection criteria, 70 clinically important tumors were identified in 54 
patients. However, the data of six patients had to be excluded: Two patients had moved 
between the 1H MRSI examination and the DWI examination, and the diffusion weighted 
images could not be accurately placed over the T2-weighted images. Three patients had no 
usable spectra. One patient had a distorted ADC map. The patient and tumor characteristics 
of the remaining 48 patients (61 tumors) are shown in Table 5.3. The average tumor volume 
at histopathology was 6.7 cm3 (range, 0.5–33.5 cm3). The average time between the MR 
examination and prostatectomy was 8 weeks (range, 0–21 weeks). The MR examination 
was performed on average 60 days (range, 19–337 days) after TRUS-guided biopsy. A total 
of 42 tumors originated in the PZ, and 19 originated in the TZ. A total of 1920 ROIs were 
identified in these tumors, of which 1556 (81%) passed the MRSI quality control by both 
spectroscopists. 
For each aggressiveness class, the medians of the three variables of ROIs are given in Table 
5.4. In the PZ, the medians of the low-grade (1.13 ·10-3 mm2/sec) and intermediate-grade 
(1.04·10-3 mm2/sec) tumors were significantly different from the medians of the high grade 
tumors (0.76·10-3 mm2/sec) for the minimum 25th percentile ADC values (P < .05) (Figure 
5.2). In the TZ, this difference was lacking for the ADC values. On the other hand, in the 
TZ, the medians of both metabolite ratios (Table 5.4) were significantly different between 
low- and high-grade tumors (P < .05) (Figure 5.2). In the PZ, the metabolite ratios were not 
significantly different for any of the aggressiveness classes.
For the PZ tumors, significant correlations were observed between the aggressiveness 
classes and the maximum (Cho+Cr)/Cit ratio (ρ = 0.36, P <0.02), maximum Cho/Cr ratio (ρ 
= 0.35, P <0.03), and minimum 25th percentile ADC value (ρ = -0.63, P <0.001). In the TZ, 
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No of patients 48
PSA level, mean, ng/ml (range) 9.9 (2.1 - 41.0)
Age, mean, yr (range) 63 (42-70)
Clinical stage 
   T2 24
   T3 23
   T4 1
Gleason score  - Peripheral zone: No of tumors:
   3+2 low 1
   3+3 low 12
   3+3+4 intermediate 1
   3+4 intermediate 11
   3+4+5 high 2
   4+3 high 10
   4+3+5 high 2
   4+4 high 1
   4+5 high 2
   5+3 high 1
Gleason score - Central gland:
   2+3 low 2
   3+2 low 5
   3+3 low 1
   3+2+4 intermediate 1
   3+4 intermediate 1
   2+4+5 high 1
   4+2+3 high 1
   4+3+5 high 4
   4+4 high 1
   4+5+2 high 1
Table 5.3.  Patient and tumor characteristics
 *The tumors are classified according to their aggressiveness 
 There were 21 low grade, 14 intermediate grade and 26 high grade tumors. 
the (Cho+Cr)/Cit ratio (ρ = 0.58, P <0.01) and Cho/Cr ratio (ρ = 0.60, P <0.01) correlated 
significantly with tumor aggressiveness; the correlation with ADC values was not significant 
(ρ = -0.43, P = 0.06). 
The AUCs for the different aggressiveness assessments are given in Table 5.5. To 
differentiate low-grade tumors from higher-grade tumors, the ADC value had the highest AUC 
(0.81) in the PZ, and the Cho/Cr ratio had the highest AUC (0.90) in the TZ. After Bonferroni 
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Figure 5.2.  Maximum (Cho+Cr)/Cit ratios of tumors in the peripheral zone (A) and the transition zone 
 (B), maximum Cho/Cr ratio of tumors in the peripheral zone (C) and the transition zone 
 (D), and the minimum 25th percentile ADC values in the peripheral zone (E) and the transition 
 zone (F). The (Cho+Cr)/Cit ratio of two tumors were cut off at 3 (original values: 16.7 and 
 58.4) and the Cho/Cr ratio of three tumors were cut off at 8 (original values 10.8, 8.5 and 12.3) 
 for display purposes. Significant differences P<0.05 (*) and P<0.001 (**) were noted between 
 the medians of the aggressiveness classes.
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correction, none of the AUCs of the individual modalities were significantly different for any 
of the comparisons between aggressiveness classes. In Table 5.5, the AUCs are given for 
the STA, and the bias-corrected AUCs are given for the LRM. The AUC obtained with the LRM 
and that obtained with the STA were not significantly different from the other variables. In 
the PZ, the STA resulted in a higher AUC than did the individual metabolite ratios. In both the 
PZ and the TZ, there was a significant difference between the median malignancy rating of 
the low-grade tumors and that of the high-grade tumors.
In Table 5.6, the Spearman correlation coefficients are given for the correlation between the 
voxels with the highest (Cho+Cr)/Cit ratio, the highest Cho/Cr ratio, and the minimum 25th 
percentile ADC value corresponding to these voxels. Also, correlations of the highest Cho/Cr 
ratio and the lowest 25th percentile ADC value and their corresponding variables are given. 
All correlations were significant, except for the minimum 25th percentile ADC value and the 
corresponding Cho/Cr ratio. 
Figure 5.3.  A) The minimum 25th percentile ADC plotted against the (Cho+Cr)/Cit ratio of the 
 corresponding voxel (ρ= -0.64, p<0.01 B) The maximum (Cho+Cr)/Cit ratios plotted against 
 the corresponding 25th percentile ADC value. (ρ= -0.59, p<0.01). For display purposes 
 (Cho+Cr)/Cit ratios higher than 3 were cut off at 3.
Low grade Intermediate grade High grade
(Cho+Cr)/Cit Peripheral zone 0.44 0.52   0.89
Transition zone 0.58 1.58 1.62
Cho/Cr Peripheral zone 2.21 2.50 3.75
Transition zone 1.36 4.01 2.86
ADC Peripheral zone 1.13·10-3 mm2/s 1.04·10-3 mm2/s 0.76·10-3 mm2/s
Transition zone 0.95·10-3 mm2/s 0.51·10-3 mm2/s 0.61·10-3 mm2/s
STA Peripheral zone 2 4 5
Tranzition zone 2 3 4
Table 5.4  Median of the maximum (Cho+Cr)/Cit ratio, the maximum Cho/Cr, minimum 25th percentile 
 of the ADC values, and maximum STA for the different aggressiveness classes.
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(Cho+Cr)/Cit
Corresponding Cho/Cr Corresponding 25th 
percentile ADC
Maximum (Cho+Cr)/Cit 0.44* -0.59*
Maximum Cho/Cr 0.43 * -0.31*
Minimum 25th percentile ADC -0.64* -0.24
Table 5.6.  The Spearman correlation coefficients between the metabolite ratio or 25th percentile ADC 
 value of the most deviating ROI and the two variables corresponding to that ROI. (*) p<.01
The variables that showed the highest correlation, that is, the maximum (Cho+Cr)/Cit ratio 
plotted against the corresponding 25th percentile ADC value of that voxel (ρ = -0.59) and 
the minimum 25th percentile ADC with the corresponding (Cho+Cr)/Cit ratio (ρ = -0.64), are 
plotted in Figure 5.3. The correlation coefficients when all accepted voxels and local ROIs 
were included were 0.64 between both metabolite ratios, -0.47 between the (Cho+Cr)/Cit 
ratio and the ADC value, and -0.2 between the ADC value and the Cho/Cr ratio. All correlations 
were significant (P <0.001).
Low grade versus high and 
intermediate grade
(Cho+Cr)/Cit Peripheral zone 0.71 (0.54 - 0.87)
Transition zone 0.82 (0.63 - 1)
Cho/Cr Peripheral zone 0.67 (0.50 - 0.84)
Transition zone 0.90 (0.75 - 1)
STA Peripheral zone 0.77 (0.63 - 0.92)
Transition zone 0.86 (0.70 - 1)
ADC PZ 0.81 (0.69 - 0.94)
Transition zone 0.80 (0.59 - 1)
LRM PZ 0.78 (0.64 - 0.92)
TZ 0.87 (0.70 – 1)
Table 5.5. Area under the ROC curves for discrimination between different aggressiveness classes 
 using the maximum (Cho+Cr)/Cit ratio, maximum Cho/C ratio and minimum of the 25th 
 percentile ADC. Also the AUCs for STA and LRM, which combine two and three variables 
 respectively, are given. Distinction is made between PZ and TZ tumors. 
Discussion
In this study, the potential of the individual and combined use of metabolite ratios and 
ADC values to discriminate between different prostate cancer aggressiveness classes was 
investigated. A significant correlation was found between the aggressiveness classes and 
the maximum (Cho+Cr)/Cit ratio, maximum Cho/Cr ratio, and minimum ADC values. For 
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differentiation between aggressiveness classes, the combination of the three variables by 
means of LRM did not result in better differentiation than that with any of the individual 
variables. 
The performance of ADC values alone in the assessment of aggressiveness was comparable 
with that of previous studies. Although some researchers found no significant correlation 
between the ADC value and the Gleason score (12-14), studies performed more recently 
have shown a significant correlation (15-18,20). Three studies used TRUS-guided biopsy 
to assess the Gleason score (13-15), which might have led to underestimation of the true 
aggressiveness. Thus, in our study, the whole-mount histopathologic slice obtained at 
radical prostatectomy was used as the reference standard, and it enabled us to confirm 
the existence of a significant negative correlation in the PZ between ADC values and tumor 
aggressiveness. In the TZ, this correlation was not significant. In two other separate studies, 
researchers evaluated ADC values in the PZ and TZ and found as we did, that there was 
a significant correlation for the PZ but not the TZ at 1.5 T (15,18). In the other studies in 
which researchers found a significant correlation, only the PZ was evaluated (17) or the 
tumors from both zones were combined in their correlation assessment (16,20). A direct 
comparison with previous studies might not be valid for several reasons. In these studies, 
the choice of ROIs was performed differently. Either the mean or the median ADC value of an 
ROI was used, and other b values for DWI were often used. Although we had a limited number 
of TZ tumors, we chose to analyze both regions separately, as the tissue composition is 
different in these regions. 
When separating these regions, both metabolic ratios—the maximum (Cho+Cr)/Cit ratio and 
the maximum Cho/Cr ratio— correlated significantly with aggressiveness class in the PZ and 
TZ. A relationship between the (Cho+Cr)/Cit ratio and the Gleason grade was demonstrated 
previously in the PZ (23,25) and in both regions combined (24). Despite the low number of 
TZ tumors, both metabolite ratios showed a significant correlation in the TZ in our study. 
The overall performance of the individual variables in the discrimination between low- 
and higher-grade tumors, which was assessed with the AUC, was comparable. However, 
although the difference was not significant, in the PZ, the ADC values yielded higher AUCs 
than did the metabolite ratios, while in the TZ, the metabolite ratios performed better than 
the ADC. Combining both modalities by means of LRM did not result in a higher AUC. The 
STA, combining both metabolic ratios, yielded better results in the PZ than the individual 
metabolite ratios; however, like the LRM, the differences lacked significance. The large 
overlap between the variables and the relative small patient numbers led to large confidence 
intervals of the AUCs. 
The lack of significantly improved performance of the LRM compared with that of the 
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individual modalities raises the question of whether ADC values and metabolic ratios 
provide complementary information for cancer characterization. The validity of this question 
is strengthened by the strong correlations between the 25th percentile ADC values and the 
(Cho+Cr)/Cit ratio. Both variables might be influenced by the same morphologic change. A 
positive correlation between the decrease in ADC value and the reduction of luminal space 
was found earlier (46). This luminal space of normal prostate tissue contains high amounts 
of Cit secreted by healthy prostate cells, which have a high level of Cit production (47,48). The 
decrease in Cit signal intensity in malignant tissue can reflect a reduction of luminal space, 
as well as an altered metabolism (oxidization of Cit due to the lack of zinc (49)). The absence 
or decrease in luminal space in patients with prostate cancer results in a simultaneous 
decrease of apparent water mobility and Cit levels. One could argue against performing the 
spectroscopic portion of an integrated MR examination for prostate cancer characterization 
to save time. However, in the TZ, the LRM performed better than ADC alone. Moreover, in the 
TZ, the metabolic ratios significantly correlated to aggressiveness, while this relationship 
was lacking for the ADC. Another aspect to take into account is the dynamic range of both 
techniques. For DWI, the range of ADC values that can be measured is restricted by the 
gradient strength and diffusion time. The length of diffusion time is limited by T2 relaxation. 
By its nature, a metabolite ratio demands a denominator that has a sufficient signal-to-noise 
ratio. However, there is no upper limit of the ratio, which implies a larger possible range in 
metabolite ratios compared with ADC values. 
The histopathologic analysis of the prostatectomy specimen was used as the reference 
standard. By blinding the radiologist who performed ROI selection for the ADC maps and 
spectra, we tried to make the ROI selection as objective as possible. Exact matching of step-
section histopathologic findings to MR imaging findings is considered difficult. As the focus 
was not on assessing values from the whole tumor but on assessing values from the most 
aberrant part, exact matching is less critical. We assumed that the most deviating voxels 
(ROIs) represented the most aggressive part of the tumor. The division of the tumors in three 
clinically relevant aggressiveness classes enabled us to take the tertiary Gleason grade into 
account. With these three classes, we could also divide Gleason 7 tumors into primary grade 
3 and primary grade 4 tumors. The primary grade 4 tumors are more aggressive (50,51), and 
a difference in ADC values between the two Gleason 7 tumors has been reported (16,18). 
The number of patients with a clinical stage T3 lesion who underwent prostatectomy in 
this study might seem high. However, the clinical stage was determined on the basis of 
histopathologic findings, which means that small amounts of tumor beyond the capsule will 
be detected. In several patients with T3 lesions, the extraprostatic extension was so minimal 
that there were no positive resection margins. 
Although we defined three aggressiveness classes to study correlations, the important 
clinical question is how well one can discriminate low-grade tumors from higher-grade 
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tumors. Thus, for most of the analyses, two groups were used: low-grade tumors and 
combined intermediate- and high-grade tumors. The ability to select with a high degree of 
certainty patients who do not need treatment is very relevant and important in this time of 
increased PSA testing. A recent study showed that to prevent one prostate cancer death 
with PSA screening, 48 patients need to undergo treatment (3). It is essential to decrease 
the number of patients who undergo unnecessary treatment, and this study is a step in this 
direction.
Our study had a number of limitations. The results of this study might not apply to the general 
patient population, as this was a single-institution validation study with a limited number of 
patients. The true clinical value of the two modalities in assessing aggressiveness needs 
to be studied in a prospective study. We did not correct for possible correlation between 
multiple tumors in one patient. (Seven patients had two clinically important tumors within 
the prostate, and one patient had three tumors within his prostate.) Four of the seven 
patients had both tumors in the PZ, and the other three patients had tumors in both regions; 
therefore, these tumors were not included in the same analysis, as we separated PZ and 
TZ tumors. It is necessary to divide the tumors into two regions because it is known that 
the ADC values and (Cho+Cr)/Cit ratios of the normal PZ and TZ are different (15,26,52). 
A consequence of separating the two regions is the limited number of TZ tumors to 
perform the analysis (19 of 61 tumors), with only two TZ tumor foci in the intermediate 
aggressiveness class. A bias in this study was created by limiting inclusion to patients who 
underwent prostatectomy. Patients with very aggressive tumors usually do not undergo 
prostatectomy, and the aberrant values of the metabolite ratios and ADC values, which these 
patients might have, are not included in the analysis. Inclusion of these patients could have 
led to a clearer discrimination between the aggressiveness classes. A final limitation was 
the assumption that patient-related movement and therefore discrepancy between the T2-
weighted sequence and the spectroscopic examination was minimal. If necessary, the ADC 
map was translated to overlap well with the T2-weighted image, but this procedure could not 
be performed for the spectroscopic grid, as there were no landmarks. 
In conclusion, this study enabled us to confirm that 1H MRSI and DWI offer potential for 
in vivo noninvasive assessment of prostate cancer aggressiveness, and both MR methods 
have comparable performance. However, there is still considerable overlap between the 
aggressiveness classes and the ADC values or metabolic ratios, possibly caused by tumor 
heterogeneity. The combination of both modalities did not result in a better performance 
for aggressiveness assessment; nonetheless, the better performance of the metabolite 
ratios in the TZ and of the ADC values in the PZ indicates that both modalities might have 
complementary value. More research is necessary to study how and to what extent these 
two functional imaging modalities can provide additional information.
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CHAPTER SIX
The Contribution of Morphological Features to Parameter 
Values in MR Spectroscopic and Diffusion-weighted 
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The contribution of morphological features to parameter values in MR spectroscopic and 
diffusion-weighted imaging of the human prostate
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Introduction
Magnetic resonance imaging (MRI) is increasingly being used for the detection, staging and 
characterization of prostate cancer. Multi-parametric MRI is often used for this purpose (1), 
preferably consisting of high-resolution T2-weighted images for anatomy, in combination with 
at least two functional MRI techniques (2). The functional techniques used most for prostate 
MR are diffusion-weighted imaging (DWI), dynamic contrast enhanced (DCE) MRI and 1H 
MR spectroscopic imaging (1H MRSI). Several studies have indicated that a combination 
of T2w-imaging with two functional techniques provides a better tumor characterization 
than with just one functional technique (3-6). This increased performance suggests that 
the functional MR images contain complementary information about morphologic and 
physiologic changes in prostate cancer. 
On cellular level, prostate tissue can be divided into two main components: stromal 
tissue (mainly connective and smooth muscle tissue) and glandular or epithelial tissue. 
Glandular tissue consists of epithelial cells surrounding the luminal space. Approximately 
30% normal peripheral zone prostate tissue consists of luminal space (7). In contrast, in 
cancer the volume percentage of luminal space is decreased, while simultaneously the 
volume percentages of epithelial nuclei and cytoplasm increase (7). The relation between 
the morphology of prostatic tissue and MR imaging has been studied for T2w imaging, DWI 
and DCE-MRI (7-9). Parameter values of DCE-MRI correlated with microvessel density (8, 9), 
and with the volume of luminal space, epithelial cytoplasm and nuclei (7). The T2 relaxation 
time and apparent diffusion coefficient (ADC) of DWI correlated inversely with the relative 
volume of nuclei and cytoplasm, and positively with amount of luminal space (7). Tissues 
with a lot of extracellular free water have a long T2 relaxation time, while the T2 is shorter in 
cell dense tissue (10). It is hypothesized that the decrease in T2 relaxation time in prostate 
cancer comes from the replacement of the luminal space by epithelial cancer cells (7). This 
structural alteration in prostate cancer tissue could also explain the decrease in ADC value, 
which is sensitive to the free water diffusivity in the luminal space. 
With 1H MRSI, the spatial distribution of the metabolites citrate (Cit), choline (Cho), spermine 
(Spm) as the main polyamine, and creatine (Cr) can be studied within the prostate gland. The 
ratio of (Cho(+Spm)+Cr)/Cit increases in tumor tissue compared to healthy tissue (11, 12), 
because the intensity of Cit decreases while the intensity of Cho often increases in spectra 
of prostate cancer tissue. Cit is an intermediate in the citric acid cycle and in most tissues 
Cit is immediately converted into isocitrate and further metabolized. The prostate, on the 
contrary, is the only organ with high Cit levels: production and storage of Cit in the luminal 
space is one of the main functions of the prostate (13). Metabolism of Cit is prevented in 
healthy prostate epithelial cells by high zinc concentrations, which inhibit mitochondrial (m-) 
aconitase activity, the enzyme that catalyzes Cit to isocitrate in the citric acid cycle (13-15). 
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However, in cancer tissue the zinc build up is lacking and Cit is oxidized. Prostatic fluids 
contain between 50-180 mM of Cit (15-17) and epithelial cells presumably only a few mM 
(based on measurements in epithelial cells of the rat prostate (13)). As the luminal space, 
where prostatic fluid with Cit comes from, occupies about 30% of the volume of the prostate 
in the healthy peripheral zone, it is expected that proportionally lower tissue levels of Cit 
are measured by 1H MRSI. This is indeed the case: these tissue levels have been estimated 
to be about 40 mM in the peripheral zone (18-21). As prostate cancer is characterized by 
dedifferentiation of epithelial cells and filling of prostate lumen with these cells, it is likely 
that the reduction in luminal space will have a substantial contribution to the decrease of Cit 
content in prostate cancer tissue as measured by 1H MRSI.
Therefore, we hypothesize that the low Cit signal observed in prostate cancer spectra reflects 
in the first place these morphological alterations, rather than changes in metabolism. These 
morphological transformations are also suggested as the cause of chances in the ADC value 
in prostate cancer (7). The present study aims to establish a relation between the parameter 
values of MRSI and DWI and tissue morphology assessed using digital image analysis of 
scanned histological sections. Better understanding of the biological mechanisms causing 
the detected MR signal changes can help to further understand the disease and improve the 
use of MR in prostate cancer management. 
Methods
Subjects
The institutional ethics review board approved this retrospective study and waived the 
need for informed consent. For this study 57 patients were included who had a clinical 
multi-parametric MR examination involving both MRSI and DWI, followed by a radical 
prostatectomy. The MR investigations were performed between January 2009 and July 
2012, as requested by a urologist, and aimed to examine the local extent of the tumor.
MR protocol and processing 
All MR examinations were performed on a whole-body 3T-system (Magnetom Trio; Siemens 
Healthcare, Erlangen, Germany). For signal reception, either an eight-element external 
phased-array coil (Siemens Healthcare) was used (n=21) or this coil was combined with 
an endorectal coil (Medrad, Pittsburgh, PA) (n=36). The balloon surrounding the endorectal 
coil was filled with perfluoropolyether liquid (Fomblin, Solvay Solexis, Bollate, Italy) to limit 
susceptibility differences between the tissue and the coil. To minimize peristaltic movement 
of the bowels, patients received intramuscular injections of 1 mg glucagon (Glucagen, 
Nordisk, Genlofte, Denmark) and 20 mg butylscopolaminebromide (Buscopan, Boehringer-
Ingelheim, Ingelheim, Germany).
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Median patient age (years) 64, range: 48 – 70
Median PSA level (ng/ml) 7.95, range: 2.9-76
Tumor stage**
   T2 21
   T3 30
   T4 3
Gleason score in selected slice*
   2+2  1    3+4+5 4
   2+3 2    3+5+4 2
   3+2 3    4+3 4
   3+3 9    4+3+5 4
   3+2+4 3    4+4 2
   2+3+4 1    4+5 1
   3+3+4 2    4+5+3 3
   3+4 12    5+4+3 1
   3+4+2 1
The MR examination started with localizers (fast gradient-echo images) to check the position 
of the coils. Next, high-resolution T2-weighted images were made in three orthogonal 
directions. The transversal slices were aligned perpendicular to the rectal wall. A single shot 
echo-planar imaging sequence was used for DWI with diffusion encoding gradients in three 
directions. The DWI images had the same orientation as the transverse T2-weighted images. 
B-values of 50, 500 and 800 s/mm2 or 100, 400 and 800 s/mm2 were used. ADC maps were 
calculated from all b-images by fitting a mono-exponential decay to the signal attenuation as 
a function of the b-value. For 1H MRSI a point resolved spectroscopy sequence (PRESS) was 
used with an echo time of 145 ms and a TR of 750 ms (22). Lipid and water suppression was 
applied using dual frequency-selective MEGA pulses and crusher gradients (23). Weighted 
acquisition of k-space was combined with a Hanning filter and zero-filling to minimize 
signal contamination from non-neighboring voxels. As a consequence, the true size of the 
spectroscopy voxels can best be approximated by spheres with a volume of 0.37, 0.64 or 
1.01 ml (24). The chosen voxel size depended on whether or not the endorectal coil was used 
and the size of the prostate. 
Histopathology and processing
After surgery, the prostates were injected with formalin and fixed overnight in 10% neutral 
buffered formaldehyde. Three different ink colors were applied to the surface of the prostate 
Table 6.1.  Patient characteristics. PSA= Prostate Specific Antigen
 * Data are given in number of tumors with that Gleason score that are included in this study.  
 ** Data are given in number of patients. 
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for orientation purposes and evaluation of surgical resection margins. Each prostate 
was cut in 4-mm thick transverse slices, perpendicular to the rectal wall. The slices were 
photographed. Of each slice, a thin section was cut, and stained with hematoxylin and eosin 
(HE). The prostate slices of patients operated before 2012 were divided in halves, quarters, 
or in rare cases in sextants. Of the other patients’ slices whole mount sections were cut. For 
each patient one slice, preferably containing a large amount of tumor tissue was selected for 
the matching. A uro-pathologist [CAHK] marked all tumor regions in this slice (Figure 6.1A) 
and determined per tumor the percentage area of each Gleason growth pattern according 
to published guidelines (25). Furthermore, regions that contained inflammation, necrosis or 
granuloma were indicated. 
The section(s) of the chosen slice and of one adjacent slice were digitally scanned with 10x 
magnification using a slide scanner (DotSlide system, Olympus, Tokyo, Japan). For slices 
consisting of multiple sections, the digital sections were copied to Adobe Photoshop (Adobe 
Systems, San Jose, CA) and combined to reconstruct one whole slice (Figure 6.1B) to enable 
matching with MR at a later stage. 
The digitized sections were segmented into lumen, nuclei and stroma & epithelial cytoplasm 
based on color deconvolution as described by Ruifrok et al (26) using Matlab (version 7.14; 
Mathworks, Natick, MA). The difference in staining of stroma and epithelial cytoplasm was 
too small to differentiate between these two and these were therefore combined into one 
feature. For the segmentation, optical density maps were generated for each color channel 
of the image (red, green and blue [RGB]). For each pixel, the difference between the minimum 
and maximum channel density was compared to a threshold to detect areas not covered 
with tissue. By grouping pixels with values below the threshold, individual lumens were 
defined. Detected lumens having an area smaller than a disk with a radius of 7 pixels (= 
Figure 6.1.  Matching example of the data of a 53-year old patient with a Gleason score 2+3 tumor. 
 A) Photograph of one of the prostate slices with the location of the tumor indicated in blue. 
 B) The four digitized sections stained with hematoxylin and eosin are combined to form one 
 slice. The regions of interest (ROIs) corresponding to the spectroscopy voxels are indicated 
 with red circles. For the correlation with the apparent diffusion coefficient (ADC), one ROI was 
 adjusted so it contained only tumor tissue (blue circle) C) The T2-weighted image with the 
 spectroscopy grid. The selected spectroscopy voxels are encircled. D) The corresponding 
 ADC map with in yellow the ROIs.
119
6
Contribution of m
orphological features in M
RSI and DW
I of the prostate
Figure 6.2.  Hematoxylin and eosin stained sections and corresponding segmentation in lumen (red), 
 nuclei (green) and stroma & cytoplasm (blue) of a 64-year old patient with a Gleason score 
 4+3 tumor. A, B) Normal transition zone tissue. C, D) Tumor tissue. 
Figure 6.3.  Adjustment of regions of interest (ROIs) in adjacent slices. A) T2-weighted image with 
 spectroscopy grid of a 68 year-old man with a 3+4+5 tumor. The yellow circles indicate 
 the true size of the selected voxels. B) Hematoxylin and eosin (H&E) slice indicating the 
 tumor regions. C) The ROIs corresponding to the voxels selected in A. D) The adjacent H&E 
 slice was used to average the histopathological parameters as the volume of the MRSI voxels 
 is substantially larger than the H&E slices. For ROIs 2, 4 and 5 the average parameters of 
 the two ROIs in the adjacent slices were determined. For ROI 1 a small adjustment was made 
 (black circle) and the average of the two ROIs was obtained. ROI 3 in slice D was not used and 
 only the histopathological parameters of ROI 3 in slice C were used. 
1.6·10-3 mm2) were considered to represent vascular lumens and were therefore excluded. 
Two datasets with training pixels representing nuclei and stroma & cytoplasm were 
compiled. The inverse matrix of their averaged optical RGB densities was determined. For 
each pixel the contribution to nuclei and stroma & cytoplasm was determined by multiplying 
the optical densities of the original image by these inverse matrices. For both nuclei and 
stroma & cytoplasm a cut off value was chosen, which allowed assignment of each pixel 
to the corresponding morphological component (Figure 6.2). As there was variation in the 
HE staining of the sections, it was not possible to use the same cut off values for all slices. 
Therefore, [TK] determined the three cut off values for each slice on a small sample. After 
segmentation, the results were inspected and if necessary, the cut off values were adjusted. 
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To study the intra-observer variability, the cut off values of four slices were determined three 
times in separate sessions at least 10 days apart. 
Matching MR(S)I and histopathology
Two readers experienced in reading prostate MRI [AH and TK] matched independently 
the stained section with a T2w imaging slice and reached consensus for the cases of 
disagreement. Next, one of the readers [TK] checked this matching with a uro-radiologist 
who also had experience with prostate histopathology [TH] and adjustments were made 
where necessary. In cases of doubt, a uro-pathologist [CAHK] was consulted. When no 
matching was possible, e.g. due to misalignment of the prostate before slicing, the patient 
was excluded from the analysis. [TH] and [TK] matched the T2w imaging slice including 
MRSI grid, the corresponding DWI slice (using anatomical landmarks), and the HE-section 
in Adobe Photoshop as separate layers (Figure 6.1). For this manual in-plane registration, 
only proportional scaling was used to overlay the slices correctly; care was taken not to 
deform the slices. Per patient 1 to 8 non-overlapping circular regions of interest (ROIs) could 
be selected that matched MRSI voxels and had the size of the true radius of these voxels 
(Figure 6.1). Blinded from the segmentation of pathology, the ROIs were placed in regions 
containing mainly peripheral zone (PZ), transition zone (TZ) or tumor tissue. As the ROIs 
had to be entirely within one section, the placement of the ROIs was somewhat restricted. 
Care was taken not to place these ROIs in fragmented parts of the section or in regions that 
contained inflammation, granuloma or necrosis. The spectroscopy matrix grid was shifted in 
the cases where this improved the placement of ROIs and a new transformation of k-space 
was calculated by the MR system. As the spectroscopy voxels are relatively large (0.36 
– 1.01 cm3) and the histopathologic sections only a few micrometer thick, the ROIs were 
copied to an adjacent section (4 mm apart), so the average histopathologic features of the 
two sections could be determined (Figure 6.3). When the ROI was partly outside the adjacent 
section or in fragmented tissue, the ROI was altered for the cases where small adjustments 
were sufficient. In the cases where no ROI on the adjacent section could be chosen, only the 
original ROIs were used and no average was obtained (Figure 6.3). 
On the ADC maps, ROIs were drawn on exactly the same regions and locations as the MRSI 
ROIs. The mean ADC value of the pixels in that ROI was determined (Figure 6.1D). The ADC 
ROIs were not necessarily restricted to the size of the spectroscopy voxels. To minimize 
partial volume effects, if necessary, new smaller tumor ROIs were drawn for the ADC analysis 
(Figure 6.1B & D). This was done while blinded for the ADC map. Furthermore, a new adjusted 
ROI was drawn if the ROIs included non-prostatic tissue on the ADC map. All ROIs had 
to consist of at least 20 ADC pixels to ensure a representative ADC value. The ROIs with 
inadequate histopathological segmentation were excluded from the analysis. For the ADC 
maps, the adjacent pathology slice was not used. The percentage areas of nuclei, lumen and 
stroma & cytoplasm were determined for all ROIs. 
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Spectroscopic data analysis 
The ratio of choline plus creatine to citrate [(Cho+Cr)/Cit] or including spermine the ratio 
of [(Cho+Spm+Cr)/Cit], are frequently used as quantitative measures in prostate MRSI. To 
determine the (Cho+Spm+Cr)/Cit ratios, the corresponding signals in MR spectra were fitted 
with LCModel (27) using a basis-set with simulated signals for Cho, Spm, Cr and Cit. Fitting 
was performed with a first order phase of 0. As there is a strong overlap between Cho, Spm 
and Cr, their individual fits are not always reliable. To make the ratio less sensitive to the 
individual fits, the concentrations given by LCModel are converted to a pseudo-integral (the 
intensity in relation to the integral of a singlet of one resonating proton in absorption mode). 
Only spectra were accepted of which the Cramér-Rao lower bounds (CRLB) of the Cit fit and 
the CRLB for the combination of Cho, Spm and Cr were 30% or smaller. Furthermore, the 
signal-to-noise ratio (SNR) determined by LCModel had to be at least 3, the full width at half 
maximum had to be smaller than 11 Hz, and the absolute zero order phase smaller than 85˚. 
Previously, we have used the Cho/Cr ratio as biomarker for the Cho increase in prostate 
cancer, for which we did not include a separate Spm fit (28, 29). As overlap between Spm 
and Cr signals can lead to inconsistent results for each of the compounds separately, we 
included, for this study, Spm in the denominator to obtain the Cho/(Cr+Spm) ratio. The fits 
are probably most reliable in cancer tissue, where the absence of polyamines and increase 
in Cho makes the fitting easier. Only spectra were accepted of which the CRLB of the Cho fit 
and the CRLB of either Cr or Spm were 30% or smaller and of which the correlation coefficient 
between Cho and Spm, as determined by LCModel, was smaller than -0.5. The SNR, full width 
at half maximum and zero order phase requirements were the same as described above.
Statistical analysis
The MR parameters were plotted against each of the quantitative features of histopathology, 
which were percentage areas of lumen, nuclei and stroma & cytoplasm, and the ratio of 
percentage areas of nuclei to lumen. As Cit is the denominator of the (Cho+Spm+Cr)/Cit 
ratio, we plotted the inverse of this ratio [Cit/(Cho+Spm+Cr)] against the percentage area 
of lumen. Furthermore, a decrease of Cit has been observed in prostatic fluids of cancer 
patients (30), so a different relationship between tissue levels of Cit in cancer tissue and 
benign tissue as measured by 1H MRSI and histopathological parameters is anticipated. 
Therefore, two separate plots were made in which the Cit/(Cho+Spm+Cr) ratio was plotted 
against lumen using either tumor or benign data points. The relationship between each pair 
of parameters was determined using linear mixed effect models. The mixed effect model 
accounts for multiple ROIs per patient and patient IDs were included as random-effect 
on the intercept. The slopes were tested against a zero slope with a t-test and Bonferroni 
correction was applied to compensate for multiple comparisons. As part of the data were 
non-parametric, the data could not be normalized, which would facilitate comparison of the 
slopes of the different MR parameters. Therefore, the upper 95%-confidence interval of the 
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slope was divided by the slope (95%-CI/slope) to obtain an impression in the goodness of 
the fits of the linear mixed models. 
All data were tested for normality using a Lilliefors test. For each tissue type, the mean and 
standard deviation of the normally distributed parameters were determined and compared 
with ANOVA and a Tukeys post-test. The median, 25th and 75th percentiles were calculated 
for non-parametric data and compared with a Kruskal-Wallis test with a Dunn’s post-test. 
The statistical analysis was performed using Matlab 7.14 and Prism 4 (GraphPath Software, 
La Jolla, CA).
Results 
Of the fifty-seven patients that met the inclusion criteria, the examination of three patients 
had to be excluded because in one patient the sections could not be segmented reliably 
and for two patients no good match between the MRI and histopathology was possible. In 
the prostates of the remaining 54 patients (see Table 6.1 for relevant patient details) 191 
ROIs could be selected. For the ADC analysis, 184 of 191 ROIs could be included, of which 
46 contained predominantly PZ tissue, 66 predominantly TZ tissue and 72 predominantly 
tumor tissue. For the spectroscopy analysis, 165 of 191 ROIs passed quality control for 
the (Cho+Spm+Cr)/Cit ratio. An example of a good fit is shown in Figure 6.4. There were 
40 voxels containing mainly PZ tissue, 63 containing mainly TZ tissue and 62 voxels with 
mainly tumor tissue. 128 voxels could be used for the analysis of the Cho/(Cr+Spm) ratio, of 
which 30 were predominantly PZ voxels, 46 predominantly TZ voxels and 50 predominantly 
tumor voxels. 
An example of the segmentation of TZ and tumor tissue is shown in Figure 6.2. The median 
percentage areas of the morphological components for benign and tumor PZ and TZ tissue 
are given in Table 6.2 and shown in Figure 6.5. For this, the ROIs drawn for the ADC analysis 
 Figure 6.4.  A) T2 weighted image with spectroscopy grid of the prostate of a 58 year-old man with 
 Gleason 3+3 tumors. The yellow circles indicate the true voxel size of the spectra in C (right 
 peripheral zone) and D (tumor in the left transition zone). B) Corresponding hematoxylin and 
 eosin stained slice with the outline of the tumors. C-D) LCModel fits of normal peripheral zone 
 tissue (C) and tumor tissue (D). 
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Figure 6.5.  Distributions of the percentage areas of lumen (A), nuclei (B) and stroma & cytoplasm (C) 
 for peripheral zone (PZ), transition zone (TZ) and tumor tissue. Distributions of the apparent 
 diffusion coefficient (ADC), the choline plus spermine plus creatine to citrate [(Cho+Spm+Cr)/ 
 Cit] and Cho/(Spm+Cr) ratio are shown in D, E and F. The horizontal bars indicate the median 
 (A, B, E and F) or mean (C, D). * p<0.05, ** p< 0.01***p < 0.001
were used. While no statistical differences were found between the means of the percentage 
areas of stroma & cytoplasm for PZ, TZ and tumor ROIs, the medians of the percentage areas 
of lumen and nuclei for tumor ROIs in the PZ and TZ were significantly different from benign 
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Lumen Nuclei Stroma & Cytoplasm
Normal peripheral zone 23.7 (16.6-29.3) 7.7 (6.0-9.3) 66.5 ± 9.2
Normal transition zone 20.0 (16.1-25.2) 8.2 (5.7-10.7) 69.0 ± 9.5
Tumor 10.7 (8.5-16.0) 12.0 (9.2-15.6) 70.4 ± 9.1
     Peripheral zone tumor 11.4 (8.7-16.0) 12.5 (9.3-15.8) 69.6 ± 9.8
     Transition zone tumor 9.8 (7.1-15.4) 11.2 (9.2-13.4) 72.3 ± 6.8
Table 6.2.  Quantitative data of morphological components of normal peripheral zone, normal transition 
 zone and tumor tissue. Data are given in median percentage areas with the 25th and 75th 
 percentiles or as mean with standard deviation. The prostate zonal tissue indicated in the 
 left column, is the dominating component in the region of interest, but other zonal tissue 
 components can be present. A very small part of the tissue could not be classified. 
ADC (x 10-3 mm2/s) (Cho+Spm+Cr)/Cit Cho/(Cr+Spm) 
Normal peripheral zone 1.58±0.23 0.33 (0.29-0.42) 0.58 (0.42-0.75)
Normal transition zone 1.26±0.20 0.48 (0.41-0.58) 0.65 (0.52-0.86)
Tumor 1.15±0.26 0.59 (0.43-0.72) 0.90 (0.59-1.32)
     Peripheral zone tumor 1.20±0.27 0.56 (0.41-0.70) 0.92 (0.59-1.38)
     Transition zone tumor 1.03±0.20 0.68 (0.51-0.97) 0.85 (0.60-1.20)
Table 6.3.  The apparent diffusion coefficient (ADC), (Cho+Spm+Cr)/Cit ratio and Cho/ 
 (Cr+Spm) ratio for normal peripheral zone, normal transition zone and tumor tissue. ADC 
 data are given as the mean with standard deviation and spectroscopy data as mean with the 
 25th and 75th percentiles. The tissue type indicated is the main component in the region of 
 interest/voxel, but other tissue components can be present.
PZ and TZ tissue (Figure 6.5). No significant differences in the fraction of histopathological 
components were found between PZ and TZ tumors. Furthermore, there was good intra-
observer-variability: the mean difference between three repeated measurements of the same 
slices was 3.0% for lumen, 7.0% for the nuclei, and 1.3% for stroma & cytoplasm. 
The mean ADC values of the two zonal tissues (p<0.001) and between tumors in these zones 
(p<0.05) were significantly different. For tumor tissue in each zone these values also differed 
with respect to normal tissue (Table 6.3, Figure 6.5). The median (Cho+Spm+Cr)/Cit ratio was 
significantly different between normal PZ tissue and tumor tissue (in PZ and TZ) (p<0.001) 
and between normal TZ tissue and TZ tumors (p<0.05) (Figure 6.5).
The ADC value had a significant positive relation with the percentage area of lumen (Figure 
6.6A, p<0.001). Negative relations were found between the ADC value and the percentage 
areas of nuclei (p<0.001), stroma & cytoplasm (p<0.01) and the ratio of nuclei/lumen 
(p<0.001) (Table 6.4, Figure 6.6E). The 95%-CI/slope ratio for the relations with lumen, nuclei 
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and nuclei/lumen were in the same range (Table 6.4), but for stroma & cytoplasm the 95%-CI/
slope ratio was 1.74, which indicates a substantial spread on the data, which is also evident 
from the larger p-value. 
The (Cho+Spm+Cr)/Cit ratio correlated positively with the percentage areas of nuclei 
(p<0.001), stroma & cytoplasm (p<0.01) and the ratio of nuclei/lumen (p<0.001) (Table 6.4, 
Figure 6.6F). The inverse of this ratio, the Cit/(Cho+Spm+Cr) ratio, related positively with the 
percentage area of lumen (p<0.001) (Figure 6.6B). These data were then separated in benign 
and cancer data points, as a decrease of Cit has been observed in prostatic fluids of cancer 
patients (30). Based on that study, a lower intercept for tumor voxels might be expected, 
which was the case (0.85 for tumor and 2.09 for benign voxels (Figure 6.6C & D)). There 
was also a large difference in the slopes of the two data sets. The fit for the benign data 
points was not significantly different from a zero-slope (p=0.05), while for the cancer voxels 
a steeper slope was found (p<0.001) compared to all data points (Table 6.4). 
For the Cho/(Cr+Spm) ratio no significance was found with the percentage area of stroma & 
cytoplasm, but with the other histopathological parameters significant relations were found 
(Table 6.4). For some of the slopes relating 1H MRSI parameters to histopathology, there was 
quite some spread on the data, indicated by larger 95%-CI/slope values (Table 6.4). 
Lumen Nuclei Stroma & Cytoplasm Nuclei/Lumen
ADC value 13.1**
(1.30)
-20.0**
(1.39)
-6.0**
(1.74)
-141.9**
(1.33)
(Cho+Spm+Cr)/Cit 0.023** 
(1.58)
0.009**
(1.75)
0.229**
(1.33)
Cit/(Cho+Spm+Cr)
0.043** (1.36) all data
0.018     (2.02) benign
0.074** (1.42) tumor
Cho/(Cr+Spm) -0.015*
(1.73)
0.053**
(1.40)
-0.003
(5.16)
0.324**
(1.52)
Discussion
In this study, the relations between the quantitative histopathological morphology of 
prostate tissue and the MR parameters of DWI and 1H MRSI were investigated. The fraction 
of morphological components derived from a histopathological analysis of prostate 
specimens showed significant relations with values for the ADC and metabolite signal ratios 
Table 6.4:  Slopes for the MR parameters versus the fraction of morphological components
 Data are tested for significance against zero slope. **p<0.001, *p<0.01
 In brackets the ratio of the upper 95% confidence interval divided by the slope. 
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Figure 6.6.  A) ADC value of all ROIs plotted against the corresponding percentage area of lumen and in 
 E) against the ratio of the percentage areas of nuclei and lumen. B) Cit/(Cho+Spm+Cr) ratio 
 of all ROIs plotted against the corresponding percentage area of lumen. These data point 
 were separated in benign voxels (C) and tumor voxels (D). F) (Cho+Spm+Cr)/Cit ratio plotted 
 against the ratio of the percentage areas of nuclei and lumen. All data were fitted with a linear 
 mixed effect model and slopes deviated significantly from zero (p<0.001), except the slope 
 between the Cit/(Cho+Spm+Cr) ratio and the percentage are lumen (p=0.05). For displaying 
 purposes, the encircled data points in E and F are moved along the x-axis from 6.5 to 3.5. 
(Cho+Spm+Cr)/Cit and Cho/(Cr+Spm). These results suggest that the differences in these 
values are at least in part due to morphological changes of prostate tissue. 
Previously, ADC values have been correlated to the percentage area of nuclei, lumen, epithelial 
cytoplasm and stroma (7). Although the researchers applied z-score normalization on their 
data and used different b-values, the results are comparable to what we obtained in this 
study. They found a significant positive slope for the normalized ADC value plotted against 
the normalized percentage area of lumen and a negative slope against the normalized 
percentage area of nuclei, which corresponds to our findings. In that study also a negative 
slope with the percentage area of cytoplasm was found, while a relation with stroma was 
lacking (7). Due to the small intensity difference in HE-staining in our study, we did not 
distinguish between epithelial cytoplasm and stromal tissue, but these results suggest 
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that the negative slope found between the ADC value and the combined percentage area of 
stroma & cytoplasm is driven by the cytoplasmic component. The relations between the ADC 
value and the amount of lumen, cytoplasm and nuclei have been explained to be dominated 
by the luminal space (7). In this view, a decrease in the ADC value is caused by a smaller 
luminal space, which is accompanied by a fractional increase in cytoplasm and nuclei 
(31). DWI of ex vivo prostate tissue at very high resolution (40 μm) also suggests that the 
ADC difference in tumor tissue depends on a change of the partial volumes of the stromal, 
epithelial and luminal space, which were estimated from three diffusion components derived 
from a tri-exponential fit (32). 
Significant relations were also found between the 1H MRSI derived metabolite ratios and 
fractional morphological components of the prostate analyzed by histology. The relation 
between tissue concentration of Cit and gland to stroma ratio has been studied previously 
in prostate tissue samples using high resolution MRS (33). In that study, more Cit was found 
for a higher amount of glands in benign prostatic hyperplasia (BPH) tissue. However, no 
significant relation between Cit and glands was found for cancer tissue (33). In our study, we 
did find a significant slope between Cit/(Cho+Spm+Cr) and the relative amount of lumen for 
tumor tissue, while this relation lacked significance for benign tissue. We combined both PZ 
and TZ benign tissue, did not study BPH separately and used a metabolite ratio. Also the fact 
that our method to quantify the morphological compounds was more accurate, can explain 
these differences. 
Costello and Franklin attributed the decrease of Cit in prostate cancer to the lack of zinc 
leading to the activation of m-aconitase and consequently the oxidation of Cit (13-15). 
They hypothesized that the transformation of normal prostate cells to citrate-oxidizing 
cells occurs before a histopathological change can be observed (34). Another theory for 
the decrease in Cit in prostate cancers is an increase in the enzyme ATP-citrate lyase in 
malignant tissue, which would result in conversion of Cit to fatty acids, necessary for cell 
membrane synthesis (35). For m-aconitase and ATP-citrate lyase a relationship between 
their expression and prostate Cit levels has been observed (36). Both enzymes influence 
the Cit level in epithelial cells (which is estimated as low as 1-2 mM in epithelial cells of the 
rat ventral prostate (13)), while the majority of Cit is excreted into the luminal space. The 
tissue levels of Cit in the PZ as estimated by MRS are approximated at 31-42 μmol/g wet 
weight (20, 37) and 48 mM (38). So the effects of m-aconitase and ATP-citrate lyase can 
only be detected with 1H MRSI if they not only affect Cit levels in the epithelial cells, but also 
disrupt the deposition of Cit to the luminal space. Although we cannot rule out with our data 
that these enzymes influence the Cit levels we observe with 1H MRSI, it is likely that these 
contributions are much smaller than the morphological change.
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We used the Cho/(Cr+Spm) ratio as biomarker for the Cho increase in prostate cancer. We 
expected a relation between Cho and the cell density (percentage area nuclei), as Cho is a 
precursor and breakdown product of phosphatidylcholine, a major cell membrane compound. 
Indeed, a significant relation was found. However, also metabolic processes (increased 
expression and activity of choline-kinase, a higher rate of choline transport and an increased 
phospholipase C and D activity) play a role in the Cho increase in cancer (39). The amount 
of Cho can thus be directly related to the cell density as well as to Cho metabolism and we 
cannot distinguish between these effects. 
Our results indicate that the ADC value and (Cho+Spm+Cr)/Cit ratio might reflect the same 
underlying morphologic basis in the prostate. Both parameters are for an important part 
determined by the amount of luminal space. However, it is likely that other independent 
factors also contribute to their values. Based on high resolution ex vivo prostate DWI 
measurements three different diffusion components have been proposed, conveniently 
assigned to epithelial cells, stroma and the luminal space (32, 40), which all influence the 
ADC value. Furthermore, the Cit/(Cho+Spm+Cr) ratio depends also on Cho and Spm changes. 
However, the reported differences of Cho concentrations between tumor (7.1 mM (38)) and 
normal PZ tissue (4.3 mM (38)) are much smaller than the differences in Cit concentrations 
between tumor tissue (3.7 and 5.9 μmol/g wet weight (20, 37) or 12.5 mM (38)) and normal 
PZ (30.9 and 42.4 μmol/g wet weight (20, 37) or 48 mM (38)) or normal TZ tissue (46.3 
and 64.5 μmol/g wet weight (20, 37)). Also reductions up to 75% of the Spm concentration 
have been observed in J-resolved MR spectroscopy experiments at high field in prostate 
cancer biopsy samples (41). Furthermore, complexation of Cit, Zn2+ and Spm (16, 42, 43) 
and interactions of these with proteins such as prostate specific antigen (44) might occur 
in prostatic fluid. In the case of tumor tissue the composition of prostatic fluid will change 
(42, 45) which may have an effect on T2 values of Cit and Spm (46). Next to this, in prostatic 
fluids of cancer patients, a decrease in Cit levels has been observed (30). Therefore, we did 
a separate analysis for benign and tumor voxels. In the case of a lower Cit concentration in 
tumor tissue, a lower intercept is expected, which we observed. Interestingly, we also found a 
large difference in the slopes of the two benign and tumor data sets. The slope for the tumor 
data points was steeper compared to all data points, while for the benign voxels the slope 
was not significantly different from a zero-slope. The lack of significance might be explained 
by the spread on the data: figure 6.6B & C show relative high Cit levels in ROIs with a relative 
small percentage area of lumen in the PZ, while in the TZ there are some outliers with low 
Cit levels and relatively high percentage areas of lumen. These might be the consequence of 
large lumen with low Cit concentrations or opposite. This demonstrates that other factors 
play a role. The Cit concentration in the prostatic fluid might for example drop in dilated 
lumen. Another aspect to consider is the fact that we used a linear model, although there 
is not necessarily a linear relation between the parameters, especially the validity of this 
model for a metabolite ratio might not be appropriate. In our study also a relation was made 
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between the ADC value and (Cho+Spm+Cr)/Cit ratio with the fraction of nuclei to lumen ratio 
(Figure 6.6 C&D). This ratio incorporates some of the above-mentioned factors.
Although in this study significant relations were found, there was still substantial spread on 
the data. This overlap can partly be explained by the limitations of our study. The matching 
between histopathology and MR imaging is a difficult task. To minimize the error, the 
matching was done in consensus, and in doubt a pathologist was consulted. Both the T2w 
image and pathology slices were made perpendicular to the rectal wall; however, there might 
still be an angulation difference. Furthermore, discrepancies in the shape of the in and ex 
vivo prostate were present in some cases. Therefore, ROIs were placed only in locations with 
a good matching. This problem could have been diminished by using a mold, based on the 
prostate shape on the MR images, to cut the slices in the same orientation and preserve the 
in vivo shape (47). The ROI corresponding to a voxel had to be completely within the section 
of the pathology. As each prostate slice consisted in most cases of several sections, the ROI/
voxels could not always consist of solely tumor tissue, leading to the introduction of partial 
volume effects. However, as these were also present in the MRSI and DWI data, these do not 
affect the relation between the MR parameters and histopathologic features. Since there is 
a volume difference between the MR(S)I slices and the thin (4 μm) histopathology sections, 
we have to assume that the HE-sections are representative for all tissue in the slice. For the 
spectroscopy voxels (volume between 0.37 and 1.0 cm3), the average parameters of two 
adjacent histopathology slices (if possible) were used to reduce the dependence on one thin 
slice.   
Although small, there were some variations between the repeated segmentations, especially 
for the smallest component: the nuclei. In some patients, the nuclei of the tumor cells were 
largely increased and the staining of these large nuclei was not homogenous and the true 
amount of nuclei might have been slightly underestimated. Due to the minimal differences 
in staining between epithelial cytoplasm and stromal tissue, no distinction could be made 
between these two, which limits the conclusions that can be drawn from this study. Although 
regions with artifacts (e.g. regions with many corpora amylacea) were not included, other 
artifacts might be present in the segmentation. For example, in some patients proteinaceous 
secretions were present in the luminal space. When these secretions were strongly stained, 
they have been erroneously classified as stromal tissue. 
The use of a pulse sequence with a long echo time and short repetition time, and 
inhomogeneous coil profiles forced us to revert to ratios for the 1H MRSI data. Therefore, it 
was not possible to directly relate Cit concentrations to the percentage area of lumen or Cho 
to the area of nuclei (or epithelial cytoplasm). To accomplish this, the water signal should be 
measured to enable absolute quantification of the metabolites. Such a measurement would 
be challenging and time-consuming. Assumptions regarding T1 and T2 of metabolites and 
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water content are required for absolute quantification and the overlap between Cho, Spm 
and Cr would still be present. However, it would allow studying the relation of the metabolites 
with morphology more directly.
In conclusion, significant relations between the histological morphology of prostate tissue 
and the MR parameters of DWI and MRSI were found. These results suggest that the 
differences in ADC values and 1H MRSI ratios between normal prostate and cancer tissue 
are largely determined by similar morphological changes, in particular the luminal space. 
Although we cannot rule out that biochemical processes (like m-aconitase or ATP-citrate 
lyase) and interactions in prostatic fluid also influence the Cit and Spm signals in 1H MRSI 
of the prostate tissue, it is likely that these contributions are smaller than the morphological 
changes.
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Introduction: 
The estimated number of prostate cancer deaths in the United States was 32,050 in 2010, 
making the disease the second leading cause of cancer-related death (1). However, prostate 
cancer is often non-aggressive and it was shown that to prevent one prostate cancer death 
over 11 years by means of prostate-specific antigen (PSA) screening, 37 men need to be 
treated (2). It is estimated that half of these treated men would not have presented any 
clinical symptoms during the rest of their life if no screening had been performed (3). To 
prevent overtreatment, an accurate assessment of prostate cancer aggressiveness is 
indispensable. 
Several MR techniques have shown promising results for a noninvasive assessment of 
cancer aggressiveness. One of these techniques is  1H MR spectroscopic imaging (1H MRSI), 
which can measure the distribution of choline (Cho) and creatine (Cr) compounds, citrate 
(Cit) and polyamines, mainly spermine (Spm), in the prostate. From these metabolites, the 
(Cho+Cr)/Cit ratio and the Cho/Cr are often used to detect prostate cancer (4-6) and to 
characterize cancer aggressiveness (7,8). 
Another metabolite that is of strong interest for cancer characterization is lactate (Lac), 
which is an end-product of glycolysis. Lac may occur in tumors because of hypoxia and even 
under aerobic conditions as a result of high glycolytic rates, which is known as the Warburg 
effect. Increased Lac levels are linked to increased aggressiveness and distant metastasis 
(9-11). Previous attempts to measure hypoxia in the prostate were performed by blood 
oxygenation level-dependent MR imaging (12). A correlation with whole mount sections of 
the excised prostate, stained for hypoxia by pimonidazole indicated high sensitivity (88%) 
for detecting hypoxia, but limited specificity (36%) (12). Another important aspect of tumor 
hypoxia is that it reduces the effectiveness of chemotherapy and radiotherapy (9), which 
makes Lac an interesting potential marker to predict treatment outcome. 
Using high resolution magic angle spinning (HR-MAS) spectroscopy, average Lac levels of 
1.6 mmol/kg were reported in snap-frozen prostate cancer biopsy samples (compared to 0.6 
mmol/kg in benign biopsy samples)(13). However, only 6 out of 16 tumor biopsy samples had 
a Gleason score of 7 or higher and the biopsy cores consisted mainly of benign tissue (only 
27% of cancer tissue on average). From these HR-MAS studies we cannot derive whether 
Lac levels in high grade prostate cancer are high enough to be detected with in vivo 1H MRSI. 
Generally point-resolved spectroscopy (PRESS) volume localization is used in 1H MRSI 
of the prostate, in combination with frequency-selective refocusing pulses and crushing 
gradients to suppress lipid and water signals (14). Since the chemical shifts of Lac and 
lipids overlap at 1.3 ppm, the Lac resonance is also affected and crushed by the frequency-
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selective refocusing pulses and gradients of conventional prostate MRSI. When a 
sequence without frequency-selective suppression is used to study Lac, periprostatic lipid 
contamination can only be prevented by accurate volume selection within the prostate and 
spatial saturation slabs positioned on periprostatic fat. Another issue that complicates 
the detection of Lac with the conventional PRESS sequence at higher field (≥ 3 T) is the 
chemical shift displacement artifact. The limited excitation and refocusing bandwidth of 
the pulses of conventional PRESS and the large chemical shift difference between the two 
Lac resonances at 1.3 ppm and 4.1 ppm means that the two resonances are excited at 
partially different locations in the prostate, which will lead to partial scalar evolution and as 
a consequence signal loss (15,16). A solution that overcomes both problems is the use of 
adiabatic pulses. Localization by adiabatic selective refocusing (LASER) uses three pairs of 
adiabatic full passage (AFP) pulses that result in a near-perfect volume excitation (17). To 
make this sequence less specific absorption rate (SAR) intense, we replaced two adiabatic 
pulses by one nonadiabatic slice-selective excitation pulse (semi-LASER) (18,19). 
The aim of this study was to evaluate the presence of Lac in patients with highly aggressive 
prostate cancer. For this purpose the semi-LASER sequence was optimized for in vivo 
Lac detection. To quantify the amount of Lac in the prostate, an LCModel basis set was 
developed. As Lac could reveal the presence of hypoxia, which induces resistance to both 
radiotherapy and chemotherapy, Lac might be a valuable biomarker in 1H MRSI for prostate 
cancer management. In MR spectra of patients without a detectable Lac resonance, we 
assessed a threshold value for Lac levels. 
Methods: 
MR Hardware, Pulse Sequence, and Timing
For all measurements a Siemens Trio 3T system (Siemens Healthcare, Erlangen, Germany) 
was used. The semi-LASER sequence for MRSI is shown in Figure 7.1 and consists of a 4 
ms Shinnar-Le-Roux 90˚ excitation pulse and four adiabatic 2nd order hyperbolic secant 
pulses (20) of 8 ms duration. A γB1 of 718 Hz was used for the adiabatic pulses, resulting in 
a bandwidth of 3 kHz. As there are four adiabatic full passage (AFP) pulses, there are four 
inter-pulse durations, τ1, τ2, τ3 and τ4, and a delay before acquisition, τ5, that can be varied 
at a given echo time (TE) (Figure 7.1). 
For scalar coupled spin systems, like Lac and Cit, the echo time, inter-pulse timing and the 
type of pulses influence the spectral modulations. Lac consists of four nonexchangeable 
protons, of which the three protons in the methyl group resonate at 1.3 ppm and the other 
proton resonates at 4.1 ppm. The scalar coupling in Lac is 6.93 Hz and it is a weakly coupled 
spin-system (21). The use of an echo time (TE) of 144 ms will lead to a doublet of Lac at 1.3 
ppm and a quartet at 4.1 ppm, both 180˚ out of phase. 
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Cit consists of two magnetically equivalent methylene groups, in which the protons in 
each methylene group are magnetically inequivalent, making it strongly coupled. The exact 
chemical shifts and scalar coupling of Cit depend on the pH (22) and cation concentration 
(23), but are ~2.57 ppm, 2.72 ppm and 15.5 Hz respectively (16). The spectral shape of Cit 
strongly depends on the TE, but also on the timing of the refocusing pulses (24,25). As Cit 
is important for prostate cancer detection and characterization with MRSI, a spectral shape 
that leads to a high signal intensity is preferable. 
In this study a TE of 144 ms was chosen, as an inverted Lac signal is desired for better 
distinction between Lac and residual lipid signals. The timing of the four AFP pulses at this 
TE influences the shape of Cit and therefore simulations were performed to obtain the best 
pulse timing for an optimal Cit shape. 
Simulation study: 
The sequence and pulses were simulated using NMR-SIM software (part of Topspin, Bruker 
BioSpin Corporation, Billerica, MA, USA). The timing between the AFP pulses was varied and 
the corresponding simulated Cit and Lac signals were studied using the Topspin software. An 
optimal timing was obtained that resulted in a spectral Cit shape with a high signal intensity.
Figure 7.1.  In the semi-LASER sequence, the delays τ1 to τ4 between slice-selection and AFP pulses 
 were varied to obtain an optimal shape of the citrate resonance at an echo time TE = 144 ms. 
 From top to bottom, RF and the gradients in three directions (Gx, Gy and Gz) are indicated.  
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Phantom study: 
After optimization of the interpulse timing, the sequence was tested on two phantoms. 
Phantom 1 contained Cit, Cho, and Cr, and phantom 2 held Lac and Cr. After localization and 
B0 shimming the optimized semi-LASER sequence was tested on both phantoms. 
Patients: 
The institutional ethics review board waived the need for informed consent as the study was 
a short extension of a clinical MR exam. Seventeen patients with biopsy-proven prostate 
cancer were measured between December 2009 and September 2011. The patients were 
referred to the department of radiology by a urologist for an MRI exam to examine the local 
extent of the tumor. Only patients with aggressive prostate cancer were included, which 
was defined as either a Gleason score of 7 or higher at biopsy or a PSA level higher than 
20 ng/ml. For signal reception an endorectal coil was combined with a body-array matrix. 
To suppress peristalsis the patients were injected intramuscularly with 1 mg glucagon 
(Glucagen, Nordisk, Gentofte, Denmark) and 20 mg of butylscopolaminebromide (Buscopan, 
Boehringer-Ingelheim, Ingelheim, Germany). The clinical exam consisted of high resolution 
T2-weighted imaging in three directions, diffusion weighted imaging, conventional PRESS 
based MRSI and dynamic contrast enhanced imaging. Before MRSI B0 shimming was 
performed to optimize field homogeneity. PRESS spectroscopy was acquired in 16 of the 
17 patients. For the PRESS based MRSI elliptical weighted k-space sampling and Hanning 
filtering was applied. The number of averages varied between 3 and 6, and between 10 and 
14 phase encoding steps were used in each direction. Depending on the size of the prostate 
an effective voxel volume between 0.37 and 1.01 cm3 was chosen. A TE of 145 ms and a TR 
of 750 ms were used (24). 
In addition to the clinical exam, 17 patients were measured with the 3D MRSI semi-LASER 
sequence. For the 3D MRSI semi-LASER sequence an effective voxel volume, after Hanning 
filtering and elliptical weighted sampling, of 1.5 cm3 was chosen. The number of phase 
encoding steps were either 8 or 10 in all directions and the number of averages varied 
between 1 and 4. Based on the T2-weighted images, the volume of interest was placed 
completely inside the prostate. To minimize lipid contamination, spatial lipid saturation slabs 
were placed around the volume of interest. The posture of the patient influences the amount 
of RF power needed for the adiabatic pulses. For each patient, the minimal TR for the semi-
LASER sequence (and thus lowest acquisition time) was chosen that led to compliance with 
the SAR limit of that patient.
Data analysis: 
A spectroscopist (TK), blinded for the spectra, selected all tumor-containing voxels in 
the PRESS and semi-LASER datasets based on the clinical reading of a radiologist of T2-
weighted images and diffusion weighted images.  Metabolite Report (Siemens Healthcare, 
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Erlangen, Germany) was used for analysis of MR spectra acquired with the PRESS sequence. 
This prototype software package fits Cho, Cr and Cit signals in the time domain and was 
used to determine the (Cho+Cr)/Cit and Cho/Cr ratios (26). All fits were visually inspected 
by a spectroscopist (TK) and only the voxels that passed the quality check for sufficient 
SNR, appropriate fit and absence of baseline distortions were included. For each patient, 
the maximum (Cho+Cr)/Cit and Cho/Cr ratio of all accepted tumor voxels were determined. 
Furthermore, for all tumor voxels the malignancy rating by the standardized threshold 
approach (7,27,28) was determined. The standardized threshold approach is a method to 
combine both metabolite ratios into one score. The initial rating is based on the (Cho+Cr)/
Cit ratio and ranges from 1 to 5, in which 5 indicates the highest malignancy probability. The 
cut off values for the (Cho+Cr)/Cit ratio are based on the values described in (26). The initial 
rating is adjusted for deviating Cho/Cr ratios and here a cut off of 2.3 is used (7). For each 
patient, the maximum malignancy rating was determined. 
To analyze the semi-LASER spectra, an LCModel (29) basis set was developed for fitting 
Cho, Cr, Spm, Cit, Lac and a singlet at 2.05 ppm. The spectral shapes of Cho, Cr, Cit, Lac and 
the 2.05 singlet were simulated. For Cr, Cho and Lac only the methyl resonances at 3.0, 3.2 
and 1.3 ppm, respectively, were included. The more downfield resonances around 4 ppm 
might be influenced by the water suppression, which could affect quantification. To obtain 
the spectral shape of Spm, a phantom containing Spm and trimethylsilyl propionic acid (as 
reference) at pH 6.8 and 310˚K was measured in the MR-scanner using the semi-LASER 
sequence. 
All spectra were analyzed twice. First it was determined whether a spectrum was 
contaminated with lipids by using the LCModel option to fit several lipid signals. For this 
fit, the Lac signal was excluded from the basis set, since the presence of Lac in the basis 
set could affect fitting of lipids. The output of these analyses was only used to determine 
whether a spectrum contained lipid signals. Next, the data were fit with Lac in the basis set, 
but without lipid fitting. The output of this fit was used to determine the Lac concentration 
in the prostate. All processing was performed without restricting the zero-order phase of the 
spectrum, a first-order phase of 0 and limited baseline flexibility. In the output, the integral 
values of the resonances with the corresponding Cramér-Rao lower bound (CRLB) were 
given. In this study, metabolite fits with a CRLB smaller than 20% were accepted. A CRLB of 
≈ 20% indicates that signal changes of approximately 40% can be detected reliably, and is 
therefore often used as cut off for reliability (30). 
Spectra were analyzed for the presence of Lac if the line-width was appropriate for small 
molecule metabolites (FWHM ≤0.1 ppm), there was no or limited lipid signal present in the 
spectra fitted for the presence of fat (CRLB of lipid fits ≥ 20%), and the SNR of the spectrum 
was sufficient (SNR ≥3). The SNR in LCModel is defined as the maximum in the spectrum 
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(minus baseline) divided by two times the root-mean-square of the residuals (30). If in 
none of the tumor voxels of a patient a Lac fit was accepted, the hypothetical minimal Lac 
concentration was determined with the use of Cr as an internal reference. A simulated Lac 
signal was added to all spectra in a dataset. As the zero-order phase varies over the spectra, 
the simulated Lac signal of each spectrum was added with the phase of the spectrum 
determined by LCModel on the original dataset. Furthermore, the estimated full width at half-
maximum of the fits of the accepted tumor voxels was used to determine the appropriate 
line-width of the added Lac signal for each patient. For all tumor voxels with a CRLB of the 
Lac fit smaller than 20%, the Lac concentration was determined as described in (31). The 
adapted formula for our purposes is:
 
     (7.1)
In which [Lac] is the Lac concentration, [Cr] the Cr concentration, I the integral of the fit and fT1 
and fT2 the correction factors for relaxation effects. Since Cr and Lac both have one methyl-
group contributing to their resonances at 3.0 and 1.3 ppm, no correction for a difference in 
number of protons is needed. 
The correction factors for relaxation effects are: 
  
     (7.2)
     (7.3)
For Cr the T1 and T2 of prostate measurements at 1.5 T were used, and these were 864 
and 209 ms, respectively (32). As the relaxation times of Lac in the prostate are unknown, 
relaxation times obtained in brain measurements at 1.5 T were used. The shortest T2 for Lac 
found in literature was 225 ms (33). For Cho and Cr in the brain relative long T1 values of 1.39 s 
and 1.54 s (34) were reported compared to the prostate (837 ms and 864 ms, respectively). 
For brain only one T1 value for Lac was found at 1.55 s (35). Assuming a comparable 
difference between brain and prostate T1 values for Lac as observed for Cr and Cho, we 
estimated a T1-value of 0.9 s for Lac in the prostate. A Cr concentration of 4.4 mM, obtained 
from an in vivo MR measurement in the prostate, was used as the standard for all voxels 
(32). The amplitude of the simulated Lac signal was iteratively lowered by 10% until in none 
of the tumor voxels Lac was detected. The lowest minimal detectable Lac concentration was 
calculated for all tumor voxels that had sufficient SNR, an appropriate line-width, no lipids 
and an accepted Cr fit. For each patient this Lac detection limit was determined. 
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Results 
At a TE of 144 ms, simulations showed an in-phase Cit spectrum with an interpulse timing 
τ1= 11 ms, τ2= 21 ms, τ3= 29 ms, τ4= 51 ms and τ5= 32 ms.  This pulse timing led to a nearly 
fully absorptive Cit shape (Figure 7.2A) and an inverted Lac doublet (Figure 7.3A). 
The sequence was tested on two phantoms. The spectral shape of Cit, obtained from a 
phantom containing Cit, Cho, and Cit closely resembled that of the simulated Cit shape 
(Figures 7.2A,B). An inverted Lac signal was obtained in the second phantom which held Lac 
and Cr (Figure 7.3B). 
Figure 7.2. Simulated and measured spectral shapes of Cit. An echo time of 144 ms with τ1= 11 ms, τ2= 
 21 ms, τ3= 29 ms, τ4= 51 ms and τ5= 32 ms is used for the simulated spectrum in A, the 
 phantom measurement in B and the in vivo measurement in C (central gland tissue). The 
 phantom contained Cho (9 mM), Cr (12 mM) and Cit (90 mM). In vivo also a signal likely rep 
 resenting an acetyl group, possibly N-acetyl neuraminic acid (NNA), was observed. 
Figure 7.3.  A) Simulated spectral shape of Lac using the semi-LASER sequence with an echo time of 144 
 ms. B) The measured spectrum in a phantom containing Cr (100 mM) and Lac (100 mM).  
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Figure 7.4.  The minimal detectable lactate concentration per patient. The mean detection limit for the 
 MR spectroscopic imaging data was 1.5 mM.
The 17 patients had an average PSA level of 20.2 ng/ml (3.7 – 79 ng/ml) and the following 
Gleason scores on biopsy: 6 (n=1), 7 (n=4), 8 (n=4), 9 (n=7) and 10 (n=1). Depending on 
patient body weight and body coil load, the TR for the semi-LASER sequence ranged from 
1400 ms to 2280 ms, and the total acquisition time between 4:26 and 11:42 minutes. 
The average of the maximum (Cho+Cr)/Cit ratio, obtained from the PRESS data, found in 
each patient was 12.6 (range 1.6 -105.3) and the average maximum Cho/Cr ratio was 12.2 
(range 3.7 - 34.3). The maximum malignancy rating of the standardized threshold approach 
was in all patients 5, which is the highest value that can be obtained. 
In the 17 patients measured with the 3D semi-LASER sequence, 897 (partially overlapping) 
tumor voxels could be selected. An effective voxel volume of 1.5 cm3 was used in a field 
of view of 64 x 64 x 64 mm or 80 x 80 x 80 mm. Of these, 302 voxels (37%) met all criteria 
of sufficient SNR, an appropriate line-width and no lipid contamination. In three patients, 
none of the voxels met the criteria and these had to be excluded from the analysis. Only in 
two spectra of one patient, Lac was fitted with a CRLB smaller than 20%. However, in both 
spectra there was a large lipid resonance present, which was too broad to be recognized by 
LCModel as lipid. Therefore, the fitted Lac signal was not reliable. 
Excluding this patient, in 11 of the remaining patients the minimum detectable Lac level 
could be determined and was 1.5 mM on average (range 0.9 - 3.5 mM) (Figure 7.4). In one 
patient the minimal detectable limit could not be determined due to technical failure and in 
one other there was a lack of a reliable Cr fit. In Figure 7.5 an original spectrum and the same 
spectrum with Lac added at the detection limit is shown for one voxel of the data set of one 
of the patients.  
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Figure 7.5.  A) T2-weighted image of the prostate of a 72-year-old male with a tumor in the right 
 peripheral and transition zone (indicated in red) with a Gleason score of 9 and a PSA level 
 of 16.3 ng/ml. In B the original spectrum of the blue voxel in A. Lac is added at the detection 
 limit in D and C (LCModel fit), leading to a minimal detectable Lac concentration of 1.4 mM. 
 The other detectable metabolites are Cho, Cr, Cit and possibly N-acetyl neuraminic acid 
 (NNA). Not indicated are the signals of spermine, of which resonances can be found close to 
 creatine.
Although the spectra of several patients were contaminated with periprostatic lipid signals, 
in one patient the origin of the lipid signals was from the tumor. The biopsy samples of this 
patient had a Gleason score of 5+5 and extensive necrosis was present. The T2-weighted 
image shows areas of higher signal intensity in the tumor, which could be caused by lipids 
(Figure 7.6). More convincingly are the spectral maps (Figure 7.6), which show the highest 
intensity of lipid signals in the center of the tumor and small lipid signals on the edge of the 
volume of interest, illustrating accurate selection of the volume of interest with the semi-
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LASER localization. If originating from periprostatic fat, the lipid signals would be largest 
in the edge of the volume of interest and lower in the center. Interestingly, the apparent 
diffusion coefficient (ADC) map has areas of low signal intensity on the rim of the tumor and 
high signal intensity in the center of the tumor (Figure 7.6).
Discussion 
In this work we investigated the presence of Lac in patients with highly aggressive prostate 
cancer using in vivo 1H MRS. For this purpose the semi-LASER sequence was optimized to 
obtain an inverted Lac signal and a maximized in-phase Cit shape. In total 17 prostate cancer 
patients were measured, but in none of the identified tumors was a Lac signal detected 
convincingly. 
The lack of a Lac signal in our spectra does not imply that there is no Lac produced by these 
highly aggressive prostate tumors. It means that if these tumors produce Lac, that either Lac 
is rapidly cleared from the prostate, or that they produce it in small amounts. For that reason, 
the minimal detectable Lac concentration was determined. Some patients had to be excluded 
as lipid contamination could not be prevented, but in 11 patients the minimal detectable 
Lac concentration was determined. From the minimal detectable Lac concentrations, we 
estimate that Lac levels stay below 1.5 mM in cancer tissue of the prostate. In contrast, in 
brain tumors increased Lac signals are observed, ranging from 1.5±1.0 mM for astrocytoma 
grade 2 to 14.2±7.1 mM for brain metastases (36). 
In astrocytomas a correlation between necrosis and lipid levels is observed, as well as an 
increase in lipid and Lac with tumor grade (36,37). In our study, all voxels with lipid signals 
were eliminated from the analysis. However, these might be the voxels of interest as the 
lipids can indicate necrosis, a consequence of hypoxia. Necrosis is not common in prostate 
cancer (38); though, in one of the patients, extensive necrosis was found in the biopsy 
tissue. The T2-weighted images of this patient showed areas in the tumor of high signal 
intensity, indicative of fat, and the spectra of tumor tissue showed large lipid resonances in 
the center of the tumor (Figure 7.6). As the lipid signals decreased to the edge of the volume 
of interest, these lipid signals did not arise from periprostatic fat. The accurate volume 
selection of the semi-LASER enabled the removal of frequency-selective lipid suppression 
and in combination with elliptical weighted sampling and Hanning filtering, intra-prostatic 
lipid signals could be detected reliably. Furthermore, the rim of the tumor had low ADC 
values, while the core of the tumor had high ADC values. It is hypothesized that these areas 
of high ADC represent necrosis (39). 
In HR-MAS spectroscopy data of human prostate biopsies, a significant increase in the Lac 
over alanine ratio was observed in malignant compared to benign samples (40). However, 
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Lac levels in ex vivo samples should be assessed with caution, as anaerobic energy 
metabolism of substrates could quickly produce Lac. This is confirmed by Swanson et al. 
(41) who performed HRMAS spectroscopy with postsurgical prostate tissues. They reported 
high Lac concentrations (~45 mmol/kg in benign and ~70 mmol/kg in malignant tissue), but 
hardly detected a glucose resonance, and did not find appreciably changes over time in the 
Lac concentration. This suggests that there was complete anaerobic conversion of glucose 
to Lac during the period of the surgery and tissue harvesting. Rather than a tumor marker 
by itself, the Lac concentration difference between benign and malignant tissue mainly 
suggests here a higher glucose level in tumor tissue (41), which can have several causes 
like a higher glycolytic activity and better/more perfusion. Tessem et al. (13) were able to 
freeze the prostatic tissue within 15 s after a biopsy. They reported Lac concentrations for 
malignant prostate tissue (mean 26% tumor in core) of 1.6 mmol/kg and 0.61 mmol/kg for 
benign tissue samples. As their Lac levels in malignant samples, which were mainly low 
grade and contained predominantly normal tissue, are higher than our detection limit in 
high grade tumors, probably still glucose was converted to Lac in the 15 s time-window. 
Nonetheless, this study ties in with our results of low Lac levels in the prostate. 
An observation that supports these findings of low Lac levels in prostate cancer is the fact 
that glucose transporter 1 (GLUT1) is immunohistochemically undetectable in most prostate 
cancers, although overexpression was observed in a small number of highly proliferative 
cancers (42). GLUT1 is a marker for increased glucose metabolism and is suggested as 
a marker for hypoxia. The lack of GLUT1 expression might also explain the limited clinical 
usability for fluorodeoxyglucose positron emission tomography in prostate cancer evaluation 
(42). However, when the prostate was stained for hypoxia with pimonidazole, staining was 
seen in 70% of areas containing predominantly tumor, and in 33% of nontumor areas(12). 
This suggests the presence of hypoxia throughout the prostate, which is difficult to explain 
in such a well-perfused organ. 
Mice studies using hyperpolarized 13C labeled pyruvate showed an increase in Lac with 
prostate cancer development and progression (43). Also in the first human in vivo studies 
using hyperpolarized 13C labeled pyruvate, Lac formation was observed and in cancer tissue 
a higher lactate/pyruvate ratio was detected (44). Hyperpolarization enables one to study 
very small concentrations of Lac, converted from pyruvate, but accurate quantification of 
Lac levels is difficult. 
We calculated a minimal detectable Lac concentration of 1.5 mM in high grade prostate 
cancer. Some aspects of our analysis should be kept in mind regarding this detection 
limit. First of all, some assumptions about the relaxation times had to be made. All used 
relaxation times were obtained from 1.5 T data, and for Lac we assumed similar effects on 
the relaxation times when going to a field strength of 3 T as for Cr. As there are no T1 and T2 
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Figure 7.6.  A) T2-weighted image of the prostate of an 80-year-old male with a tumor in the entire 
 peripheral zone (indicated in red) with a Gleason score of 5+5 and a PSA level of 6.1 ng/ml. The 
 outline of the tumor is guided by the T2-weighted and ADC images. The blue box indicates the 
 area displayed in D-E. In B the ADC map which shows areas of low signal intensity at the rim 
 of the tumor and high signal intensity in the center of the tumor. The spectrum of the 
 semi-LASER sequence in C (green voxel in D-F) contains resonances of Cho, Cr, Cit and lipids. 
 The frequency ranges of the spectral maps in (D-F) are indicated (range E and range D&F). 
 The spectral map in D and F focus on the lipid resonance at 1.3 ppm in a transversal and 
 saggittal view. There is no wraparound of lipid signals in any direction, and the highest lipid 
 resonances are observed in the center of the tumor. The spectral map in D shows the Cho and 
 Cr distribution over the prostate, with high Cho signals in the tumor and low Cho signals in 
 the transition zone. 
values available for Lac in the prostate, relaxation times from the brain were used. To prevent 
overestimation of the detection limit, the shortest T2 found in literature for Lac was chosen, 
as this leads to a higher minimal detectable Lac concentration then longer T2 values. For 
the Lac T1 value we took a value of 900 ms, assuming comparable differences between 
brain and prostate T1 values for Lac as observed for Cr and Cho. Next, for the calculation 
a constant Cr concentration was assumed of 4.4 mM. If the Cr concentration were lower in 
tumor tissue, the minimal detectable Lac concentration would be higher. 
The removal of the frequency-selective refocusing pulses for lipid and water suppression, 
also enabled detection of other metabolites. In the spectra of most patients a resonance at 
2.05 ppm was observed. It probably belongs to an acetyl group because of its chemical shift 
and persistence at longer TE. By means of simulations and phantom measurements (data 
not shown), we ruled out that this resonance belonged to Spm, glutamate or glutamine. A 
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possible candidate is the sialic acid N-acetyl neuraminic acid, which has previously been 
observed in in vitro studies of human prostate specimens (45). Several researchers have 
studied the use of serum N-acetyl neuraminic acid levels as marker for prostate cancer 
(46,47). Significant differences between serum levels of healthy and prostate cancer patients 
were found, but these increases were also found for other cancers and N-acetyl neuraminic 
acid was therefore not specific enough for screening (46,47). 
The deletion of the frequency selective refocusing pulses has the disadvantage of a higher 
chance for lipid contamination. This is evident from the relatively low number of voxels of 
acceptable quality without lipid contamination (595 voxels rejected out of 897). A comment 
needs to be made that 292 of the rejected voxels were from the patient who had extensive 
necrosis and lipid signals in the tumor. Although the chemical shift displacement error is 
only 4% for the adiabatic pulses, there is room for improvement to further eliminate lipid 
contamination. 
All tumors showed highly abnormal spectra in the PRESS spectroscopy datasets. All tumors 
had the maximum malignancy rating of 5 and very deviating metabolite ratios. Because 
the tumors in these patients were so aggressive, these patients usually do not receive a 
prostatectomy and are therefore not included in validation studies based on histopathology. 
Our results reinforce the clinical usability of the (Cho+Cr)/Cit and Cho/Cr ratios for prostate 
cancer characterization. Furthermore, our method enabled detection of lipid resonances 
that originated almost certainly from the tumor, in a patient with extensive necrosis in the 
tumor biopsy samples (Gleason score 5+5). However, the lack of Lac signals in 17 patients 
with highly aggressive prostate cancer, makes Lac measured with 1H MRS unsuitable as 
biomarker for prostate cancer characterization or as a method for treatment planning. Our 
detection limit shows that if Lac is present in highly aggressive prostate cancers, it is in low 
concentrations. 
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CHAPTER EIGHT
In vivo 31P MR Spectroscopic Imaging of the Human Prostate at 
7 T: Safety and Feasibility
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This chapter is based on the publication:
In vivo 31P MR spectroscopic imaging of the human prostate at 7 T: safety and feasibility 
T. Kobus, A.K. Bitz, M.J. van Uden, M.W. Lagemaat, E. Rothgang, S. Orzada, A. Heerschap and 
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Introduction 
Magnetic resonance (MR) is increasingly being used in the diagnosis, localization and 
staging of prostate cancer. Prostate cancer is characterized by a hypointense signal on T2-
weighted images. Unfortunately, more benign pathologies like benign prostatic hyperplasia 
and prostatitis also show this decreased signal intensity. Higher specificities for detection 
(1) and localization (2,3) of prostate cancer were obtained when proton MR spectroscopic 
imaging (1H MRSI) was added to the reading of T2-weighted images. The use of MRSI 
enables the detection of biochemical changes that are characteristic for certain diseases. 
1H MRSI has been used to discriminate noncancer tissue from cancer tissue in the prostate 
using the choline plus creatine to citrate ratio. In cancer tissue an increase in this ratio 
is observed compared to normal tissue in single institution studies (4-6) as well as in a 
multicenter setting (7).  
Phosphorus spectroscopy enables detection of metabolites with phosphorus atoms, e.g. 
phosphocreatine (PCr), inorganic phosphate (Pi), the three phosphate groups of adenosine 
triphosphate (ATP), phosphomonoesters (PME), and phosphodiesters (PDE). In the early 
nineties, in vivo phosphorus spectroscopy of the human prostate was pioneered with 
measurements that used an endorectal coil (8-11). Using merely the coil reception profile 
for localization, differences in the PME to PCr ratio, the PME to β-ATP ratio and PCr to β-ATP 
ratio were observed between normal and cancer tissue (9,10). These studies were performed 
on a 2-T system and in 10 to 30 min one spectrum of a volume between 1.5 and 3 cm3 could 
be acquired. To obtain information from different parts of the prostate, the endorectal coil 
was repositioned between different acquisitions (9). 
At a magnetic field strength of 7 T, the increased chemical shift difference between signals 
might enable detection of the individual resonances of PME, i.e. phosphoethanolamine 
(PE) and phosphocholine (PC), and PDE, i.e. glycerophosphoethanolamine and 
glycerophosphocholine. Detection of these individual resonances could improve prostate 
cancer characterization, e.g. in the assessment of aggressiveness. A significant correlation 
between the Gleason score, the histopathological measure for aggressiveness, and the 
GPC/PC ratio has been reported in prostate cancer samples (12). The increased magnetic 
field strength also results in a higher signal-to-noise ratio (13), which makes it possible to 
perform localized three dimensional (3D) 31P MR spectroscopic imaging at a relevant spatial 
resolution in a clinically acceptable measurement time with a 31P endorectal loop coil. In order 
to do so, 1H MR imaging is necessary to relate the metabolic information to anatomy. When 
obtaining anatomical, T2-weighted images of the abdomen at a field strength of 7 T severe 
inhomogeneities in the radiofrequency (RF) transmit field need to be overcome. Reaching 
refocusing flip angles in the center of the body at 7 T requires a significant amount of RF 
power, whereas the specific absorption rate (SAR) scales approximately with the square of 
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the field strength. So the increased RF power demand and RF transmit inhomogeneity is 
opposed by restrictions in RF power deposition with SAR limits, requiring the development 
of new coils and methods that enable a more efficient RF excitation.
Previously, Metzger et al. described a method to image the prostate at 7 T using multi transmit 
coils and RF shimming (14). The phase of the different coil elements was adjusted to obtain 
maximal B1
+ coherence at the location of the prostate. When combining an eight-channel 1H 
transmit/receive (TxRx) coil setup with a 31P endorectal TxRx loop coil, RF coupling between 
the eight-channel coil elements and the 31P endorectal coil needs to be investigated. 
The RF wavelength of the 1H frequency in biological tissues at 7 T is ~12 cm. With these 
wavelengths, the 31P prostate coil and cables might interfere with the eight-channel 1H coil. 
This coupling could lead to inhomogeneous flip angle distributions and increased local SAR 
levels. If coupling exists between the coils or cables, this should be prevented or at least it 
should be ensured that the SAR stays within safe limits and that the images are not affected 
by an unpredictable B1
+ distribution. 
In this feasibility study, we dealt with all prerequisites for a setup that combines an eight-
channel TxRx 1H coil with a 31P TxRx endorectal coil to study phosphorus metabolites in the 
prostate. The safety limits at our institution are based on the International Electrotechnical 
Commission (IEC) 60601-2-33 (Edition 3.0) safety guidelines (15). These state, as limits for 
local coils at normal operating level, a maximum time-averaged SAR of 10 W/kg or a maximum 
local tissue temperature of 39 °C. Since the body temperature of volunteers and patients in 
general is not measured before an MR exam, an input power leading to a maximum local 
increase of 1 °C was used in this study as a safety limit. To assess compliance with these 
limits, Finite Integration Technique (FIT) simulations of both coils as well as their combination 
were performed to study the RF, SAR and temperature distribution. From the simulations 
the locations of the highest SAR deposition and temperature increase could be obtained 
and these were validated by phantom measurements providing B1
+ and temperature maps. 
Finally, in vivo temperature measurements were performed, by placing temperature probes 
on the 31P endorectal coil at the positions with the highest determined power losses. From 
the simulations, phantom studies and in vivo measurements, the maximum input power to 
comply with the safety guidelines for transmitting with the 31P endorectal coil and eight-
channel 1H array coil could be derived. In vivo measurements in compliance with the safety 
limits were performed using adiabatic excitation and phosphorus spectra were obtained 
from the entire prostate and surrounding tissue with high spatial resolution (4 cm3) in a 
single measurement. 
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Methods
Hardware
31P TxRx endorectal coil and interface
The mechanical housing and conductors of an inflatable 1H receive endorectal coil for use at 
3 T (Medrad, Pittsburgh, PA, USA) was used for the design of the 31P TxRx endorectal coil. The 
coil was tuned and matched to 50 Ω at 120.3 MHz using small ceramic capacitors (American 
Technical Ceramics, Huntington Station, NY, USA) capable of handling a voltage up to 500 V. 
The tuning and matching can, to some extent, be adapted by inflating or deflating the 
balloon of the endorectal coil. A coaxial cable connected the RF-coil to a home-built TxRx 
switch with an integrated small band low noise preamplifier (Advanced Receiver Research, 
Burlington, CT, USA). The TxRx switch was used to interface the coil to a 7-T whole-body 
MR system (Magnetom, Siemens Healthcare, Erlangen, Germany). Figure 8.1A shows the 
electronics circuit of the 31P RF-coil.
The forward and reflected power in the 31P transmit channel are monitored by the RF 
supervision provided by the manufacturer of the MR system. To determine the reference 
voltage of the coil, the endorectal coil was placed on a phantom containing Pi. A 31P MRSI 
pulse-acquire sequence with a 1-ms block pulse was played out at different power levels to 
estimate the reference power for a flip angle of 180˚ (γB1 = 500 Hz) at a distance of 2.5 cm of 
the center of the coil, which is the distance between the coil and the center of the prostate 
in vivo. The resulting spectra were analyzed for a dip in the intensity of Pi at this distance. 
Eight-channel 1H TxRx array coil 
The eight-channel 1H TxRx coil for imaging (16) consists of two arrays with four microstrip 
line elements, each with meanders (17). Each element has a length of 25 cm, a width 
of 10 cm and a thickness of 2 cm. The arrays are placed dorsally and ventrally to the 
body. The elements of the dorsal array are arranged on a planar sliding frame inside a 
polymethylmethacrylate housing. The sliding frame is used to place the array at the desired 
position along the longitudinal axis of the patient. Including a thin cushion for patient 
comfort, the distance from the elements to the body surface is 25 mm. The elements of 
the ventral array are enclosed in individual modules made of polycarbonate. The modules 
are interconnected with a neoprene sheet making the ventral array flexible so that it can be 
accommodated to the patient’s contour. The distance between the elements and the body is 
30 mm, as determined by the module dimensions. Low input impedance preamplifiers and 
TxRx switches are placed in a separate multipurpose box at the head of the patient table, and 
the cable length was chosen accordingly to achieve preamp decoupling during reception.
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RF shimming system 
1H MR imaging was performed with an add-on system for RF shimming (18) which was 
integrated into the 7-T MR system and the flexible eight-channel array coil. The RF amplifier of 
the standard system consists of eight individual modules providing a maximum peak power 
of  1 kW each (LPPA 13080W, Dressler, Germany) with which the eight-channel RF shimming 
setup was realized. Computer-controlled attenuators and phase shifters were inserted into 
the low-power RF chain directly at the input ports of the amplifier. The eight-channel mode 
is activated by coaxial relays (CX600N, Tohtsu, Japan) connected to the output ports of the 
RF amplifiers which bypass the power combiner and power monitor of the standard system 
and make the eight individual channels available at the patient table.
Unlike the 31P transmit channel, the monitoring of the eight 1H transmit channels cannot be 
performed by the single channel manufacturer’s supervision system. Therefore, a custom-
built on-line RF supervision was realized by the use of three logarithmic root-mean-square 
power meters (TALES, Siemens Healthcare, Erlangen, Germany) which monitor forward 
and reflected power in the eight transmit channels via directional couplers (19). A real-time 
field programmable gate array (NI PXI 7852 R, National Instruments, Austin, TX, USA) with 
corresponding software performed time-averaging of the transmitted RF power over intervals 
of 10 s and 6 min according to the IEC safety guidelines (15). The correlation between 
transmit power and localized SAR was determined by RF simulations which are described 
below. If the maximum permissible input power was exceeded, the software immediately 
blanked the RF power by emergency relays located in the vector modulator circuit. The 
monitoring software further included test loops for malfunction detection of the attenuators 
and phase shifters, and thus correct adjustment of the target RF shim was checked. 
In vivo B1
+ mapping was performed with a protocol based on a presaturation single-shot 
turboFLASH sequence provided by the vendor of the MR system (20). Relative B1
+ magnitude 
Figure 8.1.  A) Schematics of the electronic circuit of the 31P TxRx endorectal coil. B) The 31P TxRx 
 endorectal coil without the outer balloon. The arrows indicate the location of the three fiber 
 optic temperature sensors at the top of the coil, feed point and coil wire to study the 
 temperature increase in the phantom study. The coil loop has a length of 7.0 cm and a 
 width of 3.7 cm. 
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Figure 8.2.  Safety validation of the 31P endorectal coil. A) FIT simulation model of the endorectal 31P 
 coil, rectum, bladder and prostate. Not shown are two muscles each lateral of the prostate 
 B) Calculated SAR10g using the model in A at an RF input power of the 
31P endorectal coil 
 of 0.95W leading to a maximum 10 W/kg assuming a worst case approximation of close 
 contact of tissue and RF-feed without any gap. C) Transient thermal simulations after a scan 
 duration of 15 min at a time-averaged input power of 1.3 W leading to a maximum temper 
 ature of 39˚C. D) Image of the temperature increase measured by MR-thermometry after 2 
 min of 9.1 W of time-averaged input power with the 31P endorectal coil in a phantom. 
 The endorectal coil is rotated 45˚ counterclockwise in plane compared to the orientation 
 in A-C. E) The temperature measured in vivo with fiber optic temperature sensors at 
 the top of the coil and at the feed point during a 15 min 31P MR spectroscopy 
 measurement with the endorectal coil at an input power of 1.9 W. The temperature 
 offset of the two sensors is due to small calibration differences. The location of the fiber 
 optic sensors is shown in A with 2 green asterisks (left: feed point, right: top of the coil).
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and relative phase maps of a single slice were acquired in vivo by low flip angle (estimated 
below 10˚) imaging with an echo time (TE) of 5 ms and a repetition time (TR) of 1 s from 
each coil without presaturation (field of view (FOV) 300x300 mm, in plane resolution 4.7 
x 4.7 mm, slice thickness 8 mm). The total acquisition time was 8 s. For the phase maps, 
the first channel was taken as reference. Thus, the argument of the complex signal ratio 
between an individual channel and the first channel gives the relative phase. To obtain 
relative B1
+ magnitude maps, the individual maps are normalized to the square root of the 
sum of squares of all individual maps. The relative B1
+ maps were imported into a graphical 
user interface which allows the selection of a region of interest (ROI) in the prostate. A RF 
shimming algorithm was applied which maximizes the magnitude of the B1
+ distribution 
inside the ROI by optimizing the transmit phase of the channels while maintaining equal 
amplitudes. After the desired shim is determined, the vector modulators are automatically 
programmed with the corresponding phase settings by the control computer. The whole RF 
shimming procedure including data acquisition, ROI selection, and calculation of the optimal 
phases takes ~3 min. The flip angle map of the prostate-optimized RF shim was obtained by 
two images acquired with and without a saturation pulse before the turboFLASH sequence. 
The cosine of the flip angle produced by the saturation pulse can be approximated by the 
signal ratio of the pre-saturated image and the reference image without saturation with the 
same TE, TR, acquisition time, FOV and resolution as for the relative maps. The flip angle 
map of the prostate-optimized RF shim was used for transmitter adjustment. 
Safety of the coil setups
Safety validation of the 31P endorectal coil  
FIT simulations, phantom studies and in vivo measurements were performed to test the 
safety of the use of the 31P endorectal coil. Numerical computations (CST Studio Suite 2011, 
Darmstadt, Germany) of the RF field distribution and the corresponding SAR produced by 
the 31P endorectal coil were performed according to previously presented safety tests for a 
1H TxRx endorectal coil (21,22). For the simulation, a detailed computer-aided design model 
of the coil and the surrounding tissues (prostate, bladder, muscles and lipids) was derived 
(Figure 8.2A). The dimensions of the prostate were determined from high-resolution MR 
images of the human prostate obtained at 3T. Permittivity and electric conductivity of the 
tissues at 120.3 MHz were taken from literature (23) and the transverse electromagnetic 
wave of the coaxial cable was used for RF field excitation at the connector of the cable. The 
feed point of the loop coil consisting of a small printed circuit board with three capacitors 
and the connections to the inner and outer conductor of the coaxial cable was modeled as 
exactly as possible, because it is expected that a high local SAR will be generated in the 
region of the feed point. With the simulation, we determined the maximum input power to 
comply with the maximum 10g-averaged SAR (SAR10g) of 10W/kg. The input power is defined 
in this study as the difference between forward and reflected power at the table plug. As the 
simulations provide the input power at the excitation port of the model, we assumed a loss 
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of 1 dB between the table plug to the connecter at the cable of the coil in the simulations to 
be able to compare results.
To validate that the SAR10g does not underestimate the RF exposure, transient thermal 
simulations were also performed. For this, the well-known bioheat-transfer equation by 
Pennes (24), implemented in the simulation software, was utilized. The thermal parameters 
(heat capacity, thermal conductivity, metabolism, blood perfusion) of the tissues in the model 
were taken from parameter sets provided with available heterogeneous body models (25). 
The heat source for the temperature simulation is given by the  power losses in the tissue 
calculated previously in the RF field simulation. By use of the simulation the time-averaged 
input power was determined at which a maximum local temperature of 39°C, specified in the 
guidelines, was reached after a scan duration of 15 min. 
The location of the highest power deposition obtained by the RF simulations was verified 
in a phantom by MR temperature mapping. A phantom was used as in vivo MR temperature 
mapping is difficult to perform in the pelvis. A gel phantom was designed with approximately 
the same dielectric properties as abdominal human tissue (23). A 2% cellulose phantom 
gel was made using a mixture of isopropanol (52%) and water (48%) (26). Before dissolving 
the cellulose, the liquid mixture was buffered with Na2HPO4 and NaH2PO4 to pH=7. Sodium 
chloride (335mM) was added to obtain a representative conductivity, taking into account the 
decreasing effect on the conductivity of cellulose and a phantom temperature of 5°C for a 
high viscosity of the gel (27). The phantom had the following dimensions: 22.5 x 15 x 11.5 
cm. The relative permittivity and conductivity of the phantom were measured and were 45 
and 0.8 S/m respectively. The 31P endorectal coil was placed in the phantom and the eight-
channel array coil was positioned around it. RF shimming was performed to minimize the 
effect of B1 inhomogeneities on the temperature measurements.
To measure the temperature increase with MR thermometry, phase images, acquired with a 
standard gradient echo sequence, were obtained with the eight-channel array coil before and 
after transmitting  excessive RF power at 120.3 MHz for 2 min with the 31P endorectal coil. 
Due to the limited sensitivity of the MR thermometry method an arbitrary high time-averaged 
input power of 9.1 W was used to acquire adequate phase images. Using the phase images, 
the temperature change in three slices of 2 mm perpendicular to the coil was calculated 
(28). The center slice was placed through the feeding point and top of the coil, at the location 
with the highest predicted SAR deposition according to the simulations. A TE of 17 ms was 
used and the in-plane resolution was 2 x 2 mm. For MR temperature map validation, three 
fiber optic temperature sensors of the Luxtron FOT Lab Kit (LumaSense Technologies, Santa 
Clara, CA, USA) were fixed on the 31P endorectal coil. The sensors were placed close to the 
feed point, the top of the coil, and on the coil wire as indicated in Figure 8.1B, measuring the 
temperature before, during and after RF transmission. 
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The fiber optic temperature sensors were also used for in vivo temperature measurements at 
the previously determined locations of the highest temperature increase. Thus, the influence 
of the active thermal regulatory system (e.g. increasing blood perfusion with temperature) 
on the RF induced temperature elevation could be taken into account. The thermal regulatory 
system cannot be modeled by simulation. The outer balloon with two temperature sensors 
was enveloped in a thin condom. It was expected that the insulating effects of the thin latex 
layer were minimal, and therefore, these were neglected. Next, measurements with increasing 
power settings were performed to determine the input power that resulted in maximal 1˚C 
temperature increase during a 15-min 31P MRSI measurement. This limit was chosen in order 
to assure that a maximum absolute temperature of 39°C is not exceeded in vivo, independent 
of the state of health of the individual volunteer.
 
Safety validation of the combined setup of the 31P endorectal coil and eight-channel 1H array coil
The coupling of the eight-channel 1H array coil with the 31P endorectal coil was assessed 
by simulations and verified in phantom measurements. The simulations were performed 
with a heterogeneous body model of a 70-kg male (25) in which the prostate, rectum, 
muscles, fat, and bones of the lower abdomen were modeled with a spatial resolution of 2 
mm. The simulations were performed with and without the previously described model of 
the endorectal coil at a realistic position aligned to the prostate in the heterogeneous body 
model. For the eight-channel array coil, a computer-aided design-based model was derived 
from the exact geometries of the implemented coil design. Further, the MR environment with 
gradient shield, bore cover, and patient table was considered in the model. Dielectric losses 
from all materials were taken into account. Using a network cosimulation the matching and 
tuning network, the feed cables, as well as the balanced-unbalanced transformer realized 
by a coax cable of a half wavelength, inserted at the feed point of every coil element, were 
considered including losses in the network components. At both transmit frequencies, 120.3 
MHz for the 31P endorectal coil and 297.2 MHz for the eight-channel 1H array coil, the coupling 
of the coil ports was monitored and a possible perturbation of the transmit fields due to 
the presence of the coil for the other nucleus was analyzed. Furthermore, it was evaluated 
whether relevant elevations of the local B1
+ field and SAR distribution generated by the eight-
channel array coil occurred close to the 31P endorectal coil which would indicate RF coupling 
between the different coils. For the calculation of the power-loss density produced by the 
1H array coil inside the body the phase settings for the applied RF shim in the volunteer 
were used and the corresponding SAR could be evaluated. Here, the RF shim for the healthy 
volunteer enrolled in the in vivo 31P MRSI measurement was utilized. The volunteer’s body 
physique agreed well with the body model. The SAR findings were additionally confirmed by 
transient thermal simulations in the human body model. 
The 31P endorectal coil was placed in the above-mentioned gel phantom. On both sides of 
the phantom, a bottle with the same conductivity and relative permittivity was placed to 
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Figure 8.2.  A) Pulse acquire sequence with a BIR-4 pulse for excitation of the free induction decay. A 
 delay of 0.42 ms between the end of the BIR-4 pulse and start of data acquisition 
 accommodates phase encode gradients in three directions (not shown) B) The RF field 
 profile illustrates that the adiabatic condition is met at a γB1 of 700 Hz and higher. The 
 on-resonance transverse magnetization is 0.71, corresponding to a flip angle of 45˚. 
 C) Excitation profile at a γB1 of 933 Hz (red) and 700 Hz (blue) resulting in an excitation 
 bandwidth of approximately 1.5 kHz and 1 kHz respectively.
approximate the loading of a human body in the eight-channel array coil, which was placed 
around the three phantoms. Using the eight-channel array coil B0 and RF shimming of a 
prostate-sized volume in the phantom gel were performed. Next, a B1
+ map was acquired 
using an Actual Flip Angle Imaging sequence (29,30). This gradient echo sequence makes 
use of two TRs (20 and 100 ms) and one TE of 2.04 ms and produces a 3D B1
+ map of 
the transmitted RF power in the phantom. The resolution was 5 x 3 x 3 mm. Since the B1
+ 
map does not provide information about the electric fields, which can induce heating of the 
patient, the spatial distribution of the local temperature increase was measured as well. To 
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this end, a relatively high time-averaged RF power of 58 W (intentionally inducing heating 
in the phantom) was transmitted with the eight-channel array coil for 2 min. Temperature 
difference maps were calculated as described in the previous section. The temperature was 
simultaneously measured with the fiber optic temperature sensors (Figure 8.1B).
Measurement protocol
31P RF excitation pulse
For 3D 31P MRSI, a pulse-acquire sequence was used with an 8 ms adiabatic excitation BIR-
4 pulse with a flip angle of 45˚ (Figure 8.2A). The phase roll, induced by the small delay 
(0.42 ms) between excitation and start of signal reception to accommodate the phase 
encode gradients, was removed by 1st order phase correction. The adiabatic condition and 
bandwidth of the RF pulse (Figure 8.2B,C) were calculated using the Bloch equations in 
NMRSIMTM (part of Topspin, Bruker BioSpin Corporation, Billerica, MA, USA). 
 
In vivo 31P MRSI measurement
The institutional review board gave approval to perform the in vivo measurements on a 
volunteer and signed informed consent was obtained. The 31P endorectal coil was positioned 
close to the prostate in the rectum of a healthy volunteer. To inflate the inner balloon of 
the coil, inert perfluoro-polyether liquid (Fomblin, Solvay Solexis, Bollate, Italy) was used. 
The use of perfluoro-polyether minimizes susceptibility differences between the endorectal 
coil and the tissue, which is a prerequisite for adequate B0 shimming. The volunteer was 
placed in supine position on the dorsal array of the eight-channel  array coil. The ventral 
array was fixed over the lower abdomen. To check the matching and loading of the 31P coil 
and the individual elements of the 1H array coil, power reflection measurements (S11) were 
performed. The coupling between the coils was assessed by determining the decoupling 
between the endorectal coil and each element of the array coil at the frequencies of 120.25 
and 297.05 MHz. An intramuscular injection of Butylscopolaminebromide (Buscopan, 
Boehringer-Ingelheim, Ingelheim, Germany) was used to suppress peristalsis. 
Fast gradient echo MR sequences were used to check the position of both the 31P endorectal 
coil and the eight-channel array coil. RF shimming was performed to obtain maximal B1
+ 
coherence at the position of the prostate. For anatomical information, six transversal T2-
weighted images of the prostate were acquired using a TE of 71 ms and a TR of 3 s. 3D 
phasemap shimming was applied to optimize the B0 homogeneity at the prostate’s position. 
For 31P MRSI, the full FOV of the endorectal coil was spatially encoded (FOV 100 x 100 x 100 
mm, matrix of 8 x 8 x 8, 15 averages). The acquisition bandwidth was set to 5000 Hz. The 
nominal voxel size was 12.5 x 12.5 x 12.5 mm, which resulted in an effective voxel volume 
of 5.8 cm3 after apodization of the k-space weighted sampling (TR 1.5 s, acquisition time 11 
min). In a second measurement, the nominal voxel size was decreased to 11 x 11 x 11 mm 
(FOV 110 x 110 x 110 mm, matrix of 10 x 10 x 10, 10 averages), representing an effective 
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voxel volume of 4.0 cm3 (acquisition time 18 min). 
With the combination of a TR of 1.5 s and an excitation angle of 45˚ we expected limited 
saturation of the phosphorus metabolites, as estimated T1 relaxation times at 2 T ranged 
from 1.1s (PCr) to 2.6 s (PME) (9), which are not reported to increase when moving to 7 T (no 
clear field strength dependence has been established (31)). 
Results
When validating compliance of a coil setup with either SAR guidelines or temperature limits 
with different models and measurements, quite a few different input powers need to be 
reported in this section. Therefore, an overview of the different input powers for three coil 
setups is given in Table 8.1 along with a short reason why this input power is reported later.
Coil setup:  Input 
power
- Reason 
- Method
31P TxRx endorectal coil
0.95 W - Power leading to a maximum 10g averaged SAR of 10W/kg 
- Derived from RF (SAR) simulations
1.3 W - Power leading to a maximum local temperature of 39˚C 
- Derived from thermal simulations
9.1 W - Arbitrary high power for sufficient temperature increase
- Phantom temperature mapping for SAR simulation validation
1.9 W - Power leading to a temperature increase in vivo of 1˚C 
- In vivo measurement with temperature probes
1H TxRx 8-channel array coil 33W - Power leading to a maximum 10g averaged SAR of 10W/kg 
- Derived from RF (SAR) simulations
Combined 31P TxRx endorectal 
coil and 1H TxRx 8-channel 
array coil
33W - Power leading to a maximum 10g averaged SAR of 10W/kg
- Derived from RF (SAR) simulations
58 W - Arbitrary high power for sufficient temperature increase
- Phantom temperature mapping for SAR simulation validation
Table 8.1.  The different input powers for the three coil setups and the reason for their use.
31P endorectal coil and eight-channel 1H array coil 
The reflection coefficient (S11) of the 
31P TxRx endorectal coil was -9 dB during use in the 
phantom and -16 dB during in vivo use at the 31P operating frequency of 120.25 MHz. The 
unloaded Q-factor of the endorectal coil was 316 and the loaded Q-factor during in vivo use 
was 34. The reference voltage of the 31P coil at a distance of 2.5 cm of the center of the coil 
to attain γB1 = 500 Hz (29 μT) was 75V. The average S11 of the eight elements of the eight-
channel array coil was -14.8 dB (range -9 to -22 dB). 
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Figure 8.4. FIT simulations of the lower abdomen surrounded by the eight elements of the 1H 
 array coil. For the simulations a RF shim maximizing the B1
+ coherence in the prostate 
 is used. A) B1
+ distribution at an input power of 33 W of the 1H array coil with the endorectal 
 coil present. B) B1
+ distribution as in A but without the endorectal coil. C) SAR10g 
 distribution at an input power of 33 W of the 1H array coil with the endorectal coil 
 present. D) SAR10g as in C but without the endorectal coil. E) Temperature distribution 
 after a scan duration of 15 min at a time-averaged input power of 33 W of the 1H array 
 coil with the endorectal coil present. F) Temperature distribution as in E but without the 
 endorectal coil. The location of the prostate is just above the endorectal coil.
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Figure 8.5.  Phantom study to investigate the presence of coupling between 31P endorectal coil and 
 eight-channel 1H array coil. A) Sagittal 3D orientation of the coils and the phantom. The 2D 
 planes in B and C are of this sagittal plane. B) Absolute B1
+ map using the eight-channel 
 array coil showing the flip angle distribution. RF shimming was used to obtain maximal B1
+ 
 coherence in the area representing the location of the prostate, below the endorectal coil- 
 loop. C) Temperature map after 2 min of RF power transmission of 58 W with the eight- 
 channel array coil. D) The temperature increase measured with the fiber optic 
 temperature sensors placed at the top of the coil (1 in C), feed point (2 in C) and coil wire 
 (3 in C). 
Safety validation of the 31P endorectal coil 
The RF simulations showed that a time-averaged input power of 0.95 W led to a maximum 
SAR10g of 10 W/kg (Figure 8.3B, Table 8.1). The transient thermal simulations showed that 
a time-averaged input power of 1.3 W led to a maximum local temperature of 39°C after a 
scan duration of 15 min (Figure 8.3C, E). The calculated S11 in the model was -8.7 dB at the 
frequency of 120.3 MHz.
Figure 8.3D illustrates the temperature increase in the phantom after 2 min exposure to 
9.1 W time-averaged input power with the 31P endorectal coil. There was good agreement 
between the SAR profile of the simulations (Figure 8.3B) and the temperature profile around 
the coil loop (Figure 8.3D). A maximum temperature increase of 3˚C was observed near the 
top and feed point of the coil.
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In the in vivo temperature measurements, a time-averaged input power of 1.9 W for the 
duration of 15 min resulted in a temperature increase of just below 1˚C, well below the IEC 
limit of 39˚C during the entire examination (Figure 8.3E). 
Safety validation of the combined setup of the 31P endorectal coil and eight-channel 1H array coil
The FIT simulations predicted that both coils at both operating frequencies were well 
decoupled by at least -50 dB. The influence of the endorectal coil on the B1
+ distribution 
of the eight-channel array coil was negligible (Figure 8.4A,B). Furthermore, the simulation 
showed that the RF shim concentrated the B1
+ in the region of the prostate. The highest 
SAR was located close to the individual elements, and the maximum SAR10g, using in vivo 
prostate RF shim settings, was close to the upper left coil element of the 1H array coil (Figure 
8.4C,D). The maximum permissible time-averaged input power of the eight-channel array 
coil at which the safety limit for the localized SAR10g of 10 W/kg was not exceeded was 33W 
(Figure 8.4C,D). There was no relevant SAR elevation close to the endorectal coil, which 
indicates that the combination of both coils could be operated under safe conditions. This 
was further supported by the temperature simulations (Figure 8.4E,F), which also showed 
no difference in temperature distribution with and without the endorectal coil after a 15-min 
experiment for an input power of 33 W.
The absolute B1
+ map (Figure 8.5B) showed the flip angle distribution over the phantom. 
The RF shimming method worked well and resulted in maximized B1
+ at the desired location 
(Figure 8.5B). No B1
+ elevation was visible near the coil wire. The MR temperature map after 2 
min of excessive RF power transmission of 58W with the eight-channel 1H array coil showed 
an increase at the top and bottom of the phantom, near the elements of the eight-channel 
coil but not close to the endorectal coil-loop or the coil-wire (Figure 8.5C). The temperature 
increase measured with the fiber optic temperature sensors was 1.3, 0.5 and 0.5˚C at the top, 
feed point and wire of the endorectal coil, respectively (Figure 8.5D). The sensor at the top of 
the coil was closest to the dorsal elements of the 1H array coil. 
The decoupling between the 31P endorectal coil and each individual element of the 8-channel 
1H array coil during in vivo use was on average -71 dB (range -60 to -80 dB) at 120.25 MHz and 
-70 dB (range -64 to -80 dB) at 297.05 MHz, demonstrating excellent decoupling. 
RF shimming
We reconstructed relative maps of the B1
+ magnitude for the individual transmit channels of 
the eight-channel array coil with the endorectal coil inserted into the rectum (Figure 8.6A). 
Though all elements contributed to the central region where the prostate was located, the 
individual maps were well separated in the outer region. No significant B1
+ distortions due 
the 31P endorectal coil located in the rectum were visible. RF shimming resulted in quite a 
homogeneous flip angle distribution for the optimized RF shim (Figure 8.6B). The achieved 
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Figure 8.6.  A) In vivo relative maps of the B1
+ magnitude for the individual transmit channels of the 
 array coil with the endorectal coil inserted into the rectum. B) Flip angle distribution 
 for the optimized phase setting of the array coil. Transmit phases were adjusted in order 
 to obtain maximum B1
+ inside the prostate (ROI: white circle). The achieved standard 
 deviation of the flip angle inside the ROI is +/- 10 %. 
standard deviation of the flip angle inside the prostate was +/- 10 %. 
 
31P RF excitation pulse
The calculations from the Bloch equations showed that the adiabatic condition for the BIR-4 
pulse of 8ms was met at a γB1 of 700 Hz and higher (Figure 8.2B). The larger γB1, the larger 
the excitation bandwidth (Figure 8.2C). The maximum permissible time-averaged power of 
1.9W was reached with the 8 ms pulse with a γB1 of 933 Hz at 2.5 cm of the coil at a TR of 
1.5 s, resulting in a homogeneous excitation bandwidth of 1.5 kHz or more within 2.5 cm 
of the coil conductors (Figure 8.2C). This led to an excitation range of 12 ppm at the 31P 
frequency at 7 T, indicating good excitation in the posterior and middle part of the prostate. 
The excitation bandwidth in the anterior part was less. The in vivo 31P MRSI experiments 
were performed with these experimental settings. 
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Figure 8.7.  In vivo 31P MRSI of the prostate at 7T. A) T2-weighted image of the prostate with one 
 slice of the 3D 31P MR spectroscopy grid. The 31P spectra of 5.8 cm3 voxels of the prostate 
 (B), muscle (C) and seminal vesicles (D) contain the following metabolites: 
 phoshocreatine (PCr), inorganic phosphate (Pi), adenosine triphosphate (ATP), 
 phosphoetanolamine (PE) and phosphocholine (PC). The red circles represent the 
 perimeter at 64% of the maximum signal intensity of the spatial response function: best 
 approximation of the true voxel size. 
In vivo measurement
Using the RF shimming algorithm, good image quality in the base, middle and apex of the 
prostate was obtained. B0 shimming of a ROI over the whole prostate resulted in a water 
line-width at half maximum of 50 Hz (magnitude). The 3D 31P MRSI grid was aligned using 
fast gradient echo and T2-weighted images (Figure 8.7A). In the prostate, the resonances 
of PC, PE, Pi, PCr and γ-, α- and β-ATP were detectable (Figure 8.7B). The intensity of β-ATP 
was attenuated due to the limited bandwidth of the BIR-4 pulse. From the seminal vesicles, 
which are at larger distance from the center of the coil, good quality spectra were obtained 
showing an increase in the PC signal (Figure 8.7D & 8.8B). In the surrounding muscles, a high 
PCr intensity compared to γ- and α-ATP was observed, while in the prostate the intensity of 
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Figure 8.8.  Spatial maps of the 31P spectra (voxels 5.8 cm3). A) The enlarged spectrum demonstrates 
 the frequency range of the spectra in the transverse (C) and saggital (B) planes. 
 The shown metabolites are phosphoethanolamine (PE), phosphocholine (PC), inorganic 
 phosphate (Pi), phosphocreatine (PCr) and γ- adenosine triphosphate (γ-ATP). The map 
 in the saggital plane demonstrates the increase in PC signal near the seminal vesicles 
 (upper right region). The signal-to-noise ratio (ratio of the signal integral and standard 
 deviation of the noise) after apodization (20 Hz) of PCr and PE in this spectrum were 
 163 and 98 respectively. D) Metabolite map of the PCr integral of 31P MR spectroscopic 
 imaging (4 cm3 voxels) placed over a T2-weighted image of the prostate. The low PCr 
 signals in the prostate are minimally contaminated with the high PCr signals of the 
 surrounding muscle. 
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PCr was almost equal to the ATP’s (Figure 8.7B,C). This could also be demonstrated with a 
metabolite map of the fitted integral of the PCr signal of the second in vivo measurement 
obtained with 4 cm3 voxels (Figure 8.8D) and a spatial map of the metabolites in the 
transversal plane (Figure 8.8C). The extent of the transmit field can also be appreciated in 
this figure. 
Discussion
We have demonstrated that our setup for in vivo 3D 31P MRSI of the human prostate at 7 
T is feasible for acquisition of this data. For this setup, we combined an eight-channel 1H 
TxRx array coil and a 31P TxRx endorectal coil to obtain both anatomical information and 
signals from the phosphorus metabolites. For both coils, the maximum input powers 
were determined to comply with the IEC 60601-2-33 (Edition 3.0) guidelines, which were a 
maximum of 10W/kg for the SAR10g or a maximum local tissue temperature of 39 °C.
To ensure that no coupling occurred between the 31P endorectal coil and the eight-channel 
1H array coil, simulations and phantom measurements were performed. The FIT simulations 
showed that the highest SAR10g of the array coil was observed near the 
1H elements, with 
as well as without the endorectal coil present. It was verified by temperature simulations, 
that the temperature elevation close to the elements of the body coil also exceeded the 
temperature increase near the endorectal coil. Similar to the SAR evaluation, the temperature 
distribution was equal with and without the endorectal coil. This was further confirmed by 
phantom studies showing neither elevated B1
+ fields nor a temperature increase near the 
endorectal coil-loop or its wire. In addition, the in vivo coupling between the endorectal coil 
and each of the 1H elements was below -60dB, demonstrating excellent decoupling between 
the coils. With the absence of coupling with the 31P TxRx coil and the local SAR10g hot-spot 
close to one of the array elements, we concluded that the presence of the 31P coil does not 
influence the SAR limitations of use of the 1H body-array coil. 
The location of the prostate in the center of the trunk, B1
+ inhomogeneities, and destructive 
B1
+ interferences make it difficult to get enough absolute B1
+ in the prostate. Therefore, phase 
modulation of the individual elements is necessary to obtain maximal B1
+ coherence in the 
prostate. RF shimming theoretically also enables that a possible perturbation of the B1
+ 
distribution of the eight-channel array coil by the endorectal coil can be taken into account 
during the RF optimization in the prostate. However, no additional B1
+ perturbations by the 
endorectal coil were observed in the simulations and phantom studies. Combining the eight-
channel array coil and RF shimming system resulted in high-quality anatomical information 
over the whole prostate and no influence on the image quality in the presence of the coil was 
seen in vivo.  
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The maximum permitted RF deposition with the 31P endorectal coil followed from the safety 
validation. To stay within the SAR10g safety limits, the maximum permitted input power was 
0.95 W according to the FIT model simulations of the prostate. The thermal simulations 
showed that a higher input power of 1.3W could be used to stay below a local temperature 
of 39˚C. In vivo an even higher power level was possible because heat can be dissipated by 
blood flow through the tissue. Limiting the in vivo temperature increase at the hot-spot of the 
endorectal coil to 1˚C during a measurement of 15 min allowed a maximum time-averaged 
RF power of 1.9 W.  
The differences in reported power limits for the 31P endorectal coil can be explained after 
having a detailed look at the results. The difference in maximum power based on the SAR 
simulations (0.95 W) and thermal simulations (1.3W), confirms that the safety limits based 
on the SAR calculations are conservative and ensure that the temperature limits will not 
be exceeded. The difference in the SAR and temperature distribution in Figure 8.3(B,C) 
demonstrates the influence of the heat capacity, thermal conductivity, metabolism and blood 
perfusion of the tissue on the temperature. When the feed point is close to badly perfused 
fat tissue, a SAR hot spot results in a larger local temperature increase than the hot spot at 
the top of the coil inside well-perfused prostate tissue (Figure 8.3C): the highest predicted 
temperature increase is not located within the prostate. Next, there is a difference between 
the simulations and the power limit determined in vivo (1.9 W). The simulations represent a 
worst case approximation that the tissue and RF-feed are only separated by the latex from 
the balloon, with no gaps from residual air or glue between the inner and outer balloon. 
Furthermore, the in vivo measurement also takes into account the active thermal regulatory 
system (e.g. increase of blood perfusion with temperature) which was not modeled by the 
bioheat transfer equation in the thermal simulations. Lastly, we cannot be completely sure 
that the location of the fiber optic temperature sensor is at the exact same location as the 
location of highest power deposition derived from the simulation. As shown in Figure 8.3C, 
also the position of the coil in the rectum is of importance. The possible differences in actual 
positioning of the coil and temperature sensors compared to the simulated positioning of 
these in the model invoked our conservative limit of a maximum 1˚C temperature increase 
during the in vivo measurement. 
The SAR limit in our study is based on the normal operating mode of the IEC guideline. In the 
first level operation mode the maximum SAR10g limit is 20 W/kg, which would result in an input 
power of 1.9W in the RF simulation (twice the simulated input power of 0.95W compliant 
with normal operating mode), which incidentally is the same as the power determined with 
the in vivo temperature measurement. 
Following an extensive safety validation, an in vivo experiment was performed. While in 
previous studies at 1.5 and 2 T in 7-30 min, one single unlocalized spectrum was obtained 
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(8-11), we were able to acquire a complete 3D MRSI dataset in the same time (11-18 min) 
with accurate localization and relatively high spatial resolution (effective voxel volume down 
to 4 cm3). A metabolite map (Figure 8.8D) indicated minimal contamination of the low PCr 
signals in the prostate by the larger PCr signals of the surrounding smooth muscles. The 
spectra of the different regions in the prostate were of high spectral quality and had a good 
signal to noise ratio (Figure 8.7). Also at larger distances from the coil (e.g. in the seminal 
vesicles and anterior part of the prostate) the spectra contained usable information (Figure 
8.7D & 8.8), demonstrating good performance of the coil. An effective voxel volume of 5.6 
cm3 makes it possible to study the different parts (base, midgland, apex) of the prostate 
(Figure 8.8). As the peripheral zone and central gland in prostate cancer patients have 
volumes in the order of 20 cm3 and larger (32), this resolution also enables detection of 
metabolic differences between the zones. 
Some differences were observed compared to the spectra obtained at 1.5 and 2 T (8-11). 
First of all, the increase in chemical shift dispersion enabled the separation of PE and PC 
signals at 7 T. At 1.5 and 2 T only one peak was visible for PME. In low field studies also a 
peak was assigned to PDE, while the spectra in the current study are lacking a clear peak 
for PDE (Figure 8.7B,D). Low glycerophosphoethanolamine and glycerophosphocholine 
levels are reported for prostate tissue in vitro (12,33). The signal-to-noise ratio might be 
insufficient to detect these peaks in our study. In the Pi region, two or three separate peaks 
were observed, compared to one peak at lower field strength. What these peaks represent, 
e.g. compartments with different pH, and how they can be of aid in unraveling metabolic 
pathways related to prostate cancer should be studied in more detail with more volunteers 
and patients. 
Conclusion 
This study demonstrated that it is safe to combine a 31P TxRx endorectal coil with an eight-
channel 1H TxRx body-array coil for prostate imaging and 31P 3D MRSI. The SAR levels of 
the eight-channel 1H coil were not influenced by the presence of the 31P endorectal coil as 
was validated by phantom studies, simulations and in vivo measurements. Furthermore, the 
maximum time-averaged input power of the 31P endorectal coil was determined. The first 
in vivo results are promising as high-quality 31P MR spectra were obtained from the whole 
prostate and surrounding tissues of a healthy volunteer using an effective voxel volume 
down to 4 cm3 in an 18-min acquisition. To investigate the value of 31P MRSI at 7 T for 
the characterization of prostate cancer, an extensive study with prostate cancer patients is 
required. 
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Summary and Future perspectives
In this thesis, the performance of two magnetic resonance (MR) techniques for in vivo 
noninvasive assessment of prostate cancer aggressiveness was studied. These techniques 
are: MR spectroscopic imaging (MRSI) and diffusion-weighted imaging (DWI). 
Summary
With prostate 1H MRSI, the spatial distribution of the metabolites choline, creatine, polyamines 
(spermine) and citrate can be studied. From these, the ratio of choline (plus spermine) plus 
creatine over citrate [(Cho+(Spm+)Cr)/Cit] can be derived and used as a marker of prostate 
cancer. The apparent diffusion coefficient (ADC) of DWI reflects the compartmentalization 
of the tissue, which is a useful measure for detection, localization and characterization of 
cancer foci (chapter 2).
Routine clinical use of prostate 1H MRSI requires more automation of data-processing than 
currently available. In addition, for a more widespread use, a general classification scheme 
for prostate cancer management would be beneficial. The appearance of the metabolite 
signals (especially that of citrate) in the spectrum does not only depend on the underlying 
anatomy, metabolism and physiology of the tissue, but also on acquisition parameters 
(echo time, repetition time, pulse sequence timing and field strength). There are differences 
between the acquisition protocols of the major MR vendors for prostate MRSI, which lead 
to (Cho+Cr)/Cit values that are not directly comparable. Classification thresholds should be 
derived for each of the available protocols to increase the clinical usability of MRSI for the 
prostate (chapter 3). 
In this thesis, it was demonstrated that the (Cho+Cr)/Cit ratio and the ratio of choline over 
creatine [Cho/Cr] offer possibilities for an in vivo, noninvasive assessment of prostate cancer 
aggressiveness. The maximum (Cho+Cr)/Cit and Cho/Cr showed a relation with cancer 
aggressiveness and gave good results for differentiation among tumor aggressiveness 
classes. The combination of the two metabolite ratios was used in a standardized threshold 
approach with promising results to discriminate between different aggressiveness classes 
(chapter 4). 
For tumors in the peripheral zone, significant correlations were found between aggressiveness 
classes and the minimum 25th percentile ADC value, the maximum (Cho+Cr)/Cit ratio, and the 
maximum Cho/Cr ratio. For transition zone tumors, the correlation was significant only for 
the maximum (Cho+Cr)/Cit and Cho/Cr ratios. MRSI and DWI have comparable performance 
for assessment of prostate cancer aggressiveness. Combining standard versions of both 
modalities in one measure did not result in a better performance. Nonetheless, better 
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performances using the metabolite ratios in the transition zone and the ADC value in the 
peripheral zone were observed, which suggest that they do have complementary value 
(chapter 5). 
To get a better understanding of (Cho+Spm+Cr)/Cit ratio (or its inverse Cit/(Cho+Spm+Cr) 
ratio) and the ADC value, these parameters were related to the underlying prostate morphology. 
The ADC value related positively with the percentage area of lumen and negatively with the 
percentage area of nuclei. A positive relation was found between the Cit/(Cho+Spm+Cr) 
ratio and the percentage area of lumen. These similar relationships of the ADC and Cit/
(Cho+Spm+Cr) ratio with the amount of luminal space indicate that this morphological 
feature is an important factor determining changes in both MR parameters. However, as 
the origin of the signals is different (water movement versus levels of metabolites and their 
environment) it is plausible that other factors will contribute as well (chapter 6). 
1H MRSI can also be used to observe lactate, an interesting marker for cancer as it is a 
reporter of the Warburg effect and a sign of hypoxia. However, in our study we found no 
convincing lactate signal in 17 patients with highly aggressive prostate cancer using a semi- 
LASER sequence optimized for in vivo lactate detection in the prostate. We estimated that on 
average the lactate levels in high-grade prostate cancer are below 1.5 mM, which indicates 
that if lactate is increased in prostate cancer, it remains at low concentrations, in agreement 
with the absence of substantial necrosis in prostate cancer. The absence of pulses and 
gradients for peri-prostatic lipid suppression made it possible to detect lipids in the prostate 
and possibly N-acetyl neuraminic acid (chapter 7). 
Metabolites with a phosphorus-atom can be studied with 31P MRSI and this could provide 
new information for prostate cancer characterization. An extensive safety validation of our 
newly developed set-up showed that we can safely use a 31P endorectal coil in combination 
with an external eight-channel 1H array coil to perform 31P MRSI of the prostate at 7 T. We 
were able to obtain spectra from the entire prostate of a healthy volunteer with a spatial 
resolution of 4 cm3. The spectral resolution enabled separate detection of phosphocholine, 
phosphoethanolamine, inorganic phosphate, and other metabolites that could play an 
important role in the characterization of prostate cancer (chapter 8).
Discussion and future perspectives 
As multi-parametric MR imaging is nowadays believed to be the optimal way to diagnose 
prostate cancer by MR, the clinical value of MRSI and DWI of the prostate should also be 
evaluated in this context. General guidelines regarding how to perform and analyze a multi-
parametric measurement of the prostate are provided by the European Society of Urogenital 
Radiology (1). For all modalities applies that the particular assessments are still largely 
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qualitative. As discussed in chapter 3, the (Cho+Cr)/Cit ratio of MRSI depends not only on 
physiology and metabolism, but also on acquisition parameters. Since the different MR-
vendors have different 1H MRSI acquisition protocols, the ratio is vendor- and field dependent. 
In principle the (Cho+Cr)/Cit ratio could be vendor-independent with similar acquisition 
protocols and post processing. To promote clinical usability of prostate MRSI it would be 
desirable if consensus could be reached on field strength dependent common acquisition 
and post processing protocols. However, also for DWI and DCE-MRI no consistency in 
imaging parameters and post-processing is established. For DWI, it is recommended to 
use ADC maps for a quantitative assessment and add high b-value images for a qualitative 
approach (1). However, quantitative ADC values should be assessed with care as there is 
no uniformity in the measured b-values, mono- and bi-exponential fits are used, and there is 
also a dependence on the field-strength. At this moment, there are no general quantitative 
classification thresholds available for DWI. 
In our studies, we have shown how 1H MRSI can, and how it cannot, be used for in vivo 
noninvasive assessment of prostate cancer aggressiveness. Both the (Cho+Cr)/Cit and the 
Cho/Cr ratio, as well as their combination in the standardized threshold approach, gave good 
results for assessment of aggressiveness. Previously, the value of 1H MRSI for detection 
and localization of prostate cancer has been demonstrated (e.g. (2-6)) and the technique 
has also been used to monitor treatment response (e.g. (7-13)). Still, the use of 1H MRSI 
as a routine clinical tool occurred up till now only at (academic) sites dedicated to its 
application. The translation to a clinical routine application depends on several factors. Not 
only a robust and automated acquisition procedure, which is able to deal with movement 
and field inhomogeneities, is necessary, but also rapid and easy digestible display of the 
results and proper training of the clinical users are important. And above all it has to be clear 
that methods are generally applicable and produce reliable and significant clinical results, 
also compared to other MR approaches or modalities. 
Especially the complementary value of 1H MRSI and DWI needs more attention. We 
demonstrated that the two modalities have comparable performance for in vivo noninvasive 
assessment of prostate cancer aggressiveness and their combination did not lead to 
improved results. Furthermore, we saw that the ADC value and citrate signal in MRSI both 
depend on the amount of luminal space in the tissue. So one might suggest to skip one 
of the two modalities during a multi-parametric prostate MR exam. The higher resolution, 
shorter acquisition time, and availability of an intuitive display of results are all in favor for 
the use of DWI instead of 1H MRSI. However, the (Cho+Cr)/Cit ratio has potentially a larger 
dynamic range (as it is not limited by gradient strength and diffusion time), had a slightly 
better performance for transition zone tumors, and might show a metabolic change in the 
tissue before a morphologic change occurs. These last two aspects need more investigation 
as no longitudinal studies were performed to investigate the changes in the (Cho+Cr)/Cit 
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ratio over time and in our studies only a limited number of transition zone tumors were 
included. In the transition zone of elderly men benign prostatic hyperplasia (BPH) is often 
present. BPH appears very heterogeneous on T2-weighted images, with areas of low signal 
intensity that are similar to prostate cancer. No improvement for detection and localization of 
transition zone tumors was observed for a multi-parametric MRI, consisting of T2 weighted 
imaging, DCE-MRI and DWI, compared to T2-weighted imaging alone (14). But the role of 
MRSI was not assessed in this study. When the (Cho+Cr)/Cit and Cho/Cr ratios of benign and 
tumor tissue in the transition zone were compared, significant differences were found (15). 
However, there was also considerable overlap present, which is similar to our results. The 
role of MRSI for the transition zone should be further explored, preferably in a prospective 
and multi-parametric setting, to fully determine the added value of each modality. 
With further improvement of MRSI acquisition technology and the use of higher fields, it 
is hoped that the set of (surrogate) prostate cancer biomarker signals can be expanded 
beyond those currently employed in MRSI to enhance the sensitivity of this technique. This 
was attempted in this thesis by optimizing a semi-LASER sequence to study a broader range 
of metabolites. In this way, we could rule out the use of lactate as in vivo prostate cancer 
biomarker, at least when obtained with 1H MRSI. However, we were able to pick up another 
signal with this sequence, possibly of N-acetyl neuraminic acid. Significant differences 
between serum levels of N-acetyl neuraminic acid in healthy and prostate cancer patients 
were found (16, 17). However, the serum levels were not specific enough for screening. The 
diagnostic value of this metabolite detected with 1H MRSI was not evaluated in our study 
and could be topic of future research. Moreover, we could confirm the presence of lipid 
signals in the prostate in one patient with highly aggressive prostate cancer (Gleason 5+5 
and necrosis). The presence of lipids is a sign of necrosis and this could explain the hyper-
intense regions in the center of this patient’s tumor observed on the T2-weighted image and 
ADC map. This was a unique observation. However, the clinical usability will be limited as 
necrosis is rare in prostate cancer. 
Because we used a semi-LASER sequence without lipid suppression techniques, we had 
to place the volume of interest completely inside the prostate to prevent peri-prostatic 
lipid contamination, which limits its clinical applicability. A semi-LASER sequence with the 
incorporation of lipid suppression pulses and gradients could be an alternative to the PRESS 
sequence, as our semi-LASER-spectra were of high quality. However, to reach adiabicity of the 
refocusing-pulses, high RF powers were needed, leading to long repetition times to comply 
with safety regulations. To limit the acquisition time, techniques could be incorporated 
that decrease the required RF power, for example by the implementation of gradient offset 
independent adiabatic pulses (GOIA) (18, 19). With adiabatic pulses less chemical shift 
displacement will occur and thus less lipid signal problems may be expected, which also 
could facilitate the use of shorter echo-times with signals of more metabolites than those 
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observed currently. Thus progress in 1H MRSI is expected to make it more robust, faster and 
with better spectral and spatial resolution and to provide more (potential) biomarkers.
The introduction of human 7T-systems enabled us to perform 3D 31P MRSI of the prostate 
in a clinical acceptable measurement time. The safety and feasibility study of our setup 
for in vivo 31P MRSI of the prostate at 7 T paved the way for a patient study to investigate 
its value for prostate cancer management. While the (Cho+Cr)/Cit ratio of 1H MRSI 
largely depends on the intensity of citrate, no citrate is detected with 31P MRSI, giving the 
technique potentially more value than 1H MRSI when used in combination with DWI. With 
the increased spectral resolution at 7 T, more metabolites could be studied than in previous 
low field studies (20-22); for example, the metabolite phosphoethanolamine can now be 
distinguished from phosphocholine. Using 31P NMR on prostate extracts, significantly lower 
levels of phosphoethanolamine were observed in prostate cancer compared to BPH tissue 
(23, 24), which could be an interesting biomarker for transition zone tumors. A patient study 
investigating the potential for 31P MRSI for prostate cancer detection is ongoing at the 
moment of writing. With a spatial resolution of 4 cm3, it will be challenging to demonstrate 
its value due to partial volume effects obscuring differences in the metabolites among 
different tissues. Currently, 7T-systems are mainly used in a research setting. While there 
has been a lot of effort to enable and optimize T2-weighted imaging at 7 T (25-27), the 
implementation of other functional techniques as DWI needs attention as well. When these 
issues are addressed and if we can demonstrate the value of 31P MRSI for the management 
of prostate cancer, 7T-systems might be used for clinical prostate examinations.
Currently the use of prostate-specific antigen levels in the blood to screen for prostate cancer 
is under investigation (e.g. (28)). Screening will not only lead to a reduction in the mortality 
rate of prostate cancer (28), but also to substantial overdiagnosis. Fifty percent of the 
patients diagnosed with prostate cancer as a result of screening would not have presented 
any clinical symptoms during their lives without screening (29). This will consequently have 
an impact on the quality of life. When 1000 men between the ages of 55 and 69 are screened 
annually over their lifetime, the life-years gained by screening (73 years) will decrease to 56 
years (23% decrease) when quality of life is taken into account (30). Reliable classification 
of tumors as indolent will prevent overtreatment in these patients and increase their quality 
of life. 1H MRSI and DWI both have value for in vivo noninvasive assessment of prostate 
cancer aggressiveness. MRSI has been incorporated in nomograms to predict insignificant 
prostate cancer (31, 32). The ADC values and 1H MRSI ratios both showed overlap between 
the aggressiveness classes; however, if we can use MR to prevent aggressive treatment 
even in a small portion of patients with an indolent cancer, this can increase the quality of 
life for these patients substantially. 
Another setting that can benefit from the information of MRSI and DWI are the MR-guided 
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prostate interventions. When performing MR-guided prostate biopsies, MRSI and DWI can 
be used to direct the needle to the part of the tumor that looks most malignant. This way, 
the pathologist can assess the Gleason score of, what is likely, the most aggressive part of 
the tumor. Also ultrasound-guided biopsies with MR images fused to the ultrasound imaging 
can be better targeted in this way. There is a growing interest in focal therapies for localized 
disease, where only the tumor itself is treated in a minimal invasive way, while the normal 
prostate and its function are preserved. MR imaging is used to guide focal therapies like 
cryotherapy, high intensity focused ultrasound, RF- and laser-techniques, which are used 
to ablate tumor tissue. Furthermore, DWI and 1H MRSI can be used to improve the dose 
distribution for intensity modulated radiotherapy. 
To conclude, DWI and 1H MRSI can both be used for a noninvasive aggressiveness 
assessment. This assessment can be used to guide biopsies and to improve the choice and 
application of therapy: active surveillance, focal therapy, or a more aggressive treatment. 
However, for routine clinical use, both methods could benefit from standardization and 
general quantitative classification thresholds. These thresholds should be assessed in a 
multi-parametric MR setting and evaluated in a prospective multi-center study. 
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In dit proefschrift zijn twee technieken die gebruik maken van magnetische resonantie (MR) 
onderzocht voor een in vivo, niet-invasieve bepaling van de agressiviteit van prostaatkanker. 
Deze technieken zijn: MR spectrosopische imaging (MRSI) en diffusie gewogen imaging 
(DWI).   
Met proton (1H) MRSI kan de spatiële verdeling van de metabolieten choline, creatine, 
polyamines (vooral spermine) en citraat in de prostaat worden bestudeerd. Hiervan kan de 
ratio van choline (plus spermine) plus creatine over citraat [(Cho+(Spm+)Cr)/Cit] worden 
bepaald en deze kan gebruikt worden als marker voor prostaatkanker. De schijnbare 
diffusiecoëfficiënt (ADC) van DWI is afhankelijk van de structuur van het weefsel en is een 
goede maat voor detectie, lokalisatie en karakterisatie van prostaatkanker (hoofdstuk 2).
Voor routinematig gebruik van prostaat 1H MRSI in de kliniek is meer automatisering van 
de dataverwerking nodig dan wat op dit moment voor handen is. Verder zou een algemeen 
classificatie schema voor de management van prostaatkanker bijdragen aan breder gebruik. 
De vorm en intensiteit van de metabolieten (vooral citraat en spermine) in het spectrum 
hangt niet alleen af van de onderliggende anatomie, stofwisseling en fysiologie van het 
weefsel, maar ook van de acquisitie parameters (echo tijd, repetitie tijd, puls timing in de 
sequentie en veld sterkte). Er zijn verschillen tussen de acquisitie protocollen van de MR 
vendors voor prostaat MRSI, wat leidt tot (Cho+Cr)/Cit waarden die niet direct vergelijkbaar 
zijn. Classificatie drempels zouden moeten worden bepaald voor alle beschikbare protocollen 
om MRSI van de prostaat meer bruikbaar te maken in de kliniek (hoofdstuk 3).  
In dit proefschrift is bewezen dat de (Cho+Cr)/Cit ratio en de ratio van choline over creatine 
(Cho/Cr) mogelijkheden bieden voor een in vivo, niet-invasieve bepaling van de agressiviteit 
van prostaatkanker. De maxima van de (Cho+Cr)/Cit en Cho/Cr ratios in de tumor relateren 
met de agressiviteit van de tumor en goede resultaten zijn behaald voor de differentiatie 
tussen agressiviteitklassen. Het combineren van de  twee metaboliet ratios leidde tot 
veelbelovende resultaten voor differentiatie tussen verschillende agressiviteitklassen 
(hoofdstuk 4). 
Vervolgens is de agressiviteitsanalyse uitgebreid met DWI. Voor tumoren in de perifere zone 
werden significante correlaties gevonden tussen de agressiviteitklassen en het minimum 
25ste percentiel van de ADC waarden, de maximum (Cho+Cr)/Cit ratio en de maximum 
Cho/Cr ratio. For tumoren in de transitie zone was de correlatie alleen significant voor de 
maximum (Cho+Cr)/Cit ratio en de Cho/Cr ratio. MRSI en DWI gaven vergelijkbare resultaten 
voor de bepaling van de agressiviteit van prostaatkanker. Het combineren van beide 
technieken leverde geen verbeterde resultaten op. Toch suggereren de betere resultaten 
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voor de metaboliet ratios in the transitie zone en de ADC waarde in de perifere zone dat MRSI 
en DWI complementaire waarde hebben (hoofdstuk 5).
Om meer inzicht te krijgen in de complementaire waarde van beide technieken is de relatie 
tussen de onderliggende morfologie en de metaboliet ratios en de ADC waarde onderzocht. 
De ADC waarde liet een positieve relatie zien met het percentage oppervlak van de luminale 
ruimte en een negatieve relatie met het percentage oppervlak van de kernen. Er is ook een 
positieve relatie gevonden tussen de Cit/(Cho+Spm+Cr) ratio en het percentage oppervlak 
van de luminale ruimte. Deze significante relaties suggereren dat de verschillen in ADC 
waarde en Cit/(Cho+Spm+Cr) ratio die we zien tussen de normaal en tumor prostaat weefsel, 
morfologische variaties representeren in de prostaat weefsel, voornamelijk in de luminale 
ruimte. Hoewel we niet kunnen uitsluiten dat er ook biochemische processen (zoals 
m-aconitase or ATP-citraat lyase) en interacties in het prostaat vocht ook de citraat and 
spermine signalen beinvloeden, is het waarschijnlijk dat deze bijdragen kleiner zijn dat de 
morphologische veranderingen (hoofdstuk 6). 
1H MRSI kan ook worden gebruikt om lactaat te detecteren, wat een interessante marker is 
voor kanker omdat het een teken is van het Warburg effect en van hypoxia. In deze studie 
hebben we geen overtuigend lactaat signaal gevonden in 17 patiënten met zeer agressieve 
prostaatkanker. We hebben hiervoor gebruik gemaakt van een semi-LASER sequentie die 
geoptimaliseerd is voor in vivo lactaat detectie in de prostaat. We hebben een schatting 
gemaakt dat de gemiddelde lactaat concentratie in agressieve prostaatkankers en deze is 
lager dan 1.5 mM. Dit laat zien dat als lactaat verhoogd is in prostaatkanker, lactaat in lage 
concentratie blijft. De afwezigheid van pulsen en gradiënten voor onderdrukking van lipiden 
rond de prostaat heeft het mogelijk gemaakt om lipiden waar te nemen in de prostaat net als 
vermoedelijk N-acetyl neuraminic zuur (hoofdstuk 7). 
Metabolieten met een fosforatoom kunnen worden bestudeerd met 31P MRSI en dit kan 
nieuwe informatie opleveren voor de karakterisatie van prostaatkanker. Een uitgebreide 
validatie van de veiligheid van onze nieuwe set-up heeft laten zien dat we veilig een 31P 
endorectale spoel kunnen gebruiken in combinatie met een externe achtkanaals 1H spoel 
om prostaat 31P MRSI te verrichten op 7 T. In een gezonde vrijwilliger hebben we spectra van 
de hele prostaat kunnen meten met een spatiële resolutie van 4 cm3. De spectrale resolutie 
maakte de detectie mogelijk van fosfocholine, fosfoethanolamine, anorganisch fosfaat 
en andere metabolieten die een belangrijke rol kunnen spelen voor de karakterisatie van 
prostaatkanker (hoofdstuk 8). 
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Dankwoord
Dit zal waarschijnlijk het meest gelezen hoofdstuk van mijn proefschrift zijn en een van de 
leukste om te schrijven! Er zijn veel personen die aan dit boekje hebben bijgedragen en in 
allerlei vormen. Verschillende mensen hebben vooral inhoudelijk bijgedragen, velen hebben 
geholpen met de nodige ontspanning, van andere heb ik juist meer ondersteuning gekregen 
en dan zijn er natuurlijk ook degene die mij geïnspireerd hebben dit onderzoek te doen. Ik heb 
een hele leuke tijd gehad in Nijmegen en ik ga mijn best doen iedereen hiervoor te bedanken!
Dit proefschrift was zeker niet zo geweest zoals het nu is zonder de bijdrage van mijn 
copromotor, Tom Scheenen. Tom, heel erg bedankt voor je super goede begeleiding. Ik 
heb veel van je geleerd en dankzij jou is mijn promotie soepel verlopen. In de tijd dat ik in 
Nijmegen heb gewerkt, heb je je eigen onderzoeksgroep op weten te zetten. Hierdoor hadden 
we een goed team voor het pionierswerk op 7 T. Het bespreken van artikelen met ons groepje 
was zeer inzichtelijk en je hebt een duidelijke en goed gefundeerde mening waar we allemaal 
wat van kunnen leren. Dankzij jouw kritische blik zijn artikelen goed wanneer ze opgestuurd 
worden en dit heeft er voor gezorgd dat we in leuke bladen hebben kunnen publiceren! Je 
hebt me aangemoedigd door te gaan met onderzoek en een fellowship aan te vragen. Ik ben 
je daar erg dankbaar voor en ik hoop nog lang met je samen te mogen werken! Naast werk 
moet er natuurlijk ook tijd voor ontspanning zijn. Gezellig biertjes drinken, hiken in California 
of Utah, en jullie achtertuin is ideaal voor barbecues, feestjes en kamperen! Heel erg bedankt!
Daarnaast wil ik graag mijn promotor, Arend Heerschap, bedanken. Arend, dank je wel dat 
je me hebt aangenomen op het Koningin Wilhelmina Onderzoeksprijs project dat je samen 
met Jelle Barentsz toegewezen hebt gekregen. Het bepalen van de agressiviteit van prostaat 
kanker is een belangrijk onderwerp en ik heb hier met veel plezier aan gewerkt. Ik denk dat we 
hele interessante en relevante artikelen hebben weten te publiceren. Jouw feedback op mijn 
artikelen was altijd relevant, to-the-point en heeft tot betere artikelen geleid. Je hebt een hele 
fijne werksfeer weten creëren in de Biomedical MR groep en mede daardoor kijk ik ernaar uit 
om na mijn post-doc in Boston terug te keren naar Nijmegen om hier mijn onderzoek voort te 
zetten. Er is totaal geen barrière om bij langs te komen met vragen, je deur staat altijd open 
en de barbecues bij jou en Gonda thuis waren erg gezellig, net als de kerst/winterdiners!
Alan Wright, heel erg leuk dat je mijn paranimf wilt zijn! We hebben veel samengewerkt, maar 
ook ontzettend veel gelachen! Samen met Isa was je m’n roomie in de ‘onderwaterkamer’ 
en na de verhuizing konden we je niet missen, dus ben je ons komen vergezellen in de 
nieuwe kamer! Je hebt me veel geleerd over de post-processing van spectra en jouw kennis 
van statistiek heeft zeker aan de kwaliteit van onze artikelen bijgedragen. Ik wens je heel 
veel succes in Cambridge en ik hoop dat je daar goed onderzoek kan gaan doen en mooie 
artikelen mag publiceren! 
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Een groot deel van mijn proefschrift zou niet mogelijk geweest zijn zonder de hulp van 
Christina Hulsbergen - van de Kaa. Christina, je hebt veel tijd besteed aan het uitlijnen van 
tumoren op prostaat coupes zodat wij deze konden correleren aan de MR-beelden. Het was 
heel inzichtelijk om met jou naar de histopathologie van prostaten te kijken. Ik denk dat 
iedereen die met prostaat MRI werkt dit eens zou moeten doen. Het was heel verhelderend 
om te zien wat voor kleine details we soms op willen pikken met MRI en waarom dat soms 
dus niet lukt. Bedankt voor je geduld. 
Thomas Hambrock, heel veel dank voor de uren dat je me hebt geholpen met het matchen 
van de pathologie met de MR beelden. Tijdens je opleiding tot radioloog heb je hier zelfs in 
je weekend tijd voor gemaakt! Je bent altijd super geïnteresseerd in onderzoek en vol goede 
ideeën over vervolg studies. Ik hoop dat je onderzoek en kliniek kan blijven combineren en 
dat je veel fantasierijke verhalen blijft vertellen!
Ook wil ik graag Jelle Barentsz bedanken. Dankzij jouw vooruitstrevende kijk op MR van de 
prostaat is het Radboud een van de meest vooraanstaande centra op dit gebied. Je hebt 
een goed team om je heen weten te verzamelen en ik ben blij dat ik in dit team heb mogen 
werken. 
Er zijn nog veel meer mensen die bij hebben gedragen aan mijn publicaties en die ik graag 
wil bedanken. Sj@kie van Asten, je hebt me erg geholpen met jouw LCModel kennis, je 
linuxbakken en je mooie bash-scriptjes. Je bent altijd heel geïnteresseerd en meelevend en 
dat waardeer ik enorm! Miriam Lagemaat, we hebben vele ritjes samen naar Essen gemaakt, 
discussies gevoerd over sequenties en gebrainstormd over van alles. Daarnaast ben je ook 
altijd in voor gezelligheid, een lekker biertje, een afdaling op de ski, een etentje bij jou en 
Sten thuis of een spelletje! Veel succes met je de volgende stap in je carrière! Mark van 
Uden, jouw vakkundige soldeerkunsten hebben geleid tot de 31P endorectale spoel voor 7 T. 
Je bent altijd bereid om nog een keer uit te leggen hoe een PIN-diode ook al weer werkt, 
wat de scattering parameters zijn of hoe je twee spoelen ontkoppeld. Gelukkig zijn onze 
gesprekken op Paaspop wat luchtiger ;-) MC Massive (aka Marnix Maas), dank je wel alle tijd 
die je hebt besteed aan LCModel en Metabolite Report. Je bent bezig het onderzoek voort 
te zetten naar het bepalen van de agressiviteit van prostaat kanker op 3 en 7 T. Succes! Al 
ons werk op 7 T was niet mogelijk zonder de goede samenwerking met het Erwin L. Hahn 
Instituut in Essen. Im Besonderen möchte ich Andreas Bitz und Stephan Orzada danken. 
Ihr wart während unserer Prostata-Messungen immer da. Andreas, du hast viele Stunden 
damit verbracht,  Spulen, Prostatae und ‘Duke’ zu simulieren. Unser Artikel in MRM hat 
eine Menge deiner Zeit in Anspruch genommen! Stephan, du hast ein großes Wissen über 
Spulen und Gerätetechnik. Dank deinem Spulen-Design waren wir in der Lage großartige 
Bilder einer Prostata zu machen. Jeroen van de Laak, dankzij jou konden we de prostaat 
coupes digitaliseren en segmenteren. Dit was onmisbaar voor het laatste artikel en heeft ons 
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Weiland from Siemens in Erlangen for their input to improve our articles.
Natuurlijk wil ik ook Caroline Bruggink en Maarten de Rooij niet overslaan. Ik vond het tof dat 
jullie je stage op onze afdeling hebben gevolgd en me hebben geholpen met het onderzoek. 
Dit heeft geleid tot twee mooie artikelen. Dank jullie wel! 
Hetty, we hebben samen veel leuke dingen gedaan: stappen in Valkenswaard, zomerfeesten, 
op reis met ons Oeike in Australië, met Alan en Willemijn naar Mayrhofen, en met de Tien 
naar Tignes! En nu zijn we allebei het avontuur aangegaan in Amerika, leuk! Isa, je was 
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Wiener Melange, Blue Fantasy en biertjes gedronken! Gezellig! Eline, jij bent altijd in voor 
gezelligheid en draait er je hand niet voor om om daarvoor vanuit Wijchen te komen fietsen! 
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Ook wil ik graag alle mannen van de Biomedical MR groep bedanken. Ik heb jullie bijna 
allemaal wel eens of meerdere keren in de MR scanner gelegd om spectra van jullie prostaat 
te verkrijgen! Thanks guys! Het leuke aan de Biomedical MR group is dat we ook buiten 
het werk veel gezellige dingen hebben gedaan. Helaas wordt dit dankwoord te lang als ik 
jullie daar allemaal persoonlijk voor ga bedanken. Dus iets minder persoonlijk, maar wel 
heel veel dank voor de samenwerking en gezelligheid aan alle andere promovendi, postdocs 
en collega’s van de Biomedical MR groep: Anne, Barbara, Bart (Van de Bank en Siemens/
Philips), Bob, Christine, Cindy, Devasish, Edwin, Fernando, Frits, Houshang, Jannie, Kim, 
Marc, Marinette, Morteza, Patricia, Rianne, Valerio, Vincent en Yi. Allemaal ook bedankt voor 
de heerlijke taarten die jullie hebben gemaakt (of soms gekocht) en het in de rij staan voor 
Bossche bollen van Jan de Groot!
Dank ook aan iedereen van de prostaat werkgroep die ik nog niet genoemd heb: Caroline, 
Derya, Esther, Henkjan, Joyce, Jurgen, Geert, Kristian, Martijn (Hoogenboom en Schouten), 
Martin, Oscar, Patrik, Pieter en Wendy.
Verder wil ik graag Marijke Hogenkamp bedanken voor het inplannen van mijn studies 
en Leonie Vos en Solange Estourgie voor het regelen van allerlei andere zaken. Vele MR-
laboranten hebben me geholpen tijdens de studies, dank daarvoor! 
Ik heb veel plezier beleefd aan het organiseren van het ISMRM Benelux congres in Hoeven. 
Naast mijn medeorganisatoren, wil ik ook mijn bestuursgenoten van de ISMRM Benelux 
bedanken voor de gezellige vergaderingen, die vaak gepaard gingen met een heerlijke maaltijd. 
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Naast werk is er natuurlijk ook tijd voor ontspanning. En een goede manier om te ontspannen 
is mountainbiken met Pieter en Eric! Maar niet alleen in de bossen zijn jullie goed gezelschap, 
het is ook altijd gezellig als we een biertje drinken in de Dollars of Aesculaaf, patatjes eten bij 
de Febo, de Kuukse kroegentocht lopen, of een filmpje pakken bij de Lux! 
Verder wil ik Oeike (aka Marcel) bedanken voor alle gezelligheid in de Aesculaaf, in Australië, 
in Boston en in het kleine Nijmegen! Kim Sweers, hoewel de wijn heeft plaatsgemaakt voor 
thee, is het nog altijd super gezellig om weer met je bij te kletsen. Ook met InfusiX is het altijd 
als van ouds! Tripjes naar Ryan-air bestemmingen, carnavallen in Oeteldonk, lekker eten bij 
de klinker, (een etappe van) de vierdaagse lopen en uitjes in Maastricht en West-Friesland! En 
dan wil ik nog Sjors en Piet bedanken voor leuke avondjes gamen en praten over opstellingen 
voor gedragsstudies en zebravisjes!
Ik luister erg graag naar muziek en gelukkig heb ik een aantal mensen gevonden die wel 
dezelfde muzieksmaak hebben als ik, namelijk de muzikanten van Joekskapel Ald Ïezer. 
Dank jullie wel voor alle repetities en leuke optredens! Saxofoon spelen is echt ontspanning 
en ik kom over een tijdje graag weer met jullie meespelen.
Verder wil ik iedereen van de familie bedanken voor hun interesse en gezelligheid! Amber, Els, 
Fleur, Jochem, Loes en Mark, jullie zijn een super uitbreiding van de familie en ik ben blij met 
jullie als broertjes en zusjes! Oma Broos, je bent heel geïnteresseerd in hoe het met me gaat 
en het is altijd gezellig bij jou op de koffie, je hebt genoeg te vertellen! Oma Kobus, of ook wel 
cybergranny! Je bent helemaal bij de tijd met skypen, facebook en emailen. Zo kunnen we 
mooi contact houden nu de afstand tussen Winterswijk en mij steeds groter wordt! Ooms, 
tantes en neefjes, super leuk dat jullie altijd geïnteresseerd zijn in hoe het gaat!
Lieve opa’s, helaas zijn jullie er geen van alle meer om dit mee te mogen maken, maar jullie 
zijn voor mij een grote inspiratie en motivatie voor kanker onderzoek en jullie verdienen dan 
ook zeker een vermelding en grote dank! Lieve opa Baard, wat ik me vooral van je herinner 
zijn de kieteldood, water in de knieën, je kriebelbaard en hoe gemeen (prostaat)kanker kan 
zijn… Lieve opa Sjaak, hoewel ik je Limburgse accent niet altijd kon verstaan, konden we 
altijd met je lachen! Lieve opa van de Heuvel, helaas was jouw prostaatkanker agressief 
en hebben de uitzaaiingen je veel pijn bezorgd... Opa Sjaak en jij hebben ons als jullie 
eigen kleinkinderen beschouwd en dat was heel fijn! Dank! Lieve opa Broos, ons medisch 
wonder, enorme doorzetter en mijn grootste inspirator. Je had geen behoefte meer aan een 
behandeling voor prostaatkanker en wie kon je ongelijk geven gezien alle behandelingen 
die je al onderging. Ik weet zeker dat je dolgraag bij mijn promotie had willen zijn en dat je 
ontzettend trots zou zijn op dit boekje!
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Lieve Ferry, Liset en Jelle, jullie zijn de beste broers en zus die je je maar kan wensen! Ik vind 
het super fijn dat we een hechte band hebben en dat jullie altijd voor me klaar staan. Weer 
eens verhuizen, in de tuin werken, blaren lopen tijdens de vierdaagse, een website bouwen, 
de kou in Boston trotseren, m’n reisgenootje zijn in Peru, Stockholm of Turkije, het maakt 
niet uit wat. Met z’n allen op wintersport, party-en op Paaspop of los gaan tijdens Ferrie’s 
Herriehok, het is altijd gezellig! Jelle, ik vind het heel tof dat je mijn paranimf wilt zijn!! Je 
staat altijd voor iedereen klaar, je bent super geïnteresseerd in mijn werk en onze band is nog 
beter geworden in Nijmegen! 
Mam en Jan, niet alleen hebben jullie me vaak mogen verhuizen, we hebben gelukkig ook 
veel leuke dingen gedaan. Gezellig elke week repeteren met de joekskapel en als ik mee 
at was er altijd een toetje in huis! Samen op vakantie naar Turkije en Barcelona of op 
sinterklaasweekend met enorme surprises en uitdagende quizzen. Pap en Marlies, het is een 
feest bij jullie te eten, er staat altijd wat lekkers op tafel met vaak een kaasplankje en af en 
toe zelfs soufflé toe! Ik hoop dat we onze jaarlijkse traditie om met kerst op wintersport te 
gaan er nog even inhouden: lekker après-ski-en, heerlijke Oostenrijkse maaltijden, lunches en 
schnaps en natuurlijk super mooie pistes! Lieve mam & Jan, lieve pap & Marlies! Dank jullie 
wel voor jullie support, interesse, gezelligheid, liefde, aandacht en dat jullie er altijd voor me 
zijn! Ik hou van jullie!
En het laatste plekje van het dankwoord is natuurlijk voor Maarten. Lieve Maarten, we 
hebben het super fijn samen, ik kan niet alleen geweldig met je lachen, je luistert ook altijd 
naar al m’n verhalen! Ik word altijd helemaal vrolijk van je, vooral als je weer heerlijke crème 
brûllée hebt gemaakt. Jummie! Ik ben heel erg blij dat we samen zijn en hoewel de afstand 
het nu natuurlijk niet makkelijk maakt, weet ik zeker dat we samen een hele mooie toekomst 
tegemoet gaan! Ik hou van je! Kus
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Thiele Kobus was born in Veghel in 1983 and grew up in Erp, a small village in Brabant. She 
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which involved selective stimulation of the cardiac fibers in the vagal nerve. She graduated 
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Thiele applied for a Marie Curie Fellowship and a fundamental cancer research fellowship 
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brain-barrier for localized treatment of tumors in the brain. After two years of experience as 
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